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Summary 
One of the greatest challenges health care professionals, organizations and system 
will be confronted with in the twenty-first century is the dramatic increase in the 
number of patients suffering from one or more chronic diseases 1, 2. It is expected 
that by the year 2020, chronic conditions will be responsible for 60% of the global 
disease burden in developed countries 2, 3. Yet, as the current health care system is 
largely organized around an acute, episodic model of care, it does not meet the 
needs of chronically ill patients. Chronically ill patients need a model of care that 
pays attention to self-management, prevention and continuity of care, which receive 
limited attention in acute care models 4. As an answer to the need to shift the model 
of care, Wagner and colleagues developed the Chronic Care Model. This model 
provides a guide for the health care organizations and systems to improve the care 
for their chronically ill patient populations 4, 5. The World Health Organization 
(WHO) revised the model to provide a global perspective resulting in the Innovative 
Care for Chronic Conditions (ICCC) framework 2, 6, 7. Evidence in a limited number 
of chronically ill patient populations (e.g., asthma and diabetes) support the 
effectiveness of implementation of (parts of) the model in view of improved patient 
outcomes (e.g., better glycemic control, improved HbA1, BMI, triclgyerides), 
reduction in the number of hospitalization, less emergency room visits, a reduction 
in the number of unscheduled visits to physicians as well as reducing days missed 
at work or school and a reduction of the total costs 4, 8-10.  
Suffering from a chronic disease implies that patients have to adopt their health 
behaviors. One important health behavior for a treatment to be effective is adhering 
to prescribed medications. Despite its importance, 25% 11 to 50% 12 are non-
adherent to treatment regimen. Non-adherence can be defined as “deviation from 
the prescribed medication regimen sufficient to influence adversely the regimen’s 
intended effect” 13 (pg. 36). Non-adherence can have serious consequences 
including poor clinical outcomes, higher (re)hospitalization rates and increased 
health care costs 12, 14-24. 
To reduce the magnitude of non-adherence, it is crucial to know which factors 
influence patients’ medication adherence. The WHO categorizes the risk factors for 
non-adherence into: 1) patient-related factors (e.g., self-efficacy, patient’s beliefs 
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about the efficacy of medications, knowledge, perceived barriers to adhere to 
regimens); 2) social and economic factors (e.g., social networks, family functioning); 
3) therapy-related factors (e.g., symptom distress associated with side effects of the 
regimen, duration of treatment, dose complexity); 4) condition related factors (e.g., 
self-care disability, complications, and psychiatric diagnoses, substance abuse); 
and 5) health care system and health care team related factors 25.  
As behavior is influenced by the system in which the patient lives, it is crucial to 
investigate the role of system factors in explaining adherence. However, until now, 
system level factors have received relatively little attention to explain medication 
non-adherence. This may explain the limited explanation in the variability in 
adherence 26. A framework which can be used in explaining the influence of system 
factors on behavior is an ecological model. In an ecological model three levels of 
influence on patient behavior are identified: 1) the micro level, which encompasses 
factors related to the interpersonal or face-to-face relationships with health care 
professionals, as well as social support 2; 2) the meso level, which refers to the 
practice patterns or the characteristics of the health care organization where the 
patient is being treated 2; and 3) the macro level, which includes the characteristics 
of the health care system in which a patient lives 2. This level includes local, state, 
and national laws and policies related to health. These three levels interact with 
and dynamically influence each other. Taking factors at these three levels into 
account in explaining patient behavior is essential. To-date, however, system level 
factors have received limited attention as potential predictors of patient medication 
adherence. Furthermore, existing evidence on the influence of these factors on 
medication adherence has not been compiled. As a consequence, the magnitude of 
the effect of different system factors on adherence is not known, a clear gap in the 
growing adherence literature. 
This system perspective is also needed when implementing interventions to improve 
adherence. These interventions can target the patient, the micro level (i.e., the 
health care provider), the meso level (i.e., health care organizations’ practice 
patterns) and the macro level (i.e., health care policy) 27. Interventions targeting the 
patient can be classified as educational/cognitive, counseling/behavioral, or 
psychological/affective interventions 28. Although most research to-date has focused 
on interventions targeting the patient, knowledge concerning which interventions 
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are used in clinical practice is scare. An example of an intervention targeting the 
health care provider which may influence adherence to medication is training 
health care professionals in the use of patient-centered methods (e.g., motivational 
interviewing) 27. Interventions targeting the health care organization mainly focus on 
changing practice patterns. The implementation of chronic care models, which has 
been shown to result in better patient outcomes, is an example of changing practice 
patterns 27, 29. However, the extent to which chronic care models are implemented in 
practice has not been investigated in certain chronically ill patient populations such 
as transplantation. One reason for this lack in evidence is the absence of a valid 
and reliable instrument to assess the level of chronic illness management 
implemented in the health care organization. Interventions focusing on the health 
care policy are “higher order interventions affecting health policy, organization and 
financing of care and quality of care programs” 27. An example of an intervention 
focusing on the health care policy is changes in medical insurance coverage for 
prescription drugs in the US 30. 
The overall purpose of this dissertation was to explore the role of system factors in 
chronic illness management, focusing on medication adherence. Five articles 
present the results of this work. 
First, a systematic review was conducted of quantitative studies addressing factors 
at the mico-, meso-, and macro levels of the health care system that are associated 
with adherence to medication regimens in individuals with HIV and organ 
transplant recipients (Chapter 3). A total of 64 studies (seven in the transplant 
literature and 57 in the HIV literature) examining the association between 
characteristics at the micro (i.e., quality of the patient-provider relationship, 
medication counseling, satisfaction with the health care provider, relationship with 
health care providers, health care provider disease-specific experience, 
trust/confidence in the health care provider, clarity of health care provider 
instructions about medications, accessibility to the health care providers, perceived 
pressure from the provider to take medications, and perceptions of non-judgmental 
attitudes of health care providers), meso (i.e., center effects, frequency of health 
care visits, access to disease-specific services, access to medications, quality of 
care, and satisfaction with the health care setting) and/or macro (i.e., health 
insurance, drug costs, distance from and access to clinical site, and 
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country/continent) level of the health care system and medication adherence were 
identified. The two factors that were most consistently related to medication 
adherence in these patient populations were trust in the health care provider (a 
micro level factor) and access to medications (a meso level factor). Both factors 
support the importance of continuity of care in the treatment of chronically ill 
patient populations. Across the factors examined, however, study findings about 
their relationships to adherence varied. One explanation for this variability may be 
the wide variability in the methodological approaches utilized in studies (e.g., 
definition adherence, measurement adherence, study design and methods of 
analysis).  
The second manuscript, a methodological paper, provides an overview of commonly 
used statistical measures (i.e., effect sizes) for expressing the strength of the 
relationships between variables such as system factors and adherence behavior 
(Chapter 4). More specifically, formulas utilized to directly calculate common effect 
sizes from summary data reported in studies, as well as examples of methods 
utilized to indirectly estimate the effect size from summary statistics are presented.  
Third, a study was conducted to describe the strategies cardiovascular nurses and 
allied health professionals utilize to assess patients’ adherence to their medication 
regimens and to enhance adherence (i.e., educational/cognitive, 
counseling/behavioral, or psychological/affective interventions) (Chapter 5). In this 
study, a 45-item questionnaire designed to assess adherence assessment and 
interventional strategies utilised in clinical practice was distributed to a 
convenience sample of attendants of the 10th Annual Spring Meeting of the 
European Society of Cardiology Council on Cardiovascular Nursing and Allied 
Professions conference in Geneva (Switzerland) in March 2010. A total of 137 health 
care professionals were included in the study. Questioning patients about non-
adherence during follow-up visits was the method used most frequently to assess 
adherence. Providing reading materials was the strategy used most frequently to 
enhance patient medication adherence, followed by training patients about 
medication taking during their inpatient recovery. Across the categories, 
educational/cognitive adherence enhancing interventions were used most 
frequently, followed by counselling/ behavioural interventions. Psychological/ 
affective interventions were less frequently used.  
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The fourth study examined adherence assessment strategies as well as the 
interventions health care professionals report using to improve adherence in 
transplant patients (Chapter 6). Furthermore this study examined the health care 
professionals’ perceptions about the effectiveness the interventions they utilize. 
Data were collected at the second International Transplant Nurses Society (ITNS) 
symposium in Germany held on June 18th – 19th, 2010. Eighty-six participants are 
included in this study. The most frequently used assessment adherence strategy 
was questioning patients about non-adherence during follow-up. Training patients 
to self-administer medications and providing printed adherence information were 
the most frequent interventions. More specifically, these interventions were used by 
79% of the participants. Providing printed medication instructions was the third 
most frequently used intervention. The intervention perceived as most effective by 
the health care professionals was medication self-administration training. 
Comparing the utilization of interventions per category, educational/cognitive 
interventions were used most frequently, followed by the counseling/behavioral 
interventions and the psychological/affective interventions. The average 
effectiveness ratings for the three categories of interventions were very similar. 
The final study (Chapter 7) describes the development, the content validity testing 
as well as the inter-rater reliability testing of the Chronic Illness Management 
Implementation – Building Research Initiative Group: Chronic Illness Management 
and Adherence in Transplantation (CIMI-BRIGHT) instrument. The development of 
the CIMI-BRIGHT instrument was based on the conceptual framework of World 
Health Organization’s Innovative Care for Chronic Conditions (ICCC) framework, as 
well as the clinical expertise of the members of the research team. Initial 
psychometric testing, more specifically content validity and inter-rating reliability 
testing, were conducted. Content validity was evaluated by 7 experts in chronic 
illness management. These experts rated the relevance of each item in terms of the 
construct ‘chronic illness management’ on a 4-point Likert scale (ranging from 1= 
not relevant to 4= highly relevant). Content validity indexes were calculated for each 
item and the survey as a whole. Of the 51 items, 42 were had good content validity. 
Two of the nine items with low content validity were deleted the remaining seven 
were revised based on recommendations from the expert reviewers. To evaluate 
inter-rater reliability, a pilot study was conducted in two transplant programs. The 
percentage agreement between the participants for total CIMI-BRIGHT instrument 
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in each center was calculated by averaging the percent agreement on individual 
items. The percentage agreement in the two centers for the total instrument scores 
was 84.6% and 74.8% respectively. 
Synthesizing the findings of the studies yields the following three key results which 
contribute to the current state of knowledge. First, there remains a significant 
knowledge deficit in view of the influence of health care system factors on 
medication adherence calling for further research investment. Second, nurses’ 
practice patterns in view of adherence-related interventions call for a change in 
curricula. The health care workforce needs to be equipped with the required 
competencies for behavioral management. Moreover, practice development focused 
on integrating behavioral strategies to improve adherence management is needed. 
Finally, The CIMI-BRIGHT instrument is the first and only tool developed to 
systematically assess the level of chronic illness management in transplant centers 
and thus provides a building block for further observational and intervention 
research in transplantation.  
These findings have several implications for future research and clinical practice. 
Firstly, to fully understand the role of system factors in medication adherence a 
large multi-continental, multi-country, multi-center study should examine the 
associations between multiple factors at the micro-, meso-, and macro level and 
non-adherence to medication regimens. Second, education and training in the 
utilization of counseling/behavior and psychological/affective interventions are 
important for health care professionals. It needs to be included in basic education 
programs, as well as in ongoing professional education and training. Health care 
curricula need to be revised to include competencies in adherence enhancing 
interventions. Finally, future studies should continue to examine the psychometric 
properties of the CIMI-BRIGHT instrument. This instrument has the potential to 
contribute to our understanding of chronic illness care in transplant centers and to 
be a useful tool in evaluating the impact of interventions designed to improve 
chronic illness management in these centers.  
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Introduction 
In order to achieve good treatment outcomes it is essential that chronically ill 
patient patients take their medication as prescribed. While patients’ medication 
adherence behavior is known to be influenced by a number of factors, those that 
have been investigated to-date fail to adequately explain the observed variability in 
adherence. This may be related to the influence of the patients’ environment, i.e., 
the system in which the patient lives, on medication adherence. System factors 
have only recently been recognized as potentially important predictors of adherence. 
To date, there is very limited research examining the impact of system factors on 
adherence. This dissertation focuses on the influence of system level factors on 
medication adherence. 
 
Chronic conditions 
The dramatic increase in the number of patients suffering from a chronic condition 
is a major challenge which health care professionals, organizations, and systems 
face in the twenty-first century 1, 2. Chronic conditions are defined by the World 
Health Organization (WHO) as “diseases which have one or more of following 
characteristics: they are permanent, leave residual disability, are caused by 
nonreversible pathological alteration, require special training of the patient for 
rehabilitation, or may be expected to require a long period of supervision, 
observation or care” 3 (pg. 4). According to this definition, chronic conditions cover a 
broad range of diseases ranging from persistent communicable diseases (e.g., HIV 
and AIDS), non-communicable diseases (e.g., cardiovascular diseases and cancer), 
and mental disorders (e.g., depression) to ongoing impairments in structures (e.g., 
amputations and joint disorders) 2. Transplant recipients are also a subset of the 
growing group of chronically ill patients, as they require ongoing management for 
the rest of their life in order to achieve successful short and long term outcomes 
after transplantation.  
The number of chronically ill patients is increasing globally, and overwhelms high 
as well as low income countries 1, 2. This increase is mostly due to the rapid aging of 
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the population and the greater longevity of persons with many chronic conditions 4. 
Currently, more than half of the global disease burden is caused by chronic 
conditions 5. It is expected that by the year 2020, chronic conditions will be 
responsible for 60% of the global disease burden in developed countries 2, 6. 
Chronically ill patients are the largest consumers of drugs in the society. The mean 
number of prescribed drugs per year for a person with no chronic conditions is 2.2; 
for a patient with one chronic condition this is 11. For a patient with three or more 
chronic conditions the mean rises to 28.3 7. 
 
Chronic care model 
The shifting balance from patients suffering from acute illnesses to those with a 
chronic condition requires a shift in the organization of health care. Currently, 
health care is “organized around an acute, episodic model of care that no longer 
meets the needs of many patients, especially those with chronic conditions” 2 (pg. 
4). The Chronic Care Model, developed by Wagner and colleagues is an answer to 
the need to shift the model of care. It provides a guide for health care organizations 
in the management of chronically ill patients 4, 8. Chronic illness management refers 
to a model of care that combines the following building blocks: 1) continuity of care; 
2) partnerships with patients, families and communities; 3) support for patients in 
improving their self-management; 4) attention to preventive measures; 5) decision-
making support for health care professionals; and 6) availability of clinical 
information systems 2, 5, 9, 10. To provide a global perspective, the WHO adapted 
Wagner’s Chronic Care Model. The revised model, the Innovative Care for Chronic 
Conditions (ICCC) framework (see Figure 1) 2, 11, 12 expanded the community and 
policy aspects of the Chronic Care Model 11.  
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Figure 1: Innovative Care for Chronic Conditions Framework 2 
 
This framework is comprised of fundamental components within the patient, family 
and the health care provider level; the organization and community level; and the 
policy level 2, 12. These components are described as “building blocks”, which can be 
used to help decision makers or those working in the health care system 
progressively create or redesign health care organizations and systems to expand 
their capacity to manage long-term health problems 2, 12.  
Improved patient outcomes are observed when the care system shifts from acute to 
a chronic care model for the management of chronically ill patients. Empirical 
evidence in asthma and diabetes suggests the effectiveness of implementation of the 
combination of building blocks in chronic care management 8, 10, 13, 14. The extent to 
which chronic care management has been implemented and shows efficacy in other 
chronically ill patient populations such as transplant recipients has not been 
examined to date. 
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Health behaviors  
Suffering from a chronic condition implies that patients have to adopt new health 
behaviors or adapt their health behaviors and need to engage in a number of 
activities to promote physical and psychosocial well-being; interact with health care 
professionals; adhere to treatment regimens; monitor their health status and make 
associated care decisions; and manage the impact of their chronic condition on 
physical, psychological and social functioning 1. The actions patients perform for 
themselves in daily life to manage their illness and treatment and to avoid 
functional and health deterioration are called “patient self-management” 2, 5, 15. 
Chronically ill patients have to perform a number of activities in their daily life. 
After receiving an organ transplant, for instance, patients need to engage in long 
term health behaviors including medication taking, avoidance of risk factors for 
cardiovascular disease and cancer, and self-monitoring for signs of rejection and 
infection, as well as regular follow-up visits to prevent poor outcomes related to 
rejection, graft loss, mortality and the progression or development of co-morbidities. 
Adherence (also called compliance) to these health behaviors can be defined as “the 
extent to which a person’s behavior –in terms of taking medications, following a 
diet, and/or executing lifestyle changes, corresponds with the agreed upon 
recommendations of a health care provider 3 (pg. 3). In renal transplantation, 
patients take on average 8 to 10 medications a day 16 with a range from 4 to 16 17. 
Lung transplant recipients take a median of 8 (Q1-Q3: 6-11) non-
immunosuppressive medications a day, while for both liver and heart transplant 
recipients the median was 3 (Q1-Q3: 2-5) 18.  
 
Non-adherence to medication regimen  
Definition medication non-adherence  
Adherence to prescribed medication regimens is a fundamental prerequisite for a 
treatment to be effective. In a report of a 2008 Consensus Conference on non-
adherence to immunosuppressive medications, Fine and colleagues 19 reported that 
although non-adherence has been examined a number of times, the absence of a 
taxonomy has resulted in much conceptual confusion, mainly because most 
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authors try to identify specific cutoffs or percentages to identify medication intake 
or drug level. These authors ignore the fact that patients’ drug taking behavior is a 
dynamic process that changes over time. They also fail to distinguish between two 
important components of adherence-related pharmacotherapy: (1) discontinuation 
or non-persistence which refers to disengagement from the prescribed regimen and 
(2) the quality of execution both in terms of taking and timing of medication intake 
while the patient is engaged with his or her therapeutic regimen 19. This group of 
adherence experts in transplantation proposed a new definition specifically of 
medication non-adherence. They defined non-adherence as followed: “deviation 
from the prescribed medication regimen sufficient to influence adversely the 
regimen’s intended effect” 19 (pg. 36). In this definition the therapeutic outcome - in 
contrast to specific medication intake or drug level, is emphasized 19. For 
transplantation, research has shown that this clinical meaningful definition for 
non-adherence is a deviation of > 5% of the daily schedule 20-22. 
 
Prevalence non-adherence 
A Cochrane review 23 and a meta-analysis 24 highlight the magnitude of non-
adherence to prescribed medication regimens in chronically ill patient populations. 
On average, 25% 24 to 50% 23 of patients do not take their medications as 
prescribed. In organ transplantation, 20% to 37% of the patients are non-adherent 
to their immunosuppressive medications 25-28. A meta-analysis in transplantation 
showed an overall non-adherence rate of 22.6 cases per 100 persons per year 29. 
Among cardiovascular patients, an average treatment non-adherence rate of 23.4% 
was reported in a meta-analysis 30. For HIV patients, estimates of non-adherence to 
antiretroviral therapy ranged from 30% to 40% 31-34. While these numbers are 
influenced by the variability in case finding and assessment methods and 
operational definitions, they demonstrate that non-adherence is a major issue in 
many patient populations. 
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Consequences of non-adherence 
Non-adherence to medication treatment can have serious consequences in 
chronically ill patient populations, including poor clinical outcomes, higher 
(re)hospitalization rates, and increased health care costs 23, 31, 35-44. A meta-analysis 
found that patients who were adherent were 26% more likely to have a good clinical 
outcome compared to patients who did not adhere to their overall treatment 
regimen (not only medication adherence) 36. Non-adherence costs the US health 
care system an estimated $100 billion annually in direct costs. Indirect costs 
exceed $1.5 billion in lost patient earnings and $50 billion in lost productivity 45. It 
can be assumed that the financial situation for Europe is similar. A recent study in 
renal transplantation examining the economic costs associated with non-adherence 
to immunosuppressive medication showed that patients who were persistently non-
adherent experienced approximately $21,600 higher medical costs in the first three 
years after transplantation compared to patients with excellent adherence 43. 
 
Factors associated with patients’ non-adherence 
To tackle the problem of non-adherence it is crucial to know which factors 
influences a patient’s behavior, i.e., which factors are associated with patients’ non-
adherence to their prescribed medication regimens. Modifiable factors can then be 
targeted for intervention. The WHO states that adherence is a multidimensional 
phenomenon, determined by the interplay of five dimensions (see Figure 2): (1) 
patient-related factors (e.g., self-efficacy, patient’s beliefs of efficacy of medications, 
knowledge, and perceived barriers to adhere to regimens); (2) social and economic 
factors (e.g., social networks, and family functioning); (3) therapy-related factors 
(e.g., symptom distress associated with side effects of the regimen, duration of 
treatment and dose complexity); (4) condition related factors (e.g., self-care 
disability, complications, and psychiatric diagnoses such as substance abuse); and 
(5) health care system and health care team related factors 46.  
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Figure 2: Five interacting dimensions affecting adherence 46 
 
Until now, most efforts to understand the remarkably high rates of non-adherence 
have focused on patient-related, social and economic, treatment-related and 
condition-related factors 46, 47. A meta-analysis in transplantation, however, showed 
that these factors only explain a small part of the variability in non-adherence 29. 
This indicates that factors not immediately associated with the patients, but rather 
with health care providers, the system of care or the characteristics of the health 
care system as a whole might explain more variability in non-adherence than 
patient or treatment related factors. Health systems can be defined as “all 
organizations, people and actions whose primary intent is to promote, restore or 
maintain health” 48 (pg. 30). However, the influence of health system level factors on 
patients’ non-adherence to medication regimens has not been examined to the same 
extent as patient-, socio-economic-, treatment- and condition-related factors 46, 49, 50, 
an obvious gap in the literature. 
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Theoretical background 
A number of theoretical approaches have been suggested to describe factors 
influencing a person’s behavior (e.g., non-adherence) 51, 52. A common problem in 
most of these models is that they ignore the influence of contextual or 
environmental factors on patients’ medication taking behavior 52. As patient 
behavior is also influenced by factors from his or her environment, it is crucial to 
integrate these factors in order to explain behavior.  
 
System thinking and the ecological model 
To reach successful behavioral change, it is important that the patient is motivated. 
However Alemi et al. (2000) also emphasis the importance of the system in 
promoting change 51. The system refers to an individual’s environment. The process 
of accounting for the influence of various people, circumstances and historical 
choices on the behavior that is to be modified is called system thinking or ecological 
thinking 53, 54. The concept of ecology originates from public health and psychology 
55. In public health, for instance, environmental influences on diseases have been 
recognized for centuries 55. In education, it is acknowledged that predicting 
achievements of students requires not only consideration of student-related 
variables such as intelligence, motivation or self-efficacy, but also variables on the 
level of the teacher, the school, and the educational system 56, 57. In 1936, Kurt 
Lewin coined the term ecological psychology to describe the study of the influence of 
the outside environment on the person 55.  
Urie Bronfenbrenner (1979) was the first person who focused specifically on the 
multiple environmental levels influencing behavior 55, 58. In Bronfenbrenner’s model, 
behavior is viewed as being affected by, as well as effecting, multiple levels of 
environmental factors 47, 58. These different levels can be divided into patient-, the 
micro-, the meso-, and the macro levels (see Figure 3) 47. 
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Figure 3: Framework for the review: the ecological model of McLeroy et 
al. (adapted) 58 
Micro
Meso
Macro
Health Care Policy
Patient
Health care provider
Health care organization
 
 
Patient level factors comprise characteristics of the individual, such as knowledge, 
self-efficacy, and attitudes. This level also incorporates the developmental history of 
the individual 58. Micro level factors encompasses factors related to the 
interpersonal or face-to-face relationships with health care professionals, as well as 
social support 2. Examples are the quality of communication between the health 
care professionals and patients and the degree of trust the patient has in the health 
care professional. Meso level factors refer to the practice patterns or the 
characteristics of the health care organization where the patient is being treated 2. 
Examples of a health care organization characteristic or a practice pattern is the 
time available for consultation or the interventions implemented in daily clinical 
practice to enhance patients’ medication adherence. Macro level factors include 
the characteristics of the health care system in which a patient lives 2. This level 
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includes local, state, and national laws and policies related to health (e.g., 
insurance coverage and regulations on reimbursement for medication).  
As depicted in Figure 3, each of these levels interacts with and dynamically 
influences the other levels. Paying attention to all these levels of patients’ 
environment or system in promoting patients’ behavior is essential as the system 
surrounding the patient is the often reason for success or failure in changing 
behavior 51. Kidd and Altman (2000) emphasize the importance of taking 
environmental factors into account in understanding a patient’s adherence to a 
medication regimen 47. This need has also been recognized by others. In 1997, an 
expert panel of the American Heart Association recommended a multi-level 
approach to improve medication adherence 50 and more recently the American 
Society of Hypertension recommended a more ecological approach to improve 
adherence to antihypertensive medications 59. In addition, policy reports from the 
WHO and clinical practice guidelines from the National Collaborating Center for 
Primary Care and Royal College of General Practitioners (UK) strongly advocate 
using a systems approach that transcends the patient level when dealing with the 
issue of poor medication adherence 46, 60. However, as stated before, most studies to 
date have examined how characteristics of the patient and of the treatment regimen 
impact adherence. System level factors have not received much attention so far. 
Furthermore, existing evidence of the influence of these factors on medication 
adherence has not been compiled. As a consequence, the magnitude of the effect of 
different system factors on adherence is not known, a clear gap in the growing 
adherence literature. 
 
Interventions improving adherence 
Given the magnitude of non-adherence and its consequences, leading to describing 
non-adherence with medication as a major public health treat developing, 
implementing and testing the efficacy and effectiveness of preventive and restorative 
adherence interventions is a high priority on both policy, research and clinical 
agendas.  
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A number of interventions can be implemented to improve patients’ adherence. 
These interventions can target the patient, the micro level (i.e., the health care 
provider), the meso level (i.e., health care organizations’ practice patterns) and the 
macro level (i.e., health care policy) 3.  
Interventions targeting the patient can be classified as educational/cognitive, 
counseling/behavioral, or psychological/affective interventions 61. 
Educational/cognitive interventions present information individually or in a group 
setting, delivering it verbally, in written form, and/or audio-visually. 
Counseling/behavioral interventions shape and/or reinforce behavior, empowering 
patients to participate in their own care, while positively changing their skill levels 
or normal routines. Psychological/affective interventions focus on patients’ feelings 
and emotions or social relationships and social support 61. However, not all 
interventions are supported by strong evidence. A Cochrane review 23 focusing on 
the efficacy of adherence enhancing interventions and measuring both adherence 
and clinical outcomes included 70 trials testing 83 interventions for long-term 
treatments. This review showed that for long-term treatments, only 36 of the 83 
interventions were significantly associated with improvements in medication 
adherence 23, while only 25 led to improvement in at least one treatment outcome 
23. No simple and few complex interventions resulted in improvement in adherence 
and clinical outcomes 23. Interventions that were effective to improve adherence for 
long-term treatments included combinations of more convenient care, information, 
reminders, self-monitoring, reinforcement, counseling, family therapy, psychological 
therapy, crisis intervention, manual telephone follow-up, and supportive care 23. In 
a meta-analysis investigating the efficacy of interventions to improve medication 
adherence in older adults, Conn et al. (2009) reported that a number of 
interventions significantly improved medication adherence, but there were large 
differences in the effect size associate with these interventions 62. In this meta-
analysis, the intervention used most often to improve adherence was education. 
However, despite an significant improvement in knowledge, these interventions did 
not improve adherence 62. Similarly, in “Adherence to long-term therapies – evidence 
for action” the WHO states that adherence interventions at the patient level have 
usually focused on increasing knowledge, i.e., patient education 3. However, 
evidence shows that knowledge alone is not enough to establish and maintain 
strong adherence behavior 3. The most effective adherence enhancing interventions 
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targeting the patient aim to enhance self-regulation or self-management capabilities 
3.  
Interventions targeting the health care providers (micro level): Although health 
care professionals have a significant role in promoting patient adherence, only few 
studies on this topic have been reported in the literature 3. A recent meta-analysis 
focusing on physician communication and patient adherence to treatment showed 
that patients whose physician communicates poorly have a 19% higher risk for 
non-adherence compared to patients whose physician communicates well 63. The 
authors emphasis that interventions focusing on communication training for 
physicians is essential and effective 63. Training health care professionals in the use 
of patient-centered methods has been shown to improve patient satisfaction with 
treatment and may also improve patients’ medication adherence 3. Health care 
professionals trained to use goal-setting, feedback and ongoing education had 
better patient outcomes 3. 
Interventions targeting the health care organization (meso level). Interventions 
targeting the health care organization mainly focus on changing practice patterns. 
One example of changing practice patterns which has been shown to result in 
better patient outcomes is the implementation of chronic care models 3, 64. In the 
Organization for Economic Co-operation and Development (OECD) report, 
Hofmarcher and colleagues reported that the chronic care model had positive effects 
for patient adherence, patient satisfaction, and patient knowledge related to their 
condition 65. However, the extent to which chronic care models are implemented in 
practice as well as their relationship to medication adherence is not yet investigated 
in certain chronically ill patient populations such as transplant recipients. One 
reason for this lack in evidence is the absence of an instrument which has the 
capacity to assess the level of chronic illness management implemented in the 
health care organization in a valid and reliable manner. Prior to introducing 
interventions to change practice patterns, it is essential to assess the current state 
of practice. To date, there is limited research examining which interventions are 
used in daily practice to enhance patients’ medication adherence.  
Interventions targeting the health care policy (macro level): Interventions 
focusing on health care policy are “higher order interventions affecting health 
policy, organization and financing of care and quality of care programs” 3. An 
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example of an intervention focusing on the health care policy is change in medical 
insurance coverage of prescription drugs in the US. Madden and colleagues 
investigated the impact of Medicare prescription drug coverage (Part D) on cost-
related medication non-adherence 66. A principle goal of the implementation of 
Medicare Part D was to increase economic access to medications, especially among 
vulnerable poor and chronically ill populations 66. The authors demonstrated that 
the implementation of Medicare Part D was associated with a significant decrease in 
the prevalence of cost-related medication non-adherence 66. The Obama’s health 
care reform 67, which would indefinitely provide immunosuppressive drug coverage 
for kidney transplant recipients has the potential to decrease cost-related non-
adherence. Immunosuppressive drugs for kidney transplant recipients are currently 
covered for only the first 36 months post-transplant 68.  
Non-adherence to medication regimens is a prevalent problem among chronically ill 
patients and is influenced by a number of factors. However, to-date research on 
adherence has focused primarily on patient-related factors and those factors failed 
to explain the broad variability in non-adherence rates. As behavior is influenced by 
the system in which the patient lives, it is crucial to investigate the role of system 
factors in explaining adherence. A framework which can be used in explaining the 
influence of system factors on behavior is the ecological model. However, system 
factors have not received much attention in explaining medication adherence, and 
their influence is unclear. The systematic review which is part of this dissertation 
summarizes current evidence about the role of individual system factors at the 
health care provider, health care organization, and policy levels in association with 
medication non-adherence.  
Also in view of interventions to improve adherence, a system perspective is needed. 
Based on this perspective, interventions will target the patient, the health care 
provider, the health care organization and health related policies. Today most 
research has focused on patient-centered interventions designed to improve 
adherence. Even within this domain, our understanding of the interventions that 
health care professionals use with their patients is limited. This dissertation 
examined health care providers’ reported patient-centered interventions utilized to 
improve adherence. 
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The Chronic Care Model, developed by Wagner and colleagues and revised by the 
WHO emphasizes the importance of a comprehensive system focused approach to 
improving clinical outcomes in persons suffering of chronic disorders. One of the 
challenges in doing research on implementation of the chronic care model is the 
lack of a valid and reliable instrument that can measure the extent to which the 
model has been implemented in health care organizations or to examine the impact 
of interventions designed to integrate the model into practice. Another study in this 
dissertation describes the development and initial psychometric testing of an 
instrument developed to measure health care professionals’ perceptions regarding 
the implementation of the chronic care model in their clinical setting. 
In summary this dissertation will address gaps in the literature by: 
• Presenting a systematic review of the evidence describing the association 
between health care system factors and medication adherence in two 
chronically ill patient populations, people living with HIV and transplant 
patients (Chapter 3).  
• Providing an overview of commonly used statistical measures for expressing 
the strength of the relationships between variables such as system factors and 
adherence behaviour (Chapter 4). 
• Describing the adherence assessment strategies and adherence enhancing 
interventions routinely used by health care providers in caring for 
cardiovascular patients (Chapter 5).  
• Examining adherence assessment strategies as well as the interventions health 
care professionals report using to improve adherence in transplant patients, as 
well as their perceptions about the effectiveness the interventions (Chapter 6).  
• Describing the development of an instrument designed to assess the level of 
chronic care implemented in transplant centers as well as its content validity 
and inter-rater reliability (Chapter 7). 
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Study aims 
Given the gaps in the evidence regarding the influence of system level factors and 
medication adherence in chronically ill patient populations, the aims of this 
research were following:  
1) To identify and summarize quantitative studies addressing factors at the 
micro-, meso-, and macro levels of the health care system that are associated 
with non-adherence to medication regimens in individuals with HIV and organ 
transplant recipients (Chapter 3). 
2) To provide an overview of the most common used measures of effect sizes and 
how these are calculated (Chapter 4). 
3) To assess the strategies cardiovascular nurses and allied health professionals 
utilize to assess patients’ adherence to their medication regimens, and to 
assess the strategies they use to enhance their medication adherence (i.e., 
educational/cognitive, counseling/behavioral, or psychological/affective 
techniques) (Chapter 5). 
4) To identify which strategies transplant health care professionals utilize to 
assess their patients’ medication adherence, to classify the medication 
adherence enhancing interventions they use (i.e., educational/cognitive, 
counseling/behavioral, or psychological/affective) and to assess how they 
perceive their chosen interventions’ effectiveness (Chapter 6). 
5) To describe the development, the content validity assessment as well as the 
inter-rater reliability assessment of the Chronic Illness Management 
Implementation - Building Research Initiative Group: Chronic Illness 
Management and Adherence in Transplantation (CIMI-BRIGHT) instrument 
(Chapter 7). 
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Abstract 
Purpose: Medication adherence is influenced not only by characteristics of the 
individual patient, but also by the micro-, meso-, and macro levels of the health 
care system. However, most research focuses on patient level factors, which offer 
limited explanation for medication adherence’s broad variability. The aim of this 
systematic review is to summarize evidence from quantitative studies examining the 
relationship between micro-, meso-, and macro level health care system factors and 
medication adherence in organ transplant (Tx) recipients and patients living with 
HIV – two populations for whom strict medication adherence is essential in 
preventing poor outcomes. 
Methods and Materials: Searches were conducted in PubMed, EMBASE and 
Cinahl databases. Quantitative studies published in English between January 1999 
and December 2009 were included. To be eligible, studies had to investigate 
medication adherence as an outcome, describe the adherence measurement method 
used, and report the relationship between one or more micro-, meso-, and/or macro 
level factors and medication adherence in post-Tx or HIV-positive adults. 
Results: Electronic searches returned 5,341 citations. Seven articles in the Tx 
literature and 57 in the HIV literature met all inclusion criteria. For most of the 
factors examined, the relationship to medication adherence was not consistent 
across studies. The micro level factor most consistently related to adherence was 
trust in the health care provider. At the meso level, it was drug access/dispensing. 
Cost-related characteristics (macro level), including medication cost, were 
significantly associated with adherence 50% of the times they were studied. 
Conclusions: While the findings of studies examining the relationship between the 
system level factors and medication adherence are inconsistent, this systematic 
review provides preliminary evidence to suggest that certain system level factors 
may contribute to the variability in medication adherence. Due to the limited ability 
of patient characteristics to explain adherence, it is critical to continue to explore 
the role of system level factors in explaining medication adherence. 
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Introduction 
Adherence to a prescribed medication regimen is influenced not only by 
characteristics of the individual patient, but also by system level factors in that 
person’s environment. These determinants can be classified into three levels: micro 
(i.e., factors related to the health care professional, social support), meso (i.e., 
factors related to the health care organization or setting in which care is received) 
and macro (i.e., health care system factors) 1. Understanding medication adherence 
requires awareness of all three levels 2, 3. To date, however, most adherence 
research has focused on patient level factors (patient, socio-demographic, condition 
and treatment related matters) with insufficient consideration of those at other 
levels. Moreover, we are unaware of any previous systematic reviews examining the 
relationship between such factors and medication adherence. Therefore, our goal 
was to conduct a systematic review with the aim to summarize evidence from 
quantitative studies examining the relationship between micro-, meso-, and macro 
level health care system factors and medication adherence in organ transplant 
recipients and patients living with the human immunodeficiency virus (HIV). 
 
Background 
The World Health Organization (WHO) defines adherence (also called compliance) to 
long-term therapy as “the extent to which a person’s behavior (i.e., taking 
medication) corresponds with the agreed recommendations of a health care 
provider” 4 (pg. 3). Although adherence is a fundamental prerequisite for a 
prescribed treatment to be effective, non-adherence to medication regimens in 
chronically ill patient populations is very common, with prevalence rates ranging 
from 22% to 57% 5, 6. The consequences can include poorer treatment outcomes 
(including hastened mortality), higher hospitalization rates and increased health 
care costs 7, 8.  
Despite its negative consequences, medication non-adherence in chronically ill 
patients remains poorly understood. Until now, most efforts to understand it have 
focused on characteristics of the individual patient (e.g., self-efficacy, knowledge, 
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intentions), the treatment regimen (e.g., regimen complexity, duration of treatment), 
socio-economic and demographic related factors (e.g., age, race, marital status), 
along with condition related factors (e.g., depression, number of co-morbidities) 4, 9. 
Factors related to health care provider, health care organization, and the health 
care system as a whole have received far less attention 2, 4, 10.  
This imbalance is well recognized. To tackle medication adherence issues, WHO 
policy reports and clinical practice guidelines published by the Royal College of 
General Practitioners’ National Collaborating Center for Primary Care strongly 
advocate system-oriented approaches beyond the patient level 4, 11. In 1997, an 
American Heart Association expert panel recommended a multi-level approach to 
improve adherence 2 and more recently the American Society of Hypertension 
recommended this approach to improve adherence with antihypertensive 
medication 12.  
Importantly, a meta-analysis in transplantation by Dew et al. (2007) suggests that 
system level factors have an impact on adherence. In that report, the authors 
observed that North American transplant patients had higher rates of non-
adherence than European ones, a difference to which they suggested health care 
system factors may contribute 13. A seven-country study investigating practice 
patterns in hemodialysis centers found that center characteristics (e.g., size, 
percentage of highly trained staff) and the country where the dialysis center was 
located were related to dialysis non-adherence (i.e., failure to attend dialysis 
sessions) 14, 15. Schoen et al. (2009) conducted an eleven country survey of primary 
care doctors, finding wide variations at a national level in practice systems, 
incentives, perceptions of access to care, use of health information technology and 
programs to improve quality 16. In a survey the following year, Schoen et al. found 
that the eleven countries surveyed also had differing systems of health care 
coverage, leading to significant differences in access to care, cost burdens and 
problems with health care insurance 17. However, they did not investigate the 
influence of these system factors on medication adherence. In the Swiss HIV cohort 
study, which did focus on medication adherence, patient followed-up centers, a 
meso level factor, accounted for significant variability in adherence rates 18. A meta-
analysis focusing on patient treatment adherence and physician communication 
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across diverse illness populations and settings found that the risk of non-adherence 
was 19% higher when communication with physicians was poor 19. 
The aim of this systematic review is to identify and summarize quantitative studies 
addressing factors at the micro-, meso-, and macro levels of the health care system 
that are associated with adherence to medication regimens in individuals with HIV 
and organ Tx recipients. These populations were selected because both conditions 
require complex, lifelong medication treatment. Furthermore, medications are life-
saving in both populations. In contrast to other chronically ill populations, even 
minor deviations from the prescribed regimen can seriously impact these patients’ 
clinical outcomes. In transplantation, for instance, non-adherence is associated 
with poor kidney function, acute rejection, and graft loss 20-23. In HIV, even slight 
deviations of the prescribed anti-retroviral treatment regimen (e.g. < 95%) are 
associated with poorer virological outcomes including higher viral loads, lower CD4 
cell counts and the development of HIV drug resistance 24-28. 
 
Conceptual framework for a multi-level approach to a system 
An approach whereby several levels of a system are considered when explaining a 
phenomenon (e.g., adherence) is called an ecological perspective 1, 9 (see Figure 1). 
From an ecological perspective, a patient’s activities overlap numerous settings – 
within self, within family, with friends, at work, during recreational activities, in the 
health care setting and within society – each of which influences his or her 
behavior. As depicted in Figure 1, each level of contact interacts with and 
dynamically influences the others. When the patient-, micro-, meso-, and macro 
level factors work effectively within and among themselves, the system is efficient 
and effective 1.  
Micro level 
The micro level encompasses factors related both to interpersonal or face-to-face 
relationships with health care providers and to social support 29, e.g., the degree of 
trust the patient has in the health care provider and the overall quality of the 
patient-provider relationship. For the purpose of this review, we focused on micro 
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level factors related to professional relationships, and not to personal social support 
factors, the significance of which was confirmed, regarding treatment adherence, in 
DiMatteo’s 2004 meta-analysis of 122 studies 30.  
Meso level 
The meso level encompasses the characteristics of the health care facility where the 
patient is being treated 29 (e.g., time available for consultation, treatment team skill 
mix).  
Macro level 
The macro level includes the characteristics of the larger health care system and 
policy that influence how the patient uses the system 29. These include local, state, 
and national legislation and policies related to health (e.g., insurance coverage and 
regulations regarding reimbursement for medication). 
Recognizing and understanding factors related to medication adherence are 
essential to the development of adherence-enhancing strategies, the identification of 
patients at risk of non-adherence and the design of interventions to target 
modifiable factors. As each style of intervention targeting medication adherence has 
significant weaknesses, the most effective systems have combined a number of 
approaches on the different levels 6, 31. Such combinations are recommended by 
policy reports and clinical guidelines 4, 11. However, to implement interventions 
effectively, it is essential to know which health care system factors at each level are 
associated with adherence to medication regimens and which explain the most 
variability in medication adherence.  
 
Methods 
We conducted systematic electronic literature searches of the PubMed, EMBASE 
and Cinahl databases to identify relevant studies published in English from 
January 1999 to December 2009. For the PubMed database, for example, our 
search terms for articles on transplant recipients were: (complian* OR 
noncomplian* OR non-complian* OR adheren* OR nonadheren* OR non-adheren* 
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OR concordance OR non-concordance OR concord* OR non-concord*) AND 
transpl*. For the HIV population: (complian* OR noncomplian* OR non-complian* 
OR adheren* OR nonadheren* OR non-adheren* OR concordance OR non-
concordance OR concord* OR non-concord*) AND HIV. Table 1 shows the specific 
search strategies utilized for each database. These strategies were kept deliberately 
broad as there is a wide use of terminology in the literature and we wanted to 
identify as many studies as possible. 
We included studies that met the following eligibility criteria: 1) quantitative 
analysis; 2) publication between January 1999 and December 2009; 3) publication 
in English; 4) adult samples (≥ 18 years old) who were Tx recipients or had HIV; 5) 
use of medication adherence as an outcome; 6) description of adherence 
measurement methods; and 7) examination and reporting on relationships between 
micro-, meso-, and/or macro level health care system characteristics and 
medication adherence. Studies were excluded if 1) they focused on treatment 
refusal (the medications was never prescribed or initiated); 2) they included 
institutionalized subjects and did not report findings separately for subjects who 
were not institutionalized; 3) their participants suffered from psychiatric disorders; 
4) they examined a group of factors including those at the patient level but did not 
report findings separately for the micro-, meso-, and/or macro level factors; 5) they 
used qualitative designs; 6) they described intervention studies examining only the 
relationships between the determinants and adherence following an intervention; or 
7) they focused on social support. If two or more studies involved the same sample, 
only one study was included in this review. Decisions on which studies to include 
were based on the number of system factors examined. We selected those 
examining the greatest numbers of system factors.   
The reference lists of retrieved studies were also examined to identify additional 
relevant studies. Using a review protocol, a single researcher (LB) reviewed all titles 
and abstracts to determine their eligibility. If any uncertainty existed, a second 
researcher (SE) was consulted. Next, both researchers (LB & SE) read and evaluated 
the full text of the studies corresponding to the selected abstracts.  
To extract data from the articles, we developed a data extraction sheet. The 
following information was extracted: design, sample characteristics, definition of 
adherence, factor(s) examined, and results. One author (LB) reviewed the extracted 
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data from the included studies; a second author checked the extracted data (SE). If 
disagreement occurred, it was resolved by discussion between the two authors. 
Quality assessment of studies included in a systematic review is essential to ensure 
that the original research is systematically appraised and evaluated 32. To assess 
the quality of studies included in this review, we adapted a criteria-based checklist 
used in prior systematic reviews 33, 34. The result was a list of 15 categorical 
questions (see Figure 3). Using this checklist, two authors (LB & SE) independently 
evaluated all included studies. Any disagreements were resolved through 
discussion. 
Data analysis 
Adherence definitions, measurements and reporting methods varied across the 
studies. Therefore, meta-analysis was not performed. Odds ratios (OR) and their 
95% confidence intervals (CI) were reported or calculated (Tables 3, 4 and 5) as 
measures of the strength of the relationship (effect size) between the micro-, meso- 
and macro level factors and adherence in this systematic review. When studies 
reported an OR and CI for non-adherence, it was converted into an OR and CI for 
adherence. If OR were not reported in the article but sufficient data were available, 
an OR and a 95% CI were calculated 35. If data were insufficient, we contacted the 
authors and asked them to provide data which would allow us to calculate an OR 
with a 95% CI. In cases where only p-values were available, a Cohen’s d was 
calculated, then converted to an approximate OR using the Effect Size Generator – 
Professional Edition version 4.1 software package (Melbourne, Australia). Chi-
square tests of independence were utilized to examine the relationship between 
study characteristics (patient population, study design, continent on which the 
study was conducted, method of measuring adherence, method of analysis and 
system factors examined) and reporting a significant relationship between a system 
factor and adherence. 
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Results  
Study selection 
The electronic searches of the three databases returned 5,341 citations (see Figure 
2). After eliminating duplicates (HIV n= 515; Tx n= 512), and including additional 
records identified through other sources, 4,370 citations were screened for eligibility 
by title and abstract. Of the 4,370 citations, 258 articles were selected for full-text 
review. Of these, 7 articles in the transplant literature and 58 articles in the HIV 
literature met all eligibility criteria. One 36 of the 58 HIV studies was, however, 
excluded because of inconsistencies in the results section and the tables. Our 
attempts to contact the corresponding author to resolve these inconsistencies were 
unsuccessful.  
 
Study characteristics 
A summary of the characteristics of the included studies is shown in Table 2. 
Almost half of the studies (n= 29; 45.3%) were conducted in North America; just 
over one-fifth (21.9%) took place in Europe. Prospective designs were used in 23.4% 
of the studies. A cross-sectional or retrospective design was used in 76.6% of the 
studies. Most studies (76.6%) used patient self-reports (either interviews or self-
administered questionnaires) to assess medication adherence. Four studies in the 
HIV population (7%) and none in the transplant population used multiple methods 
to assess adherence. Of the studies using multiple methods, we used the method 
that detected the highest prevalence of non-adherence. The studies’ adherence 
assessment periods varied widely, ranging from “ever” to the previous 2 days. The 
most prevalent time periods were the previous 4 weeks (20.3%), followed by the 
previous 3 days (14.1%). Most of the included HIV studies focused on micro level 
factors, while the transplant studies focused more on macro level factors. 
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Quality assessment 
None of the studies fulfilled all 15 of the defined quality appraisal criteria. In HIV, 
the total quality score ranged from 7 (2 studies) to 14 (7 studies) (Mean= 11.65; SD= 
1.75). For HIV studies, the quality scores ranged from 6 (one study) to 14 (3 studies) 
(Mean= 11.86; SD= 3.13). Almost all articles provided a definition of adherence (see 
Figure 3). The quality criteria fulfilled by the fewest studies was “information about 
psychometric properties of used instruments”. No studies were excluded on the 
basis of the quality appraisal. 
Micro level factors (health care provider related factors) 
The relationship between micro level factors and adherence was analyzed 
multivariately 46 times across 31 studies, and 17 times bivariately in 5 studies (see 
Table 3). The majority of these studies (56.5% of multivariately and 76.5% of 
bivariately) reported that the micro level factor examined was not significantly 
related to adherence. The factor most commonly examined was the patient-health 
care provider relationship or some aspect of it (e.g., communication, trust, 
satisfaction or quality). Of the 56 times where it was examined, 23 (41.1%) showed 
a significant positive relationship between positive patient-provider relationships 
and adherence. The specific micro level factor most consistently related to 
adherence was trust in the health care provider (examined in 8 studies), which was 
significantly associated with higher adherence in 62.5% of the studies that assessed 
it. The reported or calculated effect sizes (OR and 95% CI) between micro level 
factors and adherence are presented in Table 3. Effect sizes were not reported and 
could not be calculated for 10 of the relationships examined. None of these 
relationships were statistically significant.  
 
Meso level factors 
The relationship between meso level factors and adherence was examined 
multivariately 24 times across 18 studies and bivariately in two (see Table 4). The 
factors examined were drug access/dispensing related (n= 4 studies multivariately, 
2 bivariately), center differences (n= 7 studies multivariately), visit-related 
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characteristics (n= 5 studies multivariately), specialty care/case managements (n= 
4 studies multivariately), clinic-related factors (e.g., satisfaction, quality of care, or 
access) (n= 4 studies multivariately). Drug access or the method of dispensing the 
drugs was the only meso level factor consistently related to adherence, with 75% of 
the studies that examined it multivariately and both of studies that examined it 
bivariately reporting significant relationships. Treatment center was significantly 
related to adherence in 28.6% of the studies examining it multivariately. In most of 
the studies, the remaining meso level factors were not significantly related to 
adherence. In all of the studies with non-significant findings, the meso level factor 
was not significantly related to adherence bivariately and therefore not examined 
multivariately. Effect sizes were not reported and could not be calculated for eight of 
the relationships examined. None of the relationships were statistically significant.  
Macro level factors 
The relationship between adherence and a macro level factor was examined 
multivariately 26 times in 21 studies and bivariately 4 times in 3 studies (see Table 
5). The factor examined most frequently was cost related characteristics (e.g., type 
of health care coverage, cost to patient for medications). In half (50%) of the cases 
where it was examined multivariately, no significant relationship was found 
between this factor and adherence; however, it was significantly related to 
adherence in two of the three studies that tested for that relationship bivariately. 
The higher the cost for the patient, the lower the adherence rates. Transportation 
related issues were examined multivariately in 5 studies, none of which found 
significant relationships to adherence. One study examined the relationship 
between the continent and/or country where transplant care was delivered and 
adherence, with multivariate analysis showing a significant relationship for three of 
their four comparisons (i.e., the U.S. vs. Europe; the Netherlands vs. Belgium; and 
Switzerland vs. Belgium). Another study only examined the relationship between 
the country where the transplant occurred and adherence bivariately and reported 
no significant relationship. In seven (22.6%) of the 31 cases where a macro level 
factor’s relationship to adherence was examined multivariately, the OR and/or 95% 
CI were not reported and could not be calculated. None of these seven analyses 
found a significant relationship between the examined macro level factor and 
adherence.  
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Relationships between study characteristics and significant findings 
We analyzed for relationships between 5 study characteristics – patient population 
(HIV/AIDS or transplant), study design (prospective vs. cross-sectional and 
retrospective), continent on which the study was conducted (North America, Europe 
or other), method of adherence measurement (self-report or other [e.g., pill count, 
electronic monitor, blood assay or a combination of methods]), method of analysis 
(multivariate or bivariate), and the level of the systems factor examined (micro, 
meso or macro) – and whether a significant relationship was reported between 
systems factors and adherence. Although study design approached statistical 
significance, none of the study characteristics were significantly related to the 
likelihood of finding a significant relationship. Statistically significant relationships 
were reported in 43.0% of cross-sectional or retrospective studies compared to 
24.0% of prospective studies (p= 0.08). 
 
Discussion 
To our knowledge, this is the first systematic review of quantitative studies 
examining the association between micro-, meso-, and macro level health care 
system factors (see Figure 1) and medication adherence in any population. Overall, 
the relationships between the factors examined and adherence were inconsistent 
across the studies, with the majority the relations not being statistically significant. 
In an attempt to explain the inconsistent findings across the studies, we examined 
the likelihood of significant relations being reported in relation to a number of study 
characteristics (study design, patient population, method of measuring adherence, 
method of analysis and the level of system factor examined). Of these, the only 
characteristic that approached statistical significance was study design (p= 0.08) 
with almost twice as many of the relationships examined in cross-sectional or 
retrospective studies reported as significant than those examined in prospective 
studies. In this review, however, the proportion of factors examined in prospectively 
designed studies was relatively small (21.2%). It is possible that other study 
characteristics not examined in this review (e.g., differences in the definition of 
adherence or the period over which it was measured) can explain the inter-study 
variability. The need for a consistent definition of adherence was recognized by the 
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Ascertaining Barriers for Compliance (ABC) project, a multinational group of 
researchers and clinicians in adherence research. This group is currently working 
to achieve international consensus on the terminology used to describe adherence 
and related concepts, with the immediate goal of standardizing the way adherence 
is defined, measured and reported 37. 
Major variability also occurred in the definitions and measurements of the various 
micro-, meso-, and macro level factors examined by the studies included in this 
systematic review. In this review, the factors most consistently related to adherence 
were drug access (i.e., the better the drug accessibility, the better the adherence 
rates) and the method of dispensing drugs (e.g., dispensing at the physician’s office 
or off-site). All of the studies examining the relationship between drug accessibility 
and the dispensing of drugs were conducted in the HIV population.  
The only other factor related to adherence in more than half of the studies was trust 
in the health care provider. The literature contains a number of definitions of trust 
38-40; however, according to Hall et al. (2001), most emphasize “the optimistic 
acceptance of a vulnerable situation in which the truster believes the trustee will 
care for the truster’s interests” 39 (pg. 615). Still, trust in the health care provider is 
only part of the patient-provider relationship. When the association between the 
overall patient-provider relationship and adherence was examined, it was only 
significant in 41.1% of cases.  
Another aspect of the patient-provider relationship is communication. Few of the 
studies in our review specifically examined provider–patient communication. Again, 
the findings were mixed, with most reporting no significant relation to adherence. In 
contrast, a recent meta-analysis by Zolnierek & Dimatteo, focusing on physician–
patient communication and its association with adherence to treatment regimens 
for varying medical conditions, concluded that physician communication is 
significantly positively associated with adherence 19. More specifically, that meta-
analysis linked poor physician communication with a 19% higher risk of non-
adherence.  Possible explanations for the inconsistency between our findings and 
those of Zolnierek and Dimatteo include the small number of studies in our review 
that specifically examined this factor, as well as the methods used to assess 
communication quality. Future studies should consider using a combination of 
methods (e.g., patient report and direct observation) to assess patient-provider 
Chapter 3: Systematic review    
 
 
 
52 
communication. Our results suggest that it is not the overall relationship with the 
health care provider, but rather specific aspects of this relationship (such as trust 
in the health care provider) that are more important predictors of adherence. 
Although the continent and country where patients were followed-up was 
investigated multivariately in only one study, this factor seems to influence non-
adherence. This is consistent with the findings of Dew et al. who reported that non-
adherence rates were higher in North-American studies than those from Europe 
and other continents 13. Denhaerynck et al. 41, 42 suggest that the differences in 
adherence found between countries or continents could be based on differences in 
transcultural factors (e.g., illness beliefs) or differences in health care system 
characteristics such as health insurance coverage and regulations regarding 
reimbursement for drugs and medical treatment. In the current systematic review, 
however, two-thirds of the studies examining cost related factors multivariately 
found no significant relationship with adherence. 
In our systematic review, 3 of the 6 studies examining medication-related costs 
(50%) reported a significant relationship to adherence. Of these, 2 showed that 
receiving anti-retroviral therapy (ART) at low or no cost increased the likelihood of 
adherence. The third 43 showed the opposite – i.e., that receiving the medication for 
free was associated with lower adherence. The study’s investigators speculated that 
this finding may have occurred because patients who paid for their medications 
received more counseling and/or had more advanced disease at the time of 
treatment initiation than those who received their medication at no cost 43. 
Consequently, medication cost may have served as a proxy for other system or 
disease-related factors. In a different patient population, a study of hemodialysis 
patients in 12 countries reported that medication non-adherence was associated 
with patients reporting any out-of-pocket costs (R2= 0.298) and their average out-of-
pocket costs (R2= 0.396) 44. Another recent study, examining the insurance related 
experiences of adults in eleven countries in Europe, North-America, Australia and 
New Zealand, found significant differences in access, cost burdens, and problems 
with health insurance associated with insurance design 17. 
No other factors examined in more than three studies were consistently related to 
medication adherence. One of the issues we faced in this systematic review was that 
most of the factors showing a significant relationship to adherence were examined 
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in a low proportion of studies, which measured those factors in diverse ways. Visit-
related factors, for example, were examined as more than 6 months interval 
between visits in one study, as the number of visits a month in another and as 
having scheduled appointments in a third study. In addition, a number of factors 
were only examined in a small number of studies. Such limitations made it difficult 
to draw confident conclusions about many of the factors’ impacts on medication 
adherence.  
Strengths, Limitations, and Research Recommendations 
To the best of our knowledge this is the first systematic review comprehensively 
examine the relationship between health care system factors and medication 
adherence. This review points out the methodological challenges inherent in 
comparing findings across studies using difference methods. It identifies the need 
for additional research to understand the role of health care system factors in 
medication adherence.  
This systematic review has several limitations. The first is that only articles in 
English were included. As a result, relevant studies may have been missed. Second, 
the review of citations to select articles for review was conducted by only one 
individual. Despite the careful procedure followed in searching the literature, it is 
possible that eligible citations were overlooked. A further limitation is that the gray 
literature (i.e., studies that are unpublished or not easily located) was not searched. 
Another is that some factors were not clearly defined in the studies, e.g., scheduled 
vs. non-scheduled appointments. Further, we limited this review to two chronically 
ill patient populations.  
Because the many methodological differences across the reviewed studies, we 
strongly recommend conducting a large multi-continental, multi-country, multi-
center study to test for associations between factors at the micro-, meso-, and 
macro level and non-adherence to medication regimens. Another recommendation 
for further research and its dissemination is that authors of future studies should 
report the magnitude of the various system factors’ effects on adherence. 
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Conclusion 
Most reviewed studies on system factors associated with adherence in the HIV and 
organ transplant populations were conducted in the HIV population, with little 
research in transplant populations. While the relationships between the examined 
system level factors and adherence are inconsistent, this systematic review provides 
preliminary evidence that at least two of these factors (trust in the health care 
provider and method of dispensing medications) are important contributors to 
adherence. Further, considering the limited variability of patient level explanations 
of non-adherence, it is critical to further explore system level relationships.  
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Figure 1: Framework for the review: the ecological model of McLeroy et 
al. (adapted) 1. 
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Table 1: Search strategy 
Database 
Population 
Search terms 
Number of 
hits 
PubMed   
HIV (complian* OR noncomplian* OR non-
complian* OR adheren* OR 
nonadheren* OR non-adheren* OR 
concordance OR non-concordance OR 
concord* OR non-concord*) AND HIV 
2406 
Transplantation (complian* OR noncomplian* OR non-
complian* OR adheren* OR 
nonadheren* OR non-adheren* OR 
concordance OR non-concordance OR 
concord* OR non-concord*) AND 
transpl* 
1060 
CINAHL   
HIV (complian* OR noncomplian* OR non-
complian* OR adheren* OR 
nonadheren* OR non-adheren* OR 
concordance OR non-concordance OR 
concord* OR non-concord*) AND HIV 
837 
Transplantation (complian* OR noncomplian* OR non-
complian* OR adheren* OR 
nonadheren* OR non-adheren* OR 
concordance OR non-concordance OR 
concord* OR non-concord*) AND 
transpl* 
130 
EMBASE   
HIV 'hiv'/mj AND ('compliance' OR 
compliant OR noncompliance OR 
noncompliant OR 'non compliance' OR 
'non compliant' OR adherence OR 
66 
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adherent OR nonadherence OR 
nonadherent OR 'non adherence' OR 
'non adherent' OR concordance OR 
'non concordance' OR concordant OR 
'non concordant') 
Transplantation ('transplantation'/mj OR 'transplant') 
AND ('compliance' OR compliant OR 
noncompliance OR noncompliant OR 
'non compliance' OR 'non compliant' 
OR adherence OR adherent OR 
nonadherence OR nonadherent OR 
'non adherence' OR 'non adherent' OR 
concordance OR 'non concordance' OR 
concordant OR 'non concordant') 
842 
Total  5,341 
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Figure 2: Flow chart of study selection process
Records identified through 
database searching  
(n = 5,341) 
Additional records identified 
through other sources  
(n = 56) 
Records after duplicates removed  
(n = 4,370) 
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(n = 4,370) 
Records excluded 
(n = 4,112) 
Full-text articles 
assessed for eligibility  
(n = 258) 
Full-text articles 
excluded, with reasons 
(n = 194) 
-Not (predictors of) adherence as 
outcome: n = 81 
-Not micro-, meso-, or macro 
level factor: n = 74 
-Not transplant or HIV population: 
n = 8 
-Not relevant design: n = 19 
-Paediatric sample: n = 2 
-Sample with psychiatric disorder: 
n = 3 
-Institutionalized sample: n = 5 
-Unclear results: n = 1 
     
 
Studies included in 
quantitative synthesis  
(n = 64) 
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Table 2: Summary of characteristics of the studies 
Study location HIV (n= 57) 
n (%) 
Tx (n= 7)  
n (%) 
Total N= 64 
n (%) 
North-America 
Europe 
Africa 
Asia 
South-America 
Combined (North-America & 
Europe) 
26 (45.6) 
12 (21.1) 
9 (15.8) 
6 (10.5) 
4 (7.0) 
0 
3 (42.9) 
2 (28.6) 
0 
1 (14.3) 
0 
1 (14.3) 
29 (45.3) 
14 (21.9) 
9 (14.1) 
7 (10.9) 
4 (6.3) 
1 (1.6) 
Study design    
Cross-sectional/retrospective 
Prospective 
45 (78.9) 
12 (21.1) 
4 (57.1) 
3 (42.9) 
49 (76.6) 
15 (23.4) 
Method of adherence assessment    
Self-report 
Pharmacy refill 
Pill count 
Electronic monitoring 
Collateral report 
Blood levels 
Multiple 
46 (80.7) 
4 (7.0) 
2 (3.5) 
1 (1.8) 
0 
0 
4 (7.0) 
3 (42.9) 
0 
0 
2 (28.6) 
1 (14.3) 
1 (14.3) 
0 
49 (76.6) 
4 (6.3) 
2 (3.1) 
3 (4.7) 
1 (1.6) 
1 (1.6) 
4 (6.3) 
System level    
Micro  
Meso  
Macro  
Micro and meso 
Meso and macro  
Micro and macro 
Micro, meso and macro level 
28 (49.1) 
5 (8.8) 
11 (19.3) 
7 (12.3) 
3 (5.3) 
1 (1.8) 
2 (3.5) 
1 (14.3) 
2 (28.6) 
4 (57.1) 
0 
0 
0  
0 
29 (45.3) 
7 (11.0) 
15 (23.4) 
7 (11.0) 
3 (4.7) 
1 (1.6) 
2 (3.1) 
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Figure 3: Quality appraisal of studies 
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Table 3: Studies Examining the Relationship between Micro Level Systems Factors and Adherence 
Study/Patient 
Population 
Design/Sample/ Definition of 
Adherence/Non-Adherence 
Micro Level 
Factors 
Results Adherence Effect 
Size 
Mulltivariate Analysis 
Beach, Keruly, & 
Moore, 2006 
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 1743 (38.8% women); duration of 
ART not reported 
Non-adherence= not missed 1 dose of 
medication during the past 3 days as 
measured by self-report 
Adherence rate= 74.9% 
Quality of the 
patient-provider 
relationship 
OR= 1.33 (95% CI 1.02, 
1.72) p= 0.034 
Multivariate OR: 1.33 
(1.02, 1.72) 
 
 
Bonolo Pde, 
Cesar, Acurcio, 
Ceccato, de 
Padua, Alvares et 
al., 2005  
HIV/AIDS 
Design: Prospective 
Setting: Brazil 
Sample: 306 (35% women); newly initiated 
ART 
Non-adherence= < 95% of prescribed 
number of doses taken during previous 3 
days as measured by self-report 
Adherence rate= 63.1% 
Counseling about 
ART 
Not significantly related to 
adherence bivariately; not 
included in multivariate 
analysis 
Bivariate hazards ratio for 
non-adherence: 1.33 (95% 
CI 0.9, 1.97) 
Unable to calculate 
Carballo, 
Cadarso-Suarez, 
Carrera, Fraga, 
de la Fuente, 
Ocampo et al., 
2004  
HIV/AIDS 
Design: Cross-sectional 
Setting: Spain 
Sample: 235 (28.5% women); on ART > 3 
months 
Adherence= > 95% during the prior 3 
months; measured by self-report 
Adherence rate= 55.7% 
Satisfaction with 
health care provider 
Intermediate to high 
satisfaction vs low: OR= 
2.07 (95% CI 1.07, 3.98), 
p= 0.03 
Multivariate OR: 2.07 
(1.07, 3.98) 
Catz, Heckman, 
Kochman, & 
DiMarco, 2001 
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 84 (20% women); > 45y older 
Adherence= no skipped doses in the past 
week as measured by self-report 
Adherence rate= 69% 
Relationship with 
physician 
OR= 2.18 (95% CI 1.19, 
3.96), p= 0.01 
Multivariate OR: 2.18 
(1.19, 3.96) 
Delgado, Heath, 
Yip, Marion, 
Design: Prospective 
Setting: Canada 
Physicians' HIV-
related experience 
OR= 1.27 (95% CI: 1.13, 
1.42; p< 0.001) 
Multivariate OR: 1.27 
(1.13, 1.42) 
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Alfonso, 
Montaner et al., 
2003 
HIV/AIDS 
Sample: 886 (13.5% women); ART naive at 
enrolment and followed for the first  12 
months of therapy 
Adherence= > 95% of the time during the 1 
year of therapy; measured by prescription 
refill rates 
Adherence rate= 55.9% 
(per 100 HIV-
positive patients 
treated) 
 
Durante, Bova, 
Fennie, Danvers, 
Holness, Burgess 
et al., 2003 
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 63 women; duration of ART not 
reported 
Adherence= 100% adherence during the 
previous 3 days; measured by self-report 
Adherence rate= 67% 
Trust in physician  
 
Not significantly related to 
adherence bivariately; not 
included in multivariate 
analysis 
Bivariate analysis: Wilcoxin 
Z= -0.83, p= 0.41 
Estimated bivariate 
OR=0.67 (0.26, 1.74) 
Eholie, Tanon, 
Polneau, 
Ouiminga, 
Djadji, Kangah-
Koffi et al., 2007 
HIV/ADIS 
Design: Cross-sectional 
Setting: Côte d’Ivoire 
Sample: 308 (53% women); on ART > 1 
month 
Adherence= < 90% over the previous 7 days 
measured by self-report 
Adherence rate= 24% 
Previous counseling 
about ART  
 
Not significantly related to 
adherence bivariately; not 
included in multivariate 
analysis 
Bivariate results no 
reported. 
Unable to calculate 
Gauchet, 
Tarquinio, & 
Fischer, 2007 
HIV/AIDS 
 
Design: Cross-sectional 
Setting: France 
Sample: 127 (22% women); duration of ART 
> 2 months 
Adherence= measured as a continuous 
variable measured by a self-report scale 
Adherence rate= not reported 
Confidence in 
physician 
B= 0.30; p= 0.02 Unable to calculate 
Gremigni, 
Bacchi, Turrini, 
Cappelli, 
Albertazzi, & 
Bitti, 2007  
Transplant 
Recipients 
Design: Cross-sectional 
Setting: Italy 
Sample: 34 renal transplant recipients (62% 
women) 
> 12 months post-transplant (mean= 6 yrs) 
Adherence= taking medications exactly as 
prescribed during the past month; measured 
by self-report. 
Adherence rate= 76%   
Clarity of physician 
instructions 
 
Trust in health care 
provider 
Both factors not significant 
related to adherence in 
multivariate analysis (p 
value not reported) 
Unable to calculate 
 
 
Unable to calculate 
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Heckman, Catz, 
Heckman, Miller, 
& Kalichman, 
2004  
HIV/AIDS 
Design: Cross-sectional 
Setting: US, living in rural areas 
Sample: 329 (30% women); duration of ART 
not reported 
Adherence= 100% adherent during the 
previous week; measured by self-report 
Adherence rate= 50%  
Relationship with 
physician (good vs 
poor) 
OR= 1.82 (95% CI 0.79, 
4.17), ns 
Multivariate OR: 1.82 
(0.79, 4.17) 
Ingersoll & 
Heckman, 2005 
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 120 (38% women); duration of ART 
not reported 
Adherence= always taking medication as 
prescribed, never running out of medication 
as measured by self-report and not having 
non-adherence noted in the medical records 
Adherence rates based on meeting all three 
criteria= 29% 
 
 
 
 
Patient-physician 
relationship 
 
Physician 
communication 
Being non-adherent (based 
on meeting one or fewer of 
the 3 criteria:  
 
OR= 0.97 (95% CI 0.94, 
1.01) 
 
OR= 1.04 (95% CI 1.00, 
1.09) 
 
 
 
Multivariate OR:  
1.03 (1.00, 1.06) 
 
0.96 (0.92, 1.00) 
 
Johnson, 
Chesney, 
Goldstein, 
Remien, Catz, 
Gore-Felton et 
al., 2006 
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 276 (26% women); mean duration of 
ART= 2.4 years 
Adherence= > 90% adherence during the 
previous 3 days as measured by self-report 
Adherence rate= 68.25% 
Patient-physician 
relationship 
Not significantly related to 
non-adherence OR= 0.86 
(95% CI 0.74, 1.01) 
Multivariate OR: 1.16 
(0.99, 1.36) 
Kalichman, 
Ramachandran, 
& Catz, 1999 
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 184 subjects on triple combination 
therapy (24% women); duration of ART not 
reported 
Adherence= 100% for the past 2 days; 
measured by self-report 
Adherence rate= 80% 
Relationship with 
health care provider 
OR= 1.1 (95% CI 0.6, 1.4), 
ns 
Multivariate OR: 1.1 
(0.6, 1.4) 
McDonnell 
Holstad, Pace, 
De, & Ura, 2006  
HIV/AIDS 
 
Design: Cross-sectional 
Setting: US 
Sample: 120 (35% women); on ART > 1 
months (M=3.1 years) 
Adherence= measured as a continuous 
Interpersonal 
aspects of care (i.e., 
communication, 
concern, trust) 
 
Not significantly related to 
adherence multivariately; 
statistics not reported 
Unable to calculate 
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variable over the past 4 weeks by a self-
report survey 
Mean adherence rate= 83.1%+15.7% 
Molassiotis, 
Morris, & 
Trueman, 2007 
HIV/ADIS 
Design: Cross-sectional 
Setting: UK 
Sample: 38 (21.1% women) (average 57 
months on ART)  
Adherence > 2 doses missed in past week or 
> 2 days total non-adherence in past 3 
months as measured by self-report 
Adherence rate= 63.2% 
Level of trust in 
nurse 
SE= 0.42 
Beta= 0.52 p< 0.001 
Unable to calculate 
Moralejo, Ines, 
Marcos, Fuertes, 
& Luna, 2006 
HIV/AIDS 
Design: Cross-sectional 
Setting: Spain 
Sample: 143 (31% women); mean days on 
ART= 539.9 
Non-adherence= any reported non-
adherence by self-report > 2 days during the 
previous 5 days or any reported non-
adherence reported by pharmacy both 
measured by self-report 
Adherence rate= 67.13% 
Patient-physician 
relationship 
 
 
 
 
 
Accessibility to 
physicians 
Not significantly related to 
adherence bivariately; not 
included in multivariate 
analysis 
Bivariate OR= 2.08 (95% CI 
0.28, 15.38) 
 
Not significantly related to 
adherence bivariately; not 
included in multivariate 
analysis 
Bivariate OR= 0.88 (95% CI 
0.31, 2.56) 
Bivariate OR: 
2.08 (0.28, 15.38) 
 
 
 
 
 
Bivariate OR: 
0.88 (0.31, 2.56) 
Murphy, 
Marelich, 
Hoffman, & 
Steers, 2004 
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 115 patients who were having 
problems with adherence; duration of ART 
not reported 
Adherence= > 95% adherent during the past 
3 days, past week and past month as 
measured by self-report 
Adherence rate= 58.3% during the previous 3 
days, 34.8% during the past week and 26.1% 
during the previous month 
Patient-provider 
relationship:  
Patient Information 
Index, Patient 
Communication 
Index 
Patient Affective 
Index 
3 day adherence: 
Communication index: OR: 
1.13, (95% CI: 1.01, 1.27), 
p< 0.05 
Patient Information Index 
and Patient Affective Index 
not significant 
multivariately; no statistics 
reported 
1 week adherence:  
None of the indexes were 
significant mutivariately; 
statistics not reported 
Multivariate OR:  
1.13 (1.01, 1.27) 
 
 
Unable to calculate 
 
 
 
 
Unable to calculate 
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1 month adherence:  
None of the indexes were 
significant multivariately; 
statistics not reported 
 
Nilsson 
Schonnesson, 
Diamond, Ross, 
Williams, & 
Bratt, 2006 
HIV/AIDS 
Design: Prospective 
Setting: Sweden 
Sample: 144 (22% women); on ART > 6 
months 
Adherence= 100% adherent to ART dose and 
schedule over the past 4 days measured by 
self-report 
Mean adherence rate= 61% dose and 39% to 
schedule 
 
Patient-provider 
relationship  
 
 
Perceived pressures 
for taking 
medication from 
medical staff 
Dose adherence: no 
significant relationship; no 
statistics reported 
Schedule adherence: OR= 
1.579, B= 0.457, SE= 
0.453, p= 0.313 
Dose adherence: no 
significant relationship; no 
statistics reported 
Schedule adherence: OR= 
0.59,  
B= -0.533, SE= 0.262, p= 
0.04 
Bivariate OR: 1.08 (0.54, 
2.16) 
 
Multivariate OR:  
1.58 (0.85, 3.83) 
 
Multivariate OR:  
0.92 (0.68, 1.25) 
 
Multivariate OR:  
0.59 (0.34, 0.99) 
Nilsson 
Schonnesson, 
Williams, Ross, 
Bratt, & Keel, 
2007  
HIV/AIDS 
 
Design: Cross-sectional 
Setting: Sweden 
Sample: 193 (25% women); duration of ART 
> 6 months (mean= 47 months) 
Adherence to dose instruction= > 95%; 
adherence to schedule instructions= 100%; 
measured over the past 4 days by self-report 
Adherence rate= 88% to doses prescribed; 
63% to dosing schedule 
Patient-provider 
relationship 
Not significantly related to 
adherence bivariately; not 
included in multivariate 
analysis 
Bivariate OR for non-
adherence to dosing= 0.81 
(95% CI 0.34, 1.96) 
 
Bivariate OR for scheduling 
non-adherence= 1.04 (0.58, 
1.91) 
 
 
 
 
 
Bivariate OR (dosing): 
1.23 (0.51, 2.99) 
 
 
Bivariate OR 
(scheduling): 0.96 (0.53, 
1.76) 
Protopopescu, 
Raffi, Roux, 
Reynes, 
Dellamonica, 
Spire et al., 2009  
HIV/AIDS 
 
Design: Prospective 
Setting: France 
Sample: 1010 (21.5% women); median 
duration of ART= 0.6 years 
Adherence= 100% adherent during the 
previous 4 weeks; measured by self-report 
Adherence rate= not reported 
Confidence in 
physicians 
Not significantly related to 
adherence multivariately; 
statistics not reported 
Unable to calculate 
Reif, Whetten, Design: Cross-sectional Unmet needs for OR= 0.32, p< .01  Multivariate OR: 0.32 
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Lowe, & 
Ostermann, 2006  
HIV/AIDS 
Setting: US 
Sample: 526 (36% women); duration of ART 
not reported 
Adherence= always took medication as 
prescribed during the past month; measured 
by self-report 
Adherence rate= 62% 
counseling 
 
(CI not reported: unable 
to calculate) 
Remien, Bastos, 
Jnr, Raxach, 
Pinto, Parker et 
al., 2007  
HIV/AIDS 
Design: Cross-sectional 
Setting: Brazil 
Sample: 200 (29% women); on ART > 1 
month 
Adherence= > 90% over the previous 3 days 
measured for self-report 
Adherence rate= 86% 
Positive patient-
provider interactions 
Not significantly related to 
adherence multivariately; 
statistics not reported 
Unable to calculate 
Schneider, 
Kaplan, 
Greenfield, Li, & 
Wilson, 2004 
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 554 (15.29% women); duration of 
ART not reported 
Adherence= measured ordinally: 0-60%; 61-
90%; 91-99%; 100% over the prior 4 weeks; 
measured by self-report 
Perceptions about 
quality of physician 
relationship: 
  Communication  
 
  HIV counseling 
 
  Trust  
 
  Participatory 
  decision making 
 
  Adherence 
counseling 
 
  Overall satisfaction  
 
  Willingness to           
  recommend 
 
 
 
OR= 1.15 (95% CI 1.07, 
1.23), p< .001 
OR= 1.09 (95% CI 1.01 to 
1.16), p= .02 
OR= 1.10 (95% CI 1.01, 
1.21), p= .03 
OR= 1.07 ( 95% CI 0.99 to 
1.15), p= .12 
 
OR= 1.20 (95% CI 1.10, 
1.30), p< .001 
 
OR= 1.14 (95% CI 1.04, 
1.25), p= .004 
OR= 1.09 (95% CI 1.02, 
1.15), p= .009 
 
Multivariate OR: 
 
1.15 (1.07, 1.23) 
 
1.09 (1.01, 1.16) 
 
1.10 (1.01, 1.21) 
 
1.07 (0.99, 1.15) 
 
 
1.20 (1.10, 1.30) 
 
 
1.14 (1.04, 1.25) 
 
1.09 (1.02, 1.15) 
Shaahu, 
Lawoyin, & 
Sangowawa, 
2008  
Design: Cross-sectional 
Setting: Nigeria 
Sample: 428 (64.7% women); 74.3% had 
been on ART > 6 months 
Perception of health 
care provider as 
non-judgmental 
Not significantly related to 
adherence multivariately;  
Bivariate OR: 1.97 (1.25, 
2.12) 
Bivariate OR: 1.97 (1.25, 
2.12)  
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HIV/AIDS 
 
Adherence:= > 95% adherent between the 
onset of treatment and the time of the study 
by self-report 
Adherence rate= 62.6% 
Shah, Walshe, 
Saple, Mehta, 
Ramnani, 
Kharkar et al., 
2007 
HIV/AIDS 
Design: Cross-sectional 
Setting: India 
Sample: 278 (27.2% women); on ART > 3 
months 
Adherence= > 95% of the prescribed doses 
over the past 4 days measured by self-report 
Adherence rate= 73% 
Number of elements 
addressed during 
pre-ART counseling 
 
Not significantly related to 
adherence multivariately; 
no statistics reported 
Unable to calculate 
Sodergard, 
Halvarsson, 
Tully, Mindouri, 
Nordstrom, 
Lindback et al., 
2006  
HIV/AIDS 
Design: Cross-sectional 
Setting: Sweden 
Sample: 659 (36.7% women); on ART > 4 
months 
Adherence= > 95% of prescribed doses by 
self-report; time period not reported 
Adherence rate= 63% 
Relationship with 
health care provider 
(very good vs less 
than very good) 
OR for non-adherence= 
0.59 (95% CI 0.37, 0.95); 
p= 0.031 
Multivariate OR: 1.69 
(1.06, 2.70) 
Tadios & Davey, 
2006 HIV/AIDS 
 
Design: Cross-sectional 
Setting: Ethiopia 
Sample: 431 (49.9% women); duration of 
ART not reported 
Adherence= > 95% during the previous 7 
days as measured by self-report 
Adherence rate= 81.2% 
Patient-provider 
relationship 
 
Physician judged 
capable and 
trustworthy 
OR= 7.5 (95% CI 1.9, 28); 
p= 0.003 
 
OR= 10.8 (95% CI 1.4, 86); 
p= 0.025 
Multivariate OR: 7.50 
(1.90, 28.00) 
 
10.80 (1.40, 86.00) 
 
van Servellen & 
Lombardi, 2005  
HIV/AIDS 
Design: Cross-sectional  
Setting: US 
Sample: 85 Spanish speaking Latino’s, with 
adherence problems documented in med 
record (10% women); duration of ART not 
reported 
Adherence= > 90% adherence during the 
past 4 days; measured by self-report 
Adherence rate= not reported 
Patient-provider 
communications 
and relationships 
OR= 1.03 (95% CI 0.93, 
1.15), p= 0.53 
 
Multivariate OR: 1.03 
(0.93, 1.15) 
 
Vincke & Bolton, 
2002 HIV/AIDS 
Design: Cross-sectional 
Setting: Belgium 
Sample:86 (21.4% women); duration of ART 
Satisfaction with 
relationship with 
health care provider 
β= -0.04, ns Unable to calculate CI 
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not reported 
Adherence= measured as a continuous 
variable; self report 
SR: subjects reported that on average had 
not take ART as prescribed 1-2 days during 
past 4 weeks 
Sign others mean = 4.2+ 0.5 on a 5 point 
scale (5 = excellent adherence) 
Wang, He, Li, 
Yang, Chen, 
Fennie et al., 
2008  
HIV/AIDS 
 
Design: Cross-sectional 
Setting: China 
Sample: 308 (37.3% women); duration of 
ART >1 month (mean=17.7 months) 
Adherence= taking > 90% of ART during 
previous 7 days; measured by self-report 
Adherence rate= 79% 
Satisfaction with 
health care provider 
Not significantly related to 
adherence bivariately; not 
included in multivariate 
analysis 
Bivariate OR adherence: 
0.81 (95% CI 0.29, 2.30) 
Bivariate OR: 
0.81 (0.29, 2.30) 
Wang & Wu, 
2007 
HIV/AIDS 
 
Design: Cross-sectional 
Setting: China 
Sample: 181 (59.7% women); 24.4% on ART 
< 6 months 
Adherence= > 95% during the previous 3 
days by self-report 
Adherence rate= 81.8% 
Trust in physician OR= 7.79 (95% CI 1.26, 
48.95), p= 0.03 
Multivariate OR: 7.79 
(1.26, 48.95) 
Bivariate analysis only 
Bakken, 
Holzemer, 
Brown, Powell-
Cope, Turner, 
Inouye et al., 
2000  
HIV/AIDS 
 
Design: Cross-sectional 
Setting: US 
Sample: 707 (23% women); duration of ART 
not reported 
Adherence= measured as continuous 
variable by self report; time period no 
reported 
Adherence rate= not reported 
Relationship with 
health care provider 
r= 0.11, p= 0.005 Approximate bivariate 
OR: 1.49 (1.14, 1.96) 
 
Bogart, Bird, 
Walt, Delahanty, 
& Figler, 2004 
HIV/AIDS 
 
Design: Cross-sectional 
Setting: US 
Sample: 110 (17% women); duration of ART 
not reported 
Adherence= 100% adherent during the last 
week and last 2 weeks as measured by self-
 
 
Negative physician 
traits 
 
 
 
 
2 week adherence: r= -0.17, 
ns 
1 week adherence: r= -0.16, 
ns 
Approximate bivariate 
OR:  
0.56 (0.27, 1.11) 
 
0.53 (0.13, 1.06) 
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report 
Adherence rate= not reported 
Positive physician 
traits 
 
Positive feelings 
about physician 
2 week adherence: r= 0.02, 
ns 
 
1 week adherence: r= 0.05, 
ns 
2 week adherence: r= 0.07, 
ns 
1 week adherence: r= 0.05, 
ns 
1.08 (0.54, 2.14) 
 
 
1.20 (0.60, 2.39) 
 
1.09 (0.60, 2.39) 
 
1.29 (0.65, 2.57) 
Deschamps, 
Graeve, van 
Wijngaerden, De 
Saar, 
Vandamme, van 
Vaerenbergh et 
al., 2004  
HIV/AIDS 
Design: Prospective 
Setting: Belgium 
Sample: 43 (12% women); on ART > 1 month 
Non-adherence= taking adherence < 90%, or 
dose adherence < 75% and at least 1 drug 
holiday or a timing adherence < 80% and at 
least 1 drug holiday, or > 6 drug holidays per 
100 days over the prior 3 to 4 months; 
measured by electronic monitoring 
Adherence rate= 60.5% 
Satisfaction with 
health care provider 
Not significantly related to 
adherence bivariately (p= 
0.17) 
 
Approximate bivariate 
OR: 2.21 (0.72, 6.76) 
Dorz, Lazzarini, 
Cattelan, 
Meneghetti, 
Novara, Concia et 
al., 2003 
HIV/AIDS 
 
Design: Cross-sectional 
Setting: Italy 
Sample: 109 (19.3% women); duration of 
ART> 6 months 
Adherence= > 80%= adherent during the 
previous week as measured by self-report 
Adherence rate= 88.1% 
 
Physician-patient 
relationship  
 
Quality of the relationship: 
Adherent M= 87.3+16.6 (n= 
96); Non-adherent M= 
87.3+12.4 (n= 13), ns 
Competence and 
communication about 
therapy: Adherent M= 
82.6+17.7 (n= 96); Non-
adherent M= 75.0+19.6 (n= 
13), ns 
Availability of provider: 
Adherent M= 73.6+19.1 (n= 
96); Non-adherent M= 
70.7+19.6 (n= 13), ns 
Approximate bivariate 
OR: 
1.01 (0.35, 2.89) 
 
 
 
 
2.02 (0.70, 5.79) 
 
 
 
1.31 (0.70, 5.75) 
 
Thorburn Bird, 
Bogart, & 
Delahanty, 2004  
Design: Cross-sectional 
Setting: US 
Sample: 110 (17.3% women); duration of 
Perceived 
discrimination in 
HIV treatment 
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HIV/AIDS 
 
ART not reported 
Adherence= 100% adherent during the past 
2 weeks, past week and past 2 days; 
measured by self-report 
Adherence rate= not reported 
during interactions 
health care 
providers: 
Race based  
 
 
 
Socioeconomic-
based 
 
 
Past 2 weeks r= -0.12; ns 
Past week r= -0.14, ns 
Past 2 days r= -0.19, ns 
 
Past 2 weeks r= -0.29; p< 
0.01 
Past week r= -0.32; p< 0.01  
Past 2 days r= -0.32; p< 
0.01 
Approximate bivariate 
OR: 
0.64 (0.34, 34.99) 
0.76 (0.29, 1.20) 
0.49 (0.23, 1.00) 
 
0.33 (0.16, 0.68) 
0.29 (0.14, 0.60) 
0.29 (0.14, 0.60) 
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Table 4: Studies Examining the Relationship between Meso Level Systems Factors and Adherence 
Study/Patient 
Population 
Design/Sample/Definition of 
Adherence/Non-Adherence 
Meso Systems 
Factors  
Results Adherence Effect Size 
Mulltivariate Analysis 
Bonolo Pde, 
Cesar, Acurcio 
et al., 2005 
HIV/AIDS 
Design: Prospective 
Setting: Brazil 
Sample: 306 (35% women); newly initiated 
ART 
Non-adherence= < 95% of prescribed 
number of doses taken during previous 3 
days as measured by self-report 
Adherence rate= 63.1% 
 
Center 
 
 
 
 
 
> 6 month interval 
between visits 
 
 
 
 
Difficulty finding 
HIV-specific services 
 
Not significantly related to 
adherence bivariately 
[Relative Hazard= 1.42 
(95% CI 0.82, 2.44)] not 
included in multivariate 
analysis 
 
Not significantly related to 
adherence bivariately  
[Relative Hazard= 0.99 
(95% CI 0.60, 1.64)]: not 
included in multivariate 
analysis 
 
Not significantly related to 
adherence bivariately 
[Relative Hazard= 1.02 
(95% CI 0.68, 1.51)]; not 
included in multivariate 
analysis 
Unable to calculate 
 
 
 
 
 
Unable to calculate 
 
 
 
 
Unable to calculate 
Denhaerynck, 
Steiger, Bock et 
al., 2007 
Transplant 
recipients 
Design: Prospective 
Setting: 2 centers in Switzerland 
Sample: 291 renal (43.4% women); ≥1 year 
post-transplant (mean= 8.5 yrs) 
Non-adherence= inter-dose interval that 
deviated more than 25% from the prescribed 
interval; measured for electronic monitoring 
for 2 months following a 35 day wash-out 
period 
Dosing adherence= 98%; timing adherence= 
96% 
Center OR Center 1 vs. 2 not significant 
bivariately after adjusting 
for multiple comparisons 
[OR= 0.51 (95% CI 0.27, 
0.96)]; not included in 
multivariate analysis 
 
OR Center 1 vs. other centers= not 
significant bivariately after 
adjusting for multiple 
comparisons [OR= 0.23 
Bivariate OR: 0.51  
 
 
 
 
 
 
Bivariate OR: 0.23 
Chapter 3: Systematic review    
 
 
75 
(95% CI 0.06, 0.96)]; not 
included in multivariate 
analysis  
Ingersoll & 
Heckman, 2005  
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 120 (38% women); duration of ART 
not reported 
Adherence= always taking medication as 
prescribed, never running out of medication 
as measured by self-report and not having 
non-adherence noted in the medical records 
Adherence rates based on meeting all three 
criteria= 29% 
Organizational 
accessibility 
Being non-adherent (based 
on meeting one or fewer of 
the 3 criteria: OR= 0.97 
(95% CI 0.94, 1.01) 
 
  
 
Multivariate OR: 1.03 
(1.00, 1.06) 
 
 
 
Kapadia, 
Vlahov, Wu, 
Cohen, 
Greenblatt, 
Howard et al., 
2008 
HIV/AIDS 
Design: Prospective 
Setting: US 
Sample: 573 (100% women); median ART 
treatment= 38.7 months; median HAART= 
18.5 months 
Adherence= > 95% over the past 6 months 
based on self-report 
Adherence rate= 73% 
Had a doctor’s visit 
in last 6 months 
No significant relationship 
bivariately (p= .59); not 
examined multivariately 
Bilvariate OR=0.58 (0.33, 
1.01) 
Kleeberger, 
Phair, 
Strathdee, 
Detels, Kingsley, 
& Jacobson, 
2001  
HIV/AIDS 
Design: Prospective 
Setting: US 
Sample: 539 (not women); duration of ART 
not reported 
Adherence= 100% adherent over the past 4 
days; measured by self-report 
Adherence rate= 77.7% 
Use of health care 
(no health care 
visits within the 
previous 6 to 12 
months) 
OR non-adherence= 3.6 
(95%CI 1.5, 8.4)  
 
Multivariate OR: 0.28 
(0.12, 0.67) 
Marcellin, 
Boyer, 
Protopopescu, 
Dia, Ongolo-
Zogo, Koulla-
Shiro et al., 
2008  
HIV/AIDS 
Design: Cross-sectional 
Setting: Cameroon 
Sample: 533 (70.9 % Women) 
Mean time of ART= 13.9 m 
Non-adherence= Interruption > 2 days 
during the previous 4 weeks; measured by 
self report 
Adherence rate= 82.7% 
Pharmacy stock 
shortages 
 
 
Difficulty obtaining 
a consultation with 
physician 
Multivariate OR for non-
adherence of 3.25 (1.78, 
5.90), p< 0.0001 
 
Not significant 
multivariately; no statistics 
reported 
 
Multivariate OR: 0.31 
(0.17, 0.56) 
 
 
Unable to calculate 
 
Mellins, Chu, Design: Prospective Center Not significantly related to Unable to calculate 
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Malee, Allison, 
Smith, Harris et 
al., 2008 
HIV/AIDS 
 
Setting: US 
Sample: 309 women in 3th trimester of 
pregnancy, 220 at 6 months postpartum 
Adherence= no missed doses in the past 
month; measured by self-report 
Adherence rate= 61% during the 3rd 
trimester and 44% 6 months postpartum 
adherence multivariately; 
no statistics reported 
Merenstein, 
Schneider, Cox, 
Schwartz, 
Weber, Robison 
et al., 2009  
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 1419 (100% women); duration of 
ART not reported 
Adherence= > 95% during the previous 6 
months by self report 
Adherence rate= 76% 
Seen by a social 
worker or case 
manager since last 
visit 
OR= 1.06 (95% CI 0.95, 
1.18) 
Multivariate OR: 1.06 
(0.95, 1.18) 
Moralejo, Ines, 
Marcos et al., 
2006 HIV/AIDS 
Design: Cross-sectional 
Setting: Spain 
Sample: 143 (31% women); mean days on 
ART= 539.9 
Non-adherence= any reported non-
adherence by self-report > 2 days during the 
previous 5 days or any reported non-
adherence reported by pharmacy both 
measured by self-report 
Adherence rate= 67.13% 
Accessibility to the 
pharmacy hospital 
to collect medication 
Not significantly related to 
adherence bivariately [OR= 
0.91 (95% CI 0.41, 2.26); 
not included in multivariate 
analysis 
 
Bivariate OR: 0.91  
(0.41, 2.26) 
Muyingo, 
Walker, Reid, 
Munderi, Gibb, 
Ssali et al., 
2008  
HIV/AIDS 
Design: Prospective 
Setting: Uganda and Zimbabwe 
Sample: 2957 (65% Women) 
ART naive at enrollment; followed for 52 
weeks post-initiation 
Adherence= 100% over the prior 4 weeks by 
pill count 
49% of subjects had good adherence (> 95%) 
across all treatment visits  
100% adherence rate= 75%; 95% adherence 
rate= 93% 
Center (2 centers in 
Uganda (1 with an 
additional satellite 
site) and 1 center in 
Zimbabwe) 
 
Multivariate OR relative to 
Center A: 
Center B: 1.32 (1.20, 1.47) 
Center C: 1.89 (1.71, 2.10) 
Center D: 1.70 (1.42, 2.03) 
P< 0.001 
 
 
Multivariate OR: 
1.32 (1.20, 1.47) 
1.89 (1.71, 2.10) 
1.70 (1.42, 2.03) 
 
Nemes, 
Carvalho, & 
Design: Cross-sectional 
Setting: Brazil 
Center (number of 
patients seen: < 100 
Non-adherence OR= 1.51 
(95% CI 1.06, 2.15), p=0.02  
Multivariate OR: 0.58 
(0.38, 0.89) 
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Souza, 2004 
HIV/AIDS 
Sample: 1972 (38% women); on ART >2 
months 
Adherence= > 95% of the prescribed ART for 
the past 3 days; measured by self-report 
Adherence rate= 75% 
vs >500) 
 
Quality of care 
(best+, best, worst, 
worst-) 
 
No significant relationship 
bivariately (Non-adherence: 
OR, 95% CI) 
Best vs. best+: 0.81 (0.60, 
1.08) 
Worst vs. best+: 0.99 (0.69, 
1.42) 
Worst- vs. best +: 0.87 
(0.68, 1.12); not examined 
multivariately  
 
 
Bivariate OR: 
 
Best vs. best+: 
1.23 (0.91, 1.67) 
Worst vs. best+: 
1.01 (0.70, 1.45) 
Worst- vs. best+: 
1.15 (0.97, 1.47) 
Reif, Whetten, 
Lowe et al., 
2006  
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 526 (36% women); duration of ART 
not reported 
Adherence= always took medication as 
prescribed during the past month; measured 
by self-report 
Adherence rate= 62% 
Use of HIV case 
management 
OR= 1.23, ns (CI not 
reported) 
 
Multivariate OR: 1.23 (CI 
not reported; unable to 
calculate) 
 
Shaahu, 
Lawoyin, & 
Sangowawa, 
2008  
HIV/AIDS 
 
Design: Cross-sectional 
Setting: Nigeria 
Sample: 428 (64.7% women); 74.3% had 
been on ART> 6 months 
Adherence= > 95% adherent between the 
onset of treatment and the time of the study 
by self-report 
Adherence rate= 62.6% 
ART always 
available at the 
clinic 
OR= 5.2 (95% CI 3.1, 8.6), 
p< 0.001 
 
Multivariate OR: 5.20 
(3.10, 8.6) 
 
Shah, Walshe, 
Saple et al., 
2007  
HIV/AIDS 
Design: Cross-sectional 
Setting: India 
Sample: 278 (27.2% women); on ART> 3 
months 
Adherence= > 95% of the prescribed doses 
over the past 4 days measured by self-report 
Adherence rate= 73% 
Satisfaction with 
clinic 
Not significantly related to 
adherence multivariately; 
no statistics reported 
Unable to calculate 
Sitta, Lert, 
Gueguen, Spire, 
& Dray-Spira, 
Design: Cross-sectional 
Setting: France 
Sample: 699 (25% women); duration of ART 
Center Not significantly related to 
adherence multivariately; 
no statistics reported 
Unable to calculate 
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2009 HIV/AIDS 
 
not reported 
Adherence= scrupulously following 
treatment during the past 7 days by self-
report 
Adherence rate= 63.3% 
Tadios & Davey, 
2006 HIV/AIDS 
 
Design: Cross-sectional 
Setting: Ethiopia 
Sample: 431 (49.9% women); duration of 
ART not reported 
Adherence= > 95% during the previous 7 
days as measured by self-report 
Adherence rate= 81.2% 
Access to reliable 
pharmacy 
 
Having scheduled 
appointments 
OR= 3.0 (95% CI 1.3, 6.9); 
p= 0.009 
 
OR= 6.9 (95% CI 2.0, 22.9), 
p= 0.002 
Multivariate OR: 3.00 
(1.30, 6.90) 
 
6.90 (2.00, 22.90) 
Turner, 
Newschaffer, 
Zhang, Cosler, 
& Hauck, 2000 
HIV/AIDS 
 
Design: Retrospective 
Setting: US 
Sample: 549 HIV+ post-partum women 
prescribed ART during 1 post-partum year 
Adherence=  ≥ 80% of days during the 1st 
year post-partum measured by prescription 
refill rate 
Adherence rate= 28% 
HIV focused service  
 
 
Average number of 
physician/clinic 
visits per month 
 
OR= 2.13 (95% CI 1.05, 
4.30), p= 0.04 
 
Not significantly related to 
adherence bivariately (p= 
0.18); not included in 
multivariate analysis 
Multivariate OR: 2.13 
(1.05, 4.30) 
 
Unable to calculate 
Weng, Israni, 
Joffe, Hoy, 
Gaughan, 
Newman et al., 
2005 Transplant 
recipients 
Design: Prospective 
Setting: 8 centers in Pennsylvania (US) 
Sample: 278 renal transplant recipients 
(38.8% female) 
Recruited at time of Tx and followed up to 12 
months  
Adherence= Subjects categorized into 4 
groups: 0-50%; > 50 to 80%; > 80-95%, and 
> 95 to 100% average daily % adherence for 
up to 12 months follow-up measured by 
electronic monitoring 
Adherence rates= 95%-100%= 41%; 80%-
95%= 32.4% 
Center Significantly related to 
adherence: p< 0.001, ORs 
not reported 
Approximate multivariate 
OR (based on p-value): 
0.43 (0.28, 0.66) 
Bivariate analysis only 
Castillo, Palepu, 
Beardsell, 
Akagi, Yip, 
Design: Retrospective 
Setting: Canada 
Sample: 788 (proportion of women (varied 
HAART dispensing 
site: AIDS care 
pharmacy (with 
Adherence rates: 
   AIDS pharmacy: 70.4% 
   Off-site pharmacy: 59.2% 
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Montaner et al., 
2004  
HIV/AIDS 
from 13.7% in AIDS Pharmacies to 30.3% in 
physician offices); newly started on ART; 
followed for 1 year 
Adherence= > 90% during the first year of 
therapy; measured by pharmacy refill rates 
Adherence rate= pharmacy: 70.4% in AIDS 
pharmacies, 59.2% in off-site pharmacies 
and 55.7% in physician offices 
regular medication 
counseling), 
outpatient 
pharmacy, or 
physician office 
   Physician office: 55.7%  
AIDS pharmacy vs off-site 
and physician office p= 
.0001); Off-site vs physician 
office (p= 0.52) 
AIDS pharmacy vs off-site 
AIDS pharmacy vs 
physician office 
Off-site vs physician office  
 
 
 
 
Bivariate OR: 
1.64 (1.05, 2.56) 
1.89 (1.34, 2.65) 
 
1.15 (0.71, 1.88) 
Gross, Zhang, & 
Grossberg, 2005  
HIV/AIDS 
 
Design: Retrospective 
Setting: US 
Sample: 110 veterans (2% women); on ART> 
3 months 
 
Adherence= > 85% during the past 3 
months measured by refill rates 
Adherence rate= mail order 91; pick-up 80%; 
pill organizer 99% 
 
Dispensing of drugs Proportion of subjects with 
“good” adherence: 
100% (n= 10) with 
pharmacy dispensed pill 
organizers vs. 39% (n= 23) 
who picked up refills at 
pharmacy (p= <.001) 
 
61% (n= 25) who received 
refills via mail vs. 39% (n= 
23) who picked up 
prescriptions (p= .03)  
 
100% (n= 10) with 
pharmacy dispensed pill 
organizer vs.61% (n= 25) 
with mailed refills (p= .02) 
32.62 (3.95, 269. 19) 
 
 
 
 
 
 
 
2.45 (1.08, 5.54) 
 
 
 
 
2.61 (1.60, 115.09) 
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Table 5: Studies Examining the Relationship between Macro Level Systems Factors and Adherence 
Study/Patient 
Population 
Design/Sample/ Definition of 
Adherence/Non-Adherence 
Macro Level Factors Results Adherence Effect Size 
(OR, 95% CI) 
Mulltivariate Analysis 
Arrivillaga, 
Ross, Useche, 
Alzate, & 
Correa, 2009 
HIV/AIDS 
 
Design: Cross-sectional 
Setting: Colombia 
Sample: 269 (100% women); duration of ART 
not reported 
Adherence= complying at least 64% of the 
"treatment requirements" as measured by 
self-report 
Adherence rate= 57% 
Subsidized national 
health care plan or 
uninsured vs 
enrollment in a 
contributive plan 
OR= 3.48 (95% CI 1.96, 
6.18); p< 0.0001 
 
Multivariate OR: 0.29 
(0.16, 0.51) 
 
 
Bonolo Pde, 
Cesar, Acurcio 
et al., 2005 
HIV/AIDS 
Design: Prospective 
Setting: Brazil 
Sample: 306 (35% women); newly initiated 
ART 
Non-adherence= < 95% of prescribed 
number of doses taken during previous 3 
days as measured by self-report 
Adherence rate= 63.1% 
Not having health 
insurance 
No significant multivariate 
relationship; statistical 
results not reported 
Unable to calculate 
Byakika-
Tusiime, Oyugi, 
Tumwikirize, 
Katabira, 
Mugyenyi, & 
Bangsberg, 
2005  
HIV/AIDS 
Design: Cross-sectional 
Setting: Uganda 
Sample: 304 (53.3% women); duration of 
ART> 1 month 
Adherence= > 95% during the previous 3 
days; measured by self-report 
Adherence rate= 68% 
Cost of drugs 
 
 
Distance from home 
to treatment 
OR= 0.95 (95% CI 0.29, 
3.15) 
 
OR= 1.01 (95% CI 0.45, 
1.25) 
Multivariate OR: 0.95 
(0.29, 3.15) 
 
1.01 (0.45, 1.25) 
 
Carlucci, 
Kamanga, 
Sheneberger, 
Shepherd, 
Jenkins, 
Spurrier et al., 
2008  
Design: Prospective 
Setting: Zambia 
Sample: 424 (63% women); On ART > 2 
months 
Adherence= > 95% scheduled doses taken 
since previous appointment measured by pill 
count 
Travel duration 
 
Cost of transportation 
OR= 1.0 (95%CI 0.91, 1.1), 
p= 0.9 
 
OR= 0.7 (95% CI 0.35, 1.4), 
p= 0.3 
 
Multivariate OR: 1.0 
(0.91, 1.1) 
 
0.70 (0.35, 1.4) 
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HIV/AIDS Adherence rate= 83.7%  
Chisholm, 
Kwong, & 
Spivey, 2007 
Transplant 
recipients 
Design: Retrospective 
Setting: US 
Sample: 53,997 renal (40% women); up to 36 
months post-transplant 
Adherence= no chart report of non-
adherence during the first 36 months post 
transplant. 
Adherence rate= 94% 
Primary insurance Compared to those not on 
Medicare, Medicare 
recipients were significantly 
less likely to be non-
adherent (OR: 0.61; 95% CI 
0.54, 0.68; p< 0.001) 
Medicaid was not 
significantly related to non-
adherence (OR= 1.13; 95% 
CI: 0.92, 1.39) 
Multivariate OR: 1.64 
(1.45, 1.85) 
 
 
 
 
 
0.89 (0.72, 1.09) 
Denhaerynck, 
Desmyttere, 
Dobbels et al., 
2006 Transplant 
recipients 
 
Design: Cross-sectional 
Setting: Subjects from 3 independent but 
similar studies conducted in the US and 
Western Europe (Belgium, the Netherlands & 
Switzerland) 
Sample: Renal transplantation: 1563 US and 
614 European (EU) patients (Belgium: n= 
187; the Netherlands: n= 85; Switzerland: n= 
342); EU sample 39.5% female, US sample 
51.2% female; Mean months since 
transplantation: EU sample: 
64.2+67.25, US: 36.2+32.4 
Adherence= taking 100% of medication as 
prescribed during the past 4 weeks; 
measured by self-report 
Adherence rate= 86.8% of EU and 80.7% of 
U.S. 
Continent  
 
 
 
Country 
U.S. compared to EU: odds 
of non-adherence: OR= 
1.78 (1.10, 2.89) p=0.019  
 
The Netherlands compared 
to Belgium: OR= 0.27 (09, 
0.80), p=0.0186  
 
Switzerland vs. Belgium: 
OR= 0.17 (0.07, 0.42), p< 
.001 
 
Switzerland vs the 
Netherlands: OR= 0.61 
(0.20,1.92), p= .40 
 
Multivariate OR: 
0.56 (0.35, 0.91) 
 
 
3.70 (1.23, 11.11) 
 
 
5.88 (2.42, 14.29) 
 
 
 
1.64 (0.54, 5.00) 
 
Dew, Dimartini, 
De Vito Dabbs, 
Zomak, De 
Geest, Dobbels 
et al., 2008 
Transplant 
Design: Prospective 
Setting: US 
Sample: 178 lung 126 heart transplant 
recipients (40.6% women); enrolled 2 months 
post-tx and followed until month 24 
Non-adherence= missing primary 
Insurance status Transplant recipients 
relying on public health 
insurance were significantly 
more likely to be non-
adherent than those who 
did not: OR= 2.60 (1.06, 
Multivariate OR: 0.38 
(0.16, 0.94)  
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recipients immunosuppressant medication at least 
once/month measured by self-report 
Adherence rates decreased over in both 
transplant groups: Lung - from 90.4% at 2 
months to 80.3% at 24 months; heart - from 
88.9% at 2 months to 69.4% at 24 months 
6.25), p< 0.05 
 
Halkitis, 
Kutnick, & 
Slater, 2005 
HIV/AIDS 
 
Design: Prospective 
Setting: US 
Sample: 300 HIV+ men-who-have-sex-with-
men; mean duration of ART=1.63 years 
Adherence= > 95% measured by electronic 
monitoring and self-report over the prior 2 
weeks 
Adherence rate: electronic monitoring= 
60.7%; self-report= 67.0%  
Health care coverage No significant multivariate 
relationship; statistical 
results not reported 
Unable to calculate 
Heckman, Catz, 
Heckman et al., 
2004 HIV/AIDS 
Design: Cross-sectional 
Setting: US, living in rural areas 
Sample: 329 (30% women); duration of ART 
not reported 
Adherence= 100% adherent during the 
previous week; measured by self-report 
Adherence rate= 50%  
Barriers to obtaining 
health care and social 
services (e.g. long 
distance to hospitals, 
lack of 
transportation) 
 
OR= 1.08 (95% CI 0.76, 
1.53), ns 
 
Multivariate OR: 1.08 
(0.76, 1.53) 
 
Ingersoll & 
Heckman, 2005  
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 120 (38% women); duration of ART 
not reported 
Adherence= always taking medication as 
prescribed, never running out of medication 
as measured by self-report and not having 
non-adherence noted in the medical records 
Adherence rates based on taking > 95%= 
69.6%; meeting all three criteria= 29% 
Financial accessibility 
(defined as the 
fairness/value of the 
cost of care), 
Non-adherence measured 
as taking < 95% of 
prescribed medications: 
OR= 0.91 (95%CI 0.84–
1.00), p< .05 
Multivariate OR: 1.10 
(1.01, 1.19) 
Kapadia, 
Vlahov, Wu et 
al., 2008  
HIV/AIDS 
Design: Prospective 
Setting: US 
Sample: 573 (100% women); median ART 
treatment= 38.7 months; median HAART= 
18.5 months 
Health insurance type 
(none, private, public) 
 
No significant relationship 
bivariately (p= 0.16); not 
included in multivariate 
analysis 
Bivariate OR: 
Private vs. none: 
2.14 (0.97, 4.70) 
 
Public vs. none: 
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Adherence= > 95% over the past 6 months 
based on self-report 
Adherence rate= 73% 
1.48 (0.84, 2.62) 
 
Private vs. public: 
1.44 (0.77, 2.69) 
Kleeberger, 
Phair, Strathdee 
et al., 2001 
HIV/AIDS 
 
Design: Prospective 
Setting: US 
Sample: 539 (not women); duration of ART 
not reported 
Adherence= 100% adherent over the past 4 
days; measured by self-report 
Adherence rate= 77.7% 
Insurance coverage 
 
 
 
 
No significant relationship 
bivariately [adherence OR= 
0.85 (95% CI 0.31, 2.30)], 
not included in multivariate 
analysis  
 
 
Bivariate OR: 0.85 
(0.31, 2.30) 
 
 
 
 
Marcellin, 
Boyer, 
Protopopescu et 
al., 2008 
HIV/AIDS 
 
Design: Cross-sectional 
Setting: Cameroon 
Sample: 533 (70.9% Female); mean time of 
ART= 13.9 months 
Non-adherence= Interruption > 2 days 
during the previous 4 weeks; measured by 
self-report 
Adherence rate= 82.7 
Previous month’s 
total health 
expenditures  
 
 
 
Duration of transport 
to hospital 
No significant bivariately 
[OR for nonadherence= 
0.93 (95% CI 0.50, 1.72), 
p= 0.82]; not included in 
multivariate analysis 
 
No significant 
multivariately; no statistical 
results reported 
Bivarviate OR: 
1.08 (0.58, 2.00) 
 
 
 
 
Unable to calculate 
Ramadhani, 
Thielman, 
Landman, 
Ndosi, Gao, 
Kirchherr et al., 
2007  
HIV/AIDS 
Design: Cross-sectional 
Setting: Tanzania 
Sample: 150 (63% women); on ART > 6 
months 
Non-adherence= < 100% from the start of 
treatment as measured by self-report 
Adherence rate= 84% 
Walking time to clinic 
 
 
Proportion of months 
receiving self-funded 
treatment 
Non-adherence: OR= 1.2 
(95% CI 0.94-1.6), p= 0.14;  
 
Non-adherence: OR= 23.5 
(95% CI 1.2, 444.4) p= 0.04 
Bivariate OR: 
0.83 (0.62, 1.11) 
 
 
0.07 (0.00, 0.08) 
Reif, Whetten, 
Lowe et al., 
2006  
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 526 (36% women); duration of ART 
not reported 
Adherence= always took medication as 
prescribed during the past month; measured 
by self-report 
Adherence rate= 62% 
Unmet need for 
financial assistance 
including with 
obtaining medications 
OR= 0.95 (CI not reported), 
ns 
Multivariate OR: 0.95 
(CI not reported) 
Sarna, Pujari, 
Sengar et al., 
Design: Cross-sectional 
Setting: India 
Cost of medications: 
free or paid  out of 
Multivariate OR for non-
adherence when treatment 
Multivariate OR: 0.25 
(0.09, 0.70) 
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2008  
HIV/AIDS 
 
Sample: 310 (16% Women); duration of ART 
> 30 days 
Non-adherence= < 90% over 4 day; 
measured by self-report 
Adherence rate= 84% 
pocket  was free = 4.05 (1.42, 
11.54) p= 0.009 
 
Shah, Walshe, 
Saple et al., 
2007  
HIV/AIDS 
Design: Cross-sectional 
Setting: India 
Sample: 278 (27.2% women); on ART> 3 
months 
Adherence= > 95% of the prescribed doses 
over the past 4 days measured by self-report 
Adherence rate= 73% 
Cost of ART 
 
Not significantly related to 
adherence multivariately; 
no statistics reported 
Unable to calculate 
Sharma, Singh, 
Laishram, 
Kumar, Nanao, 
Sharma et al., 
2007  
HIV/AIDS 
Design: Cross-sectional 
Setting: India 
Sample: 226 (2.2% women); duration of ART 
not reported 
Non-adherence= ever missing a dose by self-
report 
Adherence rate= 59% 
ART provided for free 
or not 
 
Not receiving free ART was 
sign related to non 
adherence (p= 0.001)   
 
 
Approx multivariate 
OR=2.22 (based on 
reported p-values); 
unable to calculate 95% 
CI 
Turner, 
Newschaffer, 
Zhang et al., 
2000  
HIV/AIDS 
 
Design: Retrospective 
Setting: US 
Sample: 549 HIV+ post-partum women 
prescribed ART during 1 post-partum year 
Adherence= ≥ 80% of days during the 1st 
year post-partum measured by prescription 
refill rate 
Adherence rate= 28% 
Medicaid eligible 
during the entire 1st 
post-partum year 
OR= 0.33 (95% CI 0.14, 
0.78), p= 0.01 
 
Multivariate OR: 0.33 
(0.14, 0.78) 
 
Wagner, 2002  
HIV/AIDS 
 
Design: Prospective 
Setting: US 
Sample: 180 (18% women); duration of ART> 
1 month 
Adherence= a continuous variable; 
measured by electronic monitoring (n= 61, 
medication diary (n= 60) and self report (n= 
59); measured over the previous 4 weeks 
Adherence rates= 93.7% (self-report), 80.6% 
(electronic monitoring), and 92.6% 
Having health 
insurance 
Not significantly related to 
adherence multivariately; 
no statistics reported 
Unable to calculate 
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(medication diary) 
Weiser, Wolfe, 
Bangsberg, 
Thior, Gilbert, 
Makhema et al., 
2003  HIV/AIDS 
Design: Cross-sectional 
Setting: Botswana 
Sample: 109 (50% women); on ART > 3 
months 
Adherence= taking 95% of prescribed dose 
during the previous year; measure by self-
report 
Adherence rate= 54% 
Cost of ART OR= 0.11 (95% CI 0.04, 
0.3), p< 0.0001 
Multivariate OR: 0.11 
(0.04, 0.30) 
Bivariate analysis only  
Deloria-Knoll, 
Chmiel, 
Moorman, 
Wood, 
Holmberg, & 
Palella, 2004  
HIV/AIDS 
Design: Cross-sectional 
Setting: US 
Sample: 255 (14% women): duration of ART= 
4.7 + 3.1 years in non-adherent subjects and 
4.2+2.7 yrs in adherent subjects, ns 
Adherence= skipping >1 dose during the 
previous 3 days, measure by self-report 
Adherence rate= 67% 
Insurance status Adherent subjects: 62% 
private insurance, 25% 
government insurance 
Non-adherent subjects: 
55% private insurance; 
32% government insurance 
Calculate OR= 3.76 (95% CI 
2.08, 6.78)  
Bivariate OR:  
3.76 (2.08, 6.78) 
 
Liu & Zaki, 
2004  
Transplant 
recipients 
Design: Cross-sectional 
Setting: Malaysia (Kuala Lumpur) 
Sample: 246 renal Tx recipients (41.5% 
women); > 6 months post-tx 
Adherence= Cyclosporine / tracolimus blood 
level > 25 ng/ml; tacrolimus > 1 ng/ml  
Adherence rate= 90.7% 
Cost of 
immunosuppressive 
medication (free vs 
paying for) 
 
Country (China, 
India, Kuala Lumpur, 
others) 
(p= 0.87) 
 
 
 
 
Country (p= 0.27) 
China vs India 
China vs Kuala Lumpur 
India vs Kuala Lumpur 
Approximate Bivariate 
OR:  
1.21 (0.26, 5.62) 
 
 
2.53 (0.69, 9.26) 
1.10 (0.33, 3.66) 
0.43 (0.15, 1.22) 
 
Wanchu, Kaur, 
Bambery, & 
Singh, 2007  
HIV/AIDS 
Design: Cross-sectional 
Setting: North India 
Sample: 200 (31% women); on ART > 1 
month 
Non-adherence= Missed ≥ 1 dose during 
past 4 weeks as measured by self-report 
Adherence rate= 73% 
Source of funding 
(self vs. state) 
85.37% who the state paid 
for their medication were 
adherent compared to 
65.25% of those who self-
paid (difference reported as 
sign; p-value not reported) 
Bivariate OR: 3.11 
(1.51, 6.38) 
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When a study reported an OR (95% CI) for non-adherence, a OR (95%CI) was calculated for adherence using the following formula: 
 OR adherence=1/OR non-adherence 
 Lower limit (LL) OR adherence LL=Exponent (Ln(OR adherence)-(1.96*SE LnOR LL)). 
 Upper limit (UL) OR adherence LL=Exponent (Ln(OR adherence)+(1.96*SE LnOR LL))
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Introduction 
It is standard practice in nursing research to examine whether a study’s result is 
statistically significant. However, a common mistake in the interpretation of the 
results, is equating statistically significant results (i.e., a p-value of ≤ 0.05 or 0.01) 
with a clinically meaningful effect. A p-value is the probability of that the results are 
due to chance alone, or in other words, the probability of incorrectly rejecting the 
null hypothesis 1, 2. It does not, however, provide any information about the 
practical importance of the findings. Furthermore, p-values are dependent on the 
sample size. This means that a small effect could be statistically significant if the 
sample size is very large and, conversely, there can be a large effect in a small 
sample size without the p-value being significant 1. The advantage of effect size 
estimates is that they are independent of sample size and measure the extent of a 
treatment effect or strength of the association between variables. Mays and Melnyk 
(2009) define effect size as “a measure of the magnitude of the influence of an 
independent or predictor variable on a dependent or criteria variable” 3 (pg. 125). 
Effect size estimates information on both the magnitude and direction of influence. 
In addition to providing important information about the impact of a treatment on 
the outcome of interest, it also provides a common metric to compare the direction 
and strength of the relationship between variables across studies, which is key to 
conducting a meta-analysis. Meta-analysis is “a technique for quantitatively 
combining and integrating the results of multiple studies on a given topic” 2 (pg. 
723). Meta-analyses are considered the highest level of evidence for clinical practice 
2. For meta-analysis it is crucial to define a common effect size metric which is 
capable of representing the quantitative findings of a set of research studies in a 
standardized form and permits meaningful numerical comparison and analysis 
across the studies 4. Although guidelines such as the CONSORT statement, an 
evidence-based minimum set of recommendations for reporting randomized clinical 
trials 5, and the American Psychological Association manual 6 recommend reporting 
effect sizes even when results are not statistically significant, a number of research 
articles, even more recent ones, do not report effect sizes. The researcher 
conducting a meta-analysis must then rely on summary and test statistics reported 
in the article to calculate the effect size.  
Because the sample in a research study rarely totally represents the characteristics 
of the target population for the study findings, effect size estimates are only 
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estimates of the true effect in the target population. The extent to which the 
estimated effect size accurately reflects the effect in the target population will vary. 
Therefore, when investigators report the effect size for their studies, they should 
also include a measure of its precision, i.e., a confidence interval 1. The confidence 
interval is the range of values within which a population parameter is estimated to 
lie for a given probability 2. The narrower the confidence interval, the more precise 
the estimated effect size is 1. While the effect size is not influenced by the sample 
size, its precision, conveyed through the confidence interval, is. In general, the 
larger the sample size, the more precise the effect size estimate (as evidenced by a 
narrower confidence interval) will be.  
This article will focus on effect size calculation based on data and statistics reported 
in published studies. We will provide the formulas utilized to directly calculate 
common effect sizes when researchers report summary data from their studies, as 
well as examples of methods utilized to indirectly estimate the effect size from 
summary statistics. 
 
Methods to calculate effect sizes 
The method utilized to calculate an effect size will vary with the results reported in 
the primary study. The effect size can be calculated directly when the published 
study results include certain basic information such as the mean and SD, exact 
correlation coefficient or the number events and non-events in two groups. 
Unfortunately, many published studies fail to report the summary statistics needed 
to directly calculate an effect size. While one can (and should) attempt to contact 
the author(s) to obtain the missing data, such attempts are often unsuccessful. 
When the basic information needed to directly calculate an effect size is not 
available, there may be methods available to estimate the effect size from less than 
optimal statistical information 7. We will present and illustrate methods utilized to 
directly calculate an effect size and its 95% confidence interval based on reported 
(1) means and standard deviations, (2) correlation coefficients and (3) number of 
events and non-events in two groups. These summary statistics are utilized to 
calculate the most common effect size indices used in meta-analysis, the 
standardized mean difference (e.g., Cohen’s d), correlation coefficient (r) and odds 
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ratio (OR) 8. We will also present examples of methods utilized to indirectly estimate 
the effect size from summary statistics. 
 
Effect size based on means and standard deviations 
When studies compare continuous outcomes in two groups and report the mean (M) 
and standard deviation (SD) in both groups, the raw mean or standardized mean 
difference are the preferred effect sizes 9. If the outcome of the studies was 
measured using a meaningful scale and all of the studies for which an effect size is 
being calculated used the same scale, the effect size can be calculated as the raw 
mean difference between the two groups:  
Mean difference = Mgroup 1 – Mgroup 2. In reality, however, is rare to have a set of 
studies that all measure the outcome of interest using the same scale. This is 
particularly true in behavioural research. More commonly, studies use different 
methods of measuring the outcome of interest. When this is the case, the most 
commonly used effect size calculation is the standardized mean difference which is 
calculated as the difference between the two group means divided by their pooled 
standard deviation. This effect size (ES), the standardized mean difference, is often 
referred to as Cohen’s d or Hedge’s g 7. The standardized mean difference is 
calculated as 10:   𝐸𝑆𝑠𝑚 = 𝑀1−𝑀2𝑆𝑝𝑜𝑜𝑙𝑒𝑑 where 𝑆𝑝𝑜𝑜𝑙𝑒𝑑 = �(𝑛1−1)𝑠12+(𝑛𝑠−1)𝑠12𝑛1+𝑛2−2 . 
 
 
Calculation of the confidence interval around the standardized mean differences 
requires calculation of the variance. The formula used to calculate the variance is 
10:  
𝑉𝑠𝑚 = 𝑛1+𝑛2𝑛1𝑛2 + 𝐸𝑆𝑠𝑚22(𝑛1+𝑛2) .   
 
The standard error of the standardized mean difference is the square root of its 
variance: 
ESsm= effect size: standardized mean difference 
M1= mean of group 1 
M2 = mean of group 2 
Spooled = pooled standard deviation 
s21 = squared standard deviation in group 1 
s22 = squared 1standard deviation in group 2 
 
Vsm = the variance of the standardized 
mean difference 
𝐸𝑆𝑠𝑚
2
  = the squared effect size 
n1 = the sample size in group 1 
n2 = the sample size in group 2 
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𝑆𝐸𝑠𝑚 = �𝑉𝑠𝑚  and the 95% confidence interval (95% CI) around the standardized 
mean differences is calculated as: 95% CI = ESsm ± (1.96 x SEsm). 
Example 
This fictitious study examined the impact of motivational interviewing on 
medication taking adherence to antihypertensive drugs in patients identified as 
poor adherers after baseline screening with electronic event monitoring (EM). Those 
whose adherence rate during the 6 weeks of baseline monitoring was less than 80% 
were eligible to participate in the intervention phase of the study. These subjects 
were randomly assigned to a motivation interviewing intervention or to a usual care 
group. The outcome was the percent change in adherence rates measured by EM at 
the end of the 8 week intervention compared to baseline. The mean taking 
adherence rate increased 10.54 (SD=2.11) percent in the intervention group (n=66) 
and 3.21 (SD=2.00) percent in the usual care control group (n=65; p<0.001). To 
calculate the effect size, we first need to calculate the pooled standard deviation: 
𝑆𝑝𝑜𝑜𝑙𝑒𝑑 = �(𝑛1 − 1)𝑠12 + (𝑛2 − 1)𝑠22𝑛1 + 𝑛2 − 2 = �(66 − 1)2.112 + (65 − 1)2.00266 + 65 − 2 = �545.39129 = √4.23 = 2.06 
The pooled standard deviation is then is used to calculate the standardized mean 
difference: 𝐸𝑆𝑠𝑚 = 𝑀1−𝑀2𝑆𝑝𝑜𝑜𝑙𝑒𝑑 = 10.54−3.212.06 =  7.332.06 = 3.55.  
Next, we need to calculate the variance of the standardized mean difference: 
𝑉𝑠𝑚 = 𝑛1 + 𝑛2𝑛1𝑛2 + 𝐸𝑆𝑠𝑚22(𝑛1 + 𝑛2) = 66 + 6566 × 65 + 3.5522(66 + 65) = 1314209 + 12.60262 = 0.03 + 0.05 = 0.08 
The standard deviation of the standardized mean difference effect size (SEsm) is 
calculates as the square root of the variance Vsm:  𝑆𝐸𝑠𝑚 = �𝑉𝑠𝑚 =  √0.08 =  0.28  and 
the 95% confidence interval (CI) around the standardized mean difference is 
calculated as: 95% 𝐶𝐼 = 𝐸𝑆𝑠𝑚 ±  1.96(𝑆𝐸𝑠𝑚) =  3.55 ± (1.96 × 0.28) =  3.55 ± 0.55 =3.00, 4.10. 
In this example, the effect size and its 95% CI are 3.55 (3.00, 4.10). 
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Effect size based on correlation coefficients 
When studies examine the associations between scores on two variables the 
correlation coefficient itself can serve as an effect size estimate: ESr = r. In order to 
calculate the 95% CI around the correlation coefficient, its standard error needs to 
be calculated. Because simply using the correlation coefficient to calculate the 
standard error is problematic, correlations are generally transformed using Fisher’s 
Zr transformation prior to calculating the effect size and its 95% CI 4, 10. Fisher’s Zr 
is calculated as: 
𝐸𝑆𝑧𝑟 = 0.5 × 𝑙𝑛 �1+𝑟1−𝑟�. 
To calculate the 95% CI, the standard error of Zr (𝑆𝐸𝑧𝑟) needs to be calculated by 
first calculating the variance (𝑉𝑧𝑟) and then its square root:  𝑉𝑧𝑟 = 1𝑛−3 and 𝑆𝐸𝑧𝑟 = �𝑉𝑧𝑟  . 
The 95% CI can then be calculated as:  95% 𝐶𝐼 = 𝐸𝑆𝑧𝑟 ± 1.96 × 𝑆𝐸𝑧𝑟 . This is the 
confidence interval for the transformed effect size. While this will be used for meta-
analysis, when reporting effect sizes and confidence intervals in a table or forest 
plot in a systematic review or meta-analysis you need to report the effect size for the 
original correlation coefficient (ESr) and its corresponding 95% CI. To do this, you 
will need to transform the upper and lower bounds of the Zr confidence interval 
back into the standard correlational form. The formula to transform the 𝐸𝑆𝑧𝑟 95% 
CI back to a ESr 95% CI is: 𝑟 = 𝑒2𝐸𝑆𝑧𝑟−1
𝑒2𝐸𝑆𝑧𝑟+1
. 
This transformation needs to be done for both the lower and upper bound of the ESr 
95% CI. 
Example 
Papelbaum and colleagues (2010) examined the association between quality of life 
and the characteristics of subjects with type 2 diabetes (n=100) and reported that 
the univariate correlation between duration of diabetes and quality of life (measured 
by the Problem Areas of Diabetes scale) was r = 0.30 11. First, we need to transform 
r to Fisher’s z (𝐸𝑆𝑧𝑟): 𝐸𝑆𝑧𝑟 = 0.5 × 𝑙𝑛 �1+𝑟1−𝑟� =  .05 × 𝑙𝑛 �1+0.301−0.30� = 0.5 × ln(1.86) = 0.31.  Next, 
we need to calculate the variance  𝑉𝑧𝑟 = 1𝑛−3 = 1100−3 = 0.01 and the standard error: 
𝐸𝑆𝑧𝑟 = Fisher transformed effect size for the correlation           
 coefficient (r) 
 ln = the natural logarithm  
 
e = the base of the natural logarithm 
𝐸𝑆𝑧𝑟 = the effect size based on Fisher’s z 
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𝑆𝐸𝑧𝑟 = �𝑉𝑧𝑟 = √0.01 = 0.10. Finally, we calculate the 95% CI: 95% 𝐶𝐼 = 𝐸𝑆𝑧𝑟 ± 1.96 ×
𝑆𝐸𝑧𝑟 = 0.31 ± (1.96 × 0.10) = 0.31 ± 0.20 = 0.11, 0.51.  If you are doing meta-analysis, 
you will use the 𝐸𝑆𝑧𝑟, but if you are reporting the effect size in the manuscript or 
table of studies, the r and its 95% CI are easier to interpret than the 𝐸𝑆𝑧𝑟 and its 
95% CI. Thus, experts recommend converting the upper and lower bound of the 
𝐸𝑆𝑧𝑟CI back to the r metric 4: 𝐸𝑆𝑟𝑙𝑜𝑤𝑒𝑟 𝑏𝑜𝑢𝑛𝑑 = 𝑒2𝐸𝑆𝑧𝑟−1𝑒2𝐸𝑆𝑧𝑟+1 =  𝑒2×0.11−1𝑒2×0.11+1 = 0.252.25 = 0.11 and 
𝐸𝑆𝑟𝑢𝑝𝑝𝑒𝑟 𝑏𝑜𝑢𝑛𝑑 = 𝑒2𝐸𝑆𝑧𝑟−1𝑒2𝐸𝑆𝑧𝑟+1 = 𝑒1.02−1𝑒1.02+1 = 1.773.77  = 0.47.  
In this example, the effect size and its 95% CI are 0.30 (0.11, 0.47). 
 
Effect size based on the number of events and non-events in two groups 
Studies often report dichotomous outcomes in two study groups, e.g., the number 
and proportion of subjects whose adherence improved in a treatment and control 
group or the number of patients who were and were readmitted after hospital 
discharge for heart failure. While there are several effect size indices that can be 
calculated to describe the direction and magnitude of the relationship between a 
dichotomous independent and dependent variable (e.g., relative risk, risk ratio, risk 
difference and odds ratio), odds ratio is probably the most commonly reported effect 
size. The odds ratio (OR) is based on a 2 x 2 contingency table such as the one 
below. 
 Adherent Not Adherent   
𝑂𝑅 = 𝐴𝐷
𝐵𝐶
 
Treatment A  B n1 
Control C D n2 
The odds ratio is the odds of an outcome (e.g., being adherent) in one group (e.g., 
the treatment group) relative to its odds in the other group (e.g., the control group). 
To compensate for the fact that the odds ratio is centered around 1 (which indicates 
no relationship) rather than zero, all analyses are preformed on the natural log of 
the odds ratio (lnOR) 4. First, the lnOR (ESlnOR) and its standard error (SElnOR) are 
calculated:  
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𝐸𝑆𝑙𝑛𝑂𝑅 = ln (𝑂𝑅) and 𝑆𝐸𝑙𝑛𝑂𝑅 = �1𝐴 + 1𝐵 + 1𝐶 + 1𝐷 and used to calculate the 95% CI: 
95% 𝐶𝐼 =  𝐸𝑆𝑙𝑛𝑂𝑅 ± 1.96 × 𝑆𝐸𝑙𝑛𝑂𝑅. While the natural log values will be used during 
meta-analysis, they should be transformed back into the odds ratio and its 95% CI 
when reported in the text or tables of a manuscript or in a forest plot. The following 
formulas are used to calculate the lower and upper limits of the 95% CI around the 
OR: 𝐿𝑜𝑤𝑒𝑟 𝑙𝑖𝑚𝑖𝑡𝑂𝑅 = 𝑒(𝐸𝑆ln𝑂𝑅−1.96𝑆𝐸𝑙𝑛𝑂𝑅) and 𝑈𝑝𝑝𝑒𝑟 𝑙𝑖𝑚𝑖𝑡𝑂𝑅 = 𝑒(𝐸𝑆𝑙𝑛𝑂𝑅+1.96𝑆𝐸𝑙𝑛𝑂𝑅). 
Example 
Beeckman et al. (2010) examined the effectiveness of the Pressure Ulcer 
Classification education tool in increasing nurses’ ability to correctly classify 
photographs of pressure ulcers and incontinence-associated dermatitis (IAD) 12. 
Following the educational intervention nurses in the intervention group correctly 
classified 70.2% of the photographs of IAD compared to 35.8% of photographs that 
were correctly classified by the control group. 
 IAD Correctly Identified  
𝑂𝑅 = 𝐴𝐷
𝐵𝐶
= 1360 × 1058577 × 587 = 4.23 
 
 Yes No 
Treatment 1360 577 
Control 589 1058 
  
After calculating the odds ratio, we need to calculate the natural log of the OR 
(ESlnOR) and its standard error (SElnOR): 𝐸𝑆𝑙𝑛𝑂𝑅 = ln (𝑂𝑅)=ln(4.23)=1.44 and 𝑆𝐸𝑙𝑛 =
�
1
𝐴
+ 1
𝐵
+ 1
𝐶
+ 1
𝐷
= � 1
1360
+ 1
577
+ 1
587
+ 1
1058
= √0.0051 = 0.07.  
These values are used to calculate the 95% CI for the natural log of the OR. 95% 𝐶𝐼 =  𝐸𝑆𝑙𝑛𝑂𝑅 ± 1.96 × 𝑆𝐸𝑙𝑛𝑂𝑅 = 1.44 ± (1.96 × 0.07) = 1.44 ± 0.14 = 1.3, 1.58.  
Finally, to present the effect size in a manuscript, we need to transform the lower 
and upper bound of the 95% CI for the natural log OR to a 95% for the OR: 
𝐿𝑜𝑤𝑒𝑟 𝑙𝑖𝑚𝑖𝑡𝑂𝑅 = 𝑒(𝐸𝑆ln𝑂𝑅−1.96𝑆𝐸𝑙𝑛𝑂𝑅) = 𝑒(1.44−(1.96×0.07)) = 3.67and𝑈𝑝𝑝𝑒𝑟 𝑙𝑖𝑚𝑖𝑡𝑂𝑅 =
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𝑒(𝐸𝑆𝑙𝑛𝑂𝑅+1.96𝑆𝐸𝑙𝑛𝑂𝑅) = 𝑒(1.44+(1.96×0.07)) = 4.85. In this example, the odds ratio effect size 
and its 95% CI are 4.23 (3.67, 4.85).   
When using OR’s as the ES measure in a systematic review or meta-analysis, you 
need to be sure that they all reflect the same outcome (e.g., that all reflect the odds 
of adherence). If you use the OR and 95% CI reported in studies, this may not be 
the case. For example, some studies report the OR/95% CI for adherence and 
others for non-adherence. To change the direction of a OR for the reported outcome 
to the desired outcome, e.g. from modeling non-adherence to modeling adherence, 
you need to compute the inverse of the OR: 𝐼𝑛𝑣𝑒𝑟𝑠𝑒 𝑂𝑅 = 1
𝑂𝑅
. The standard error of 
the lower limit of the natural log odds ratios of the original 95% CI also needs to be 
calculated.  The formula to do this is: 
𝑆𝐸𝐿𝐿𝑂𝑅 = −(ln�𝐿𝐿𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑂𝑅�−ln [𝑂𝑅])1.96 . This value is utilized to calculate the 95% CI for the 
inverse odds ratio: 
𝐿𝐿𝑂𝑅 = 𝑒(ln[Inverse OR]−(1.96×SELLln [OR]]))and 𝑈𝐿𝑂𝑅 = 𝑒(ln[Inverse OR]−(1.96×SEULln [OR])). 
Example 
Ingersoll and Heckman (2005) examined the association between patients’ 
perceptions of clinician’s knowledge about them (knowledge of patient) and 
adherence to HIV medications 13. They reported that the OR and 95% CI for 
knowledge or patient and non-adherence was 0.97 (0.94, 1.01). In our review, we 
want to report the effect sizes for adherence so we need to convert this OR and 95% 
CI for non-adherence to the odds of adherence and its 95% CI. First we need to 
convert the OR for non-adherence to the OR for adherence: 𝐼𝑛𝑣𝑒𝑟𝑠𝑒 𝑂𝑅 = 1
𝑂𝑅
= 1
0.97 =1.03. Then, we need to calculate the standard error for the log odds ratio based on 
the lower limit of the original 95% CI: 
𝑆𝐸𝐿𝐿𝑙𝑛𝑂𝑅 = −(𝑙𝑛𝐿𝐿 𝑂𝑅−𝑙𝑛𝑂𝑅)1.96 = −(ln[0.94]−ln[0.97])1.96 = 0.016. The 𝑆𝐸𝐿𝐿𝑙𝑛𝑂𝑅 is used to calculate the 
95% CI for the inverse OR: 𝐿𝐿𝑂𝑅 = 𝑒(ln[Inverse OR]−(1.96×SELLln [OR]])) = 𝑒ln[1.03]−(1.96×−0.016) =0.998 and 𝑈𝐿𝑂𝑅 = 𝑒(ln[Inverse OR]+(1.96×SELLln [OR])) = 𝑒ln[1.03]+(1.96×0.06) = 1.063. Thus, in this 
example, the OR and 95% CI for adherence is 1.03 (0.998, 1.063). 
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Indirect methods to calculate the effect size 
As previously noted, published studies often fail to report the summary statistics 
needed to directly calculate an effect size. If one is unable to obtain the missing 
data from the author(s) of the manuscript, there may be methods available to 
estimate the effect size from less than optimal statistical information 7. Readers are 
referred to the Lipsey and Wilson (2001) 4 or Rosenthal (1991) 14 books for 
procedures for calculating effect sizes from a variety of reported statistics.      
One example of indirectly calculating the effect size when summary statistics 
(means and standard deviations) are not reported is calculating it from a reported t-
statistic in a study comparing a continuous outcome in two independent groups 
(student’s t-test). If the author(s) report(s) a t-statistic and the sample size for each 
of the two groups, a standardize mean effect size (ESsm) can be calculated as4: 
𝐸𝑆𝑠𝑚 = 𝑡�𝑛1+𝑛2𝑛1×𝑛2. 
Example 
A fictitious study examined the impact of an intervention on perceived barriers to 
regular exercise. They compared scores on a barrier scale in treatment (n=25) and 
control subjects (n=26). The test statistics reported were t=7.2, p<0.001. Using the 
formula above, we can calculate: 𝐸𝑆𝑠𝑚 = 𝑡�𝑛1+𝑛2𝑛1×𝑛2 = 7.2�25+2625×26 = 2.017. If only the total 
sample is reported, Rosenthal 14 suggests that the effect size can be calculated as: 
𝐸𝑆𝑑 = 𝑡�𝑑𝑓
2
. The estimated effect size will be a somewhat less precise than when 
using the Lipsey and Wilson formula 4. 
In some studies, the only test statistic reported is a p-value. As long as an exact p-
value and sample size are reported, an estimated effect size (ES) can be calculated. 
Calculation of ES requires p-value to be converted to a Z score (standard normal 
deviate).  This can be done using a table of Z score. There are also websites that will 
convert p-values to z scores. One example is: 
http://sampson.byu.edu/courses/z2p2z-calculator.html. If the p is two tailed, 
convert it to a one-tailed (p divided by 2) before entering it into the program. Once 
you have the Z score, the following formula can be used to calculate an effect size 
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correlation (ESr): 𝐸𝑆𝑟 = 𝑍√𝑛 14. If you want to report standardized mean effect sizes 
rather than correlation effect sizes, ESr can be converted to a Cohen’s d (a 
standardized mean effect size measure): 𝐸𝑆𝑑 = 2𝑟√1−𝑟2.    
Example 
If a study only reports that the p-value was 0.043 and the sample size is 150, we 
can estimate the effect size (ESr). First, we need to find the Z score that corresponds 
to the reported p-value. If there is no reason to assume that a one tailed test was 
used (e.g., explicitly stated by the author(s) or the presence of a hypothesis that 
stated that a one-direction outcome was expected), it is probably best to assume 
that the study used a two-tailed test and divide the p-value by 2 prior to finding in 
the corresponding Z score. In our example, we assumed a 2-tailed test was used 
and divided out reported p-value (0.043) by two and used a p-value of 0.0215 to 
find the corresponding Z score of 2.024.  Now we can calculate the effect size for r: 
𝐸𝑆𝑟 = 𝑍√𝑛 = 2.024√150 = 0.17 and use to compute Cohen’s d: 𝐸𝑆𝑑 = 2𝑟√1−𝑟2  2×0.17√1−0.172 = 0.345. 
Unfortunately, it is not uncommon to find that in addition to not reported the 
summary statistics need to directly calculate an effect size or the test statistics need 
to indirectly calculate it, authors do not report an exact p-value which means that 
you cannot estimate the effect size with any degree of confidence. This is 
particularly problematic if you want to statistically combine the result of studies 
included in a review (perform meta-analysis) or to graphically display them in a 
forest plot. Not uncommonly when study findings are negative, the p-value is simply 
reported as not significant or p >0.05. Even when the study findings are positive 
(i.e., significant), the exact p-value may not be reported. Instead, authors may 
report p<0.05 or may include a table legend that indicates which p-values are less 
than pre-determined levels (e.g., *p<0.05, **p<0.001, ***p<0.0001). 
The first approach when there is insufficient information to calculate an effect size 
is to contact the author(s) to request the needed information. Unfortunately, this is 
not always successful for a variety of reasons. Lipsey and Wilson (2001) discuss 
several other approaches to dealing with studies where an effect size cannot be 
calculated 4. The first is to only include studies where an effect size can be 
calculated. This issue with this approach is that studies with negative findings are 
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generally less likely report the data needed to calculate an effect size. If these study 
findings are ignored, it is likely that the effect in the target population is 
overestimated. Another approach is to code all effect sizes for studies that reported 
that their findings were non-significant as zero. If studies report that the findings 
were significant without an exact p-value or simply report that p≤0.05, the effect 
size calculation can be based on the assumption that p=0.05. These approaches 
are, however, conservation and will result in downward bias in the mean effect size 
across studies and underestimate the population effect size. If the author(s) do not 
report an exact p-value for significant findings but instead report that p-values are 
less than several predetermined levels (e.g., p<0.05, p<0.01, p<0.001), it will be 
somewhat less conservative to use p-values that are half between the adjacent p-
values when estimating the effect size. For example, we would assume (based on 
this example) that all effects noted to have a p-value less than 0.05 are half way 
between 0.05 and 0.01 and those noted to have a p-values <0.01 to have a value 
half way between 0.01 and 0.001. 
 
Software to calculate effect sizes 
Fortunately, there is software available to help with many effect size calculations. 
There are a number of freeware programs available on the web. One of sites that the 
authors have used and recommend was developed by David Wilson, co-author of 
the Lipsey and Wilson book on meta-analysis (2001) 4. This website, The Practical 
Meta-Analysis Effect Size Calculator 
(http://gunston.gmu.edu/cebcp/EffectSizeCalculator/index.html), was recently 
updated and can be utilized to compute effect sizes and 95% CIs based on a variety 
of reported statistics. There are also a number of commercial software packages 
that calculate effect sizes such as Effect Size Generator-Pro (Melbourne, Australia) 
and Comprehensive Meta-Analysis (Biostat, Englewood NJ). 
 
Interpreting effect size results 
While Cohen (1988) suggested rules of thumb for interpreting effect sizes for 
Cohen’s d (small= 0.20, medium= 0.50 and large= 0.80) and correlations (r: 
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small= 0.10, medium= 0.30 and large= 0.50) for the social sciences, the 
interpretation of effect sizes in terms of their magnitude and clinical 
significance varies with the area of scientific study 15. More specifically, it 
varies with the how precisely the independent and dependent (or X and Y) 
variables are measured. In behavior research, there is generally a lot of noise 
in the measurement of variables, making them less precise than many 
physiologic measures. Consequently, effect sizes often need to be higher in 
physiologic than in behavioral research to be considered clinically 
significant. 
 
Conclusions 
Secondary to limitations of many traditional test statistics and the p-value in 
providing information about the clinical significance of research findings, most 
current research guidelines recommend that investigators also report the effect size 
for the interventions or association that they examined. Unfortunately, effect sizes 
are not included in publications of many research studies. In these situations, 
clinicians and researchers need to be able to calculate effect sizes and their 95% 
confidence interval in order to know if statistically significant findings are also 
clinically meaningful and are a precise representative of the effect in the target 
population.  
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Abstract  
Background: Complex medication regimens are often required to manage 
cardiovascular diseases. As non-adherence, which can have severe negative 
outcomes, is common among cardiovascular patients, various interventions to 
improve adherence should be implemented in daily practice. 
Aim: To assess which strategies cardiovascular nurses and allied health 
professionals utilize to (1) assess patients’ adherence to medication regimen, and (2) 
enhance medication adherence via educational/cognitive, counseling/behavioral, 
and psychological/affective interventions.  
Method: A 45-item questionnaire to assess adherence assessment and 
interventional strategies utilised by health care professionals in daily clinical 
practice was distributed to a convenience sample of attendants of the 10th Annual 
Spring Meeting of the European Society of Cardiology Council on Cardiovascular 
Nursing and Allied Professions conference in Geneva (Switzerland) in March 2010. 
Respondents not in direct clinical practice were excluded. Descriptive statistics were 
used to describe practice patterns regarding adherence management.  
Results: Of 276 distributed questionnaires, 171 (62%) were returned, of which 34 
(20%) were excluded as respondents performed no direct patient care. Questioning 
patients about non-adherence during follow-up was the most frequently reported 
assessment strategy (56%). Educational/cognitive adherence enhancing 
interventions were used most frequently, followed by counselling/behavioural 
interventions. Psychological/affective interventions were less frequently used. The 
most frequent intervention used was providing reading materials (66%) followed by 
training patients regarding medication taking during inpatient recovery (48%). 
Slightly over two-thirds (69%) reported using a combination of interventions to 
improve patient’s adherence. 
Conclusion: Educational interventions are used most in clinical practice, although 
evidence shows they are less effective than behavioural interventions at enhancing 
medication adherence.  
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Background 
Cardiovascular disease is the leading cause of death worldwide 1, 2, accounting for 
approximately 17.1 million deaths in 2004 1. In the UK alone, about 2.6 million 
people currently suffer from cardiovascular disease 3, while in the US a third of all 
people aged 18 and more live with one or more cardiovascular disease 4. Managing a 
cardiovascular disease generally necessitates a complex regimen of medications to 
prevent and/or delay the disease’s progression, control symptoms, decrease re-
hospitalization and improve survival 5. 
For a prescribed treatment to be effective, adherence to the medication regimen is 
essential. Medication adherence (also called compliance) can be defined as “the 
extent to which a patient acts in accordance with the prescribed interval and dose 
of a dosing regimen” 6 (pg. 46). Medication persistence, on the other hand, is “the 
duration of time from initiation to discontinuation of therapy” 6 (pg. 46). Non-
adherence to medication regimens in the cardiovascular patient population is 
common. A meta-analysis showed an average adherence among cardiovascular 
patients of 77% (CI: 73.4-79.8) 7. In a group of 58,744 medication naive patients 
with a cardiovascular disease, 32% discontinued their medication treatment during 
the first 30 days of treatment 8. Large variations in adherence rates among studies 
are observed, partly due to variations in measurement methods and operational 
definitions.  
Medication non-adherence can have serious consequences, including poor clinical 
outcomes, higher (re)hospitalization rates, increased health care costs, and higher 
mortality 9-16. Non-adherence is associated with a significantly elevated risk of 
recurrent myocardial infarction 9, 10, 12. Examining the reasons for hospital 
readmission in heart failure patients, Annema et al. (2009) found that one-third of 
patients described improvement of adherence to their treatment regimens as the 
most important condition to prevent readmission 17.  
The reasons for medication non-adherence in patients suffering from chronic 
diseases, including cardiovascular disease, are only partially understood 18. 
However, associated factors have been identified and can be categorized in five 
dimensions: (1) patient-related factors (e.g., self-efficacy, knowledge, intentions), (2) 
therapy-related factors (e.g., dose frequency, duration of treatment), (3) socio-
economic factors (e.g., social isolation, cost of treatment), (4) condition-related 
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factors (e.g., depression, number of co-morbidities), and (5) health care team- and 
system-related factors (e.g., quality of provider communication, trust in the health 
care worker) 18.  
Adherence can be measured using different strategies (e.g., self-report, collateral 
report, pill count, electronic monitoring, pharmacy refill, observation, assay) 19-21. 
Once an adherence issue is identified, a range of interventions can be implemented 
to target the patient, health care provider, health care organization or health care 
system 22. Interventions focusing on the patient can be classified as 
educational/cognitive, counseling/behavioral, and psychological/affective 
interventions 23. Educational/cognitive interventions present information individually 
or in a group setting, delivering it verbally, in written form, and/or audio-visually. 
Counseling/behavioral interventions shape and/or reinforce behavior, empowering 
patients to participate in their care, and building skills or routines. 
Psychological/affective interventions focus on the patient’s feelings, emotions, 
relationships and social support 23. 
Not all types of interventions are supported by evidence. A Cochrane review 24, 
focusing on the efficacy of adherence enhancing interventions and measuring both 
adherence and clinical outcomes, included 70 trials testing 83 interventions for 
long-term treatments. This review showed that for long-term treatments, only 36 of 
the 83 interventions showed significant associations with improvements in 
medication adherence 24, while only 25 led to improvement in at least one treatment 
outcome 24. No simple and few complex interventions resulted in improvement of 
adherence and clinical outcomes. Conn et al. (2009), in a meta-analysis 
investigating the efficacy of interventions to improve medication adherence in older 
adults, showed that a number of interventions significantly improved medication 
adherence, but reported large differences in the effect size of different interventions 
on medication adherence 25. In this meta-analysis, interventions also significantly 
improved knowledge and diastolic blood pressure; however, no significant effects 
were found for systolic blood pressure, other health outcomes or health services 
utilization 25.  
In a recent study focusing on physicians of patients with chronic myeloid leukemia, 
it has been shown how widely perceptions of the utility and applicability of 
adherence enhancing interventions differed among physicians 26. Although the 
importance of developing interventions to enhance patient adherence is recognized, 
little is known which interventions are implemented in routine cardiovascular care.  
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The aim of this study was therefore to assess the strategies cardiovascular nurses 
and allied health professionals utilize to (1) assess patients’ adherence to their 
medication regimens, and (2) enhance their medication adherence 
(educational/cognitive, counseling/behavioral, or psychological/affective 
techniques). 
 
Methods 
Design, setting and sample 
This study used survey methodology. All attendees of the 10th Annual Spring 
Meeting of the European Society of Cardiology Council on Cardiovascular Nursing 
and Allied Professions (CCNAP) in Geneva (Switzerland) on March 12th & 13th, 2010, 
were invited to participate in this study. To be included in this study, participants 
had to have direct patient contact. This study was supported by the UNITE budget 
and by Eli Lilly. 
 
Variables and measurement 
A structured questionnaire in English assessed the following set of variables:  
Demographic information: Demographic information was collected from all 
participants (Table 1).   
Adherence Assessment and Intervention Strategies: The questionnaire presented 29 
items to survey adherence assessment and interventions. Participants were asked 
to indicate on a 5-point Likert-type scale, ranging from never (1) to all the time (5), 
the frequency with which they utilized each of three strategies to assess medication 
adherence: (1) questioning patients about medication adherence during follow-up 
visits; (2) screening patients for risk factors for medication non-adherence during 
follow-up; and (3) using an electronic monitoring device to assess adherence/risk 
factors. Furthermore, participants were given a list of educational/cognitive (6 
items), counseling/behavioral (11 items), and psychological/affective (9 items) 
interventions and asked to indicate on a 5-point Likert-type scale ranging from 
never (1) to all the time (5) the frequency with which they used each to increase 
patients’ medication adherence.  
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The questionnaire was developed for this study. The interventions and assessment 
strategies in the list were derived from interventions found in the literature 18, 24, 27-
29. The draft questionnaire was discussed and adapted a number of times in the 
research group before being finalized. To evaluate the understandability and 
feasibility of this scale, it was piloted on 13 health care professionals working with 
patients post organ transplantation in the US and the UK. As findings showed 
highly skewed answer patterns for most items, responses to the Likert-scale 
questions were collapsed prior to analysis, into never= 0 (‘never’), seldom= 1 
(‘occasionally’ and ‘sometimes’), and frequently= 2 (‘frequently’ and ‘all the time’). 
 
Data collection 
All delegates attending the 2010 Spring Meeting of the European Society of CCNAP 
were informed about the study at the time of registration and given a copy of the 
questionnaire. The study was also introduced at the opening session of the 
conference. Attendees were asked to put their completed questionnaires into the 
designated collection boxes. Questionnaires could be submitted during both 
conference days. The distribution process guaranteed that only one questionnaire 
was distributed per attendee. Research associates were available throughout the 
conference to provide information and support to the attendees on filling out their 
questionnaires as well as to motivate them to participate in the survey.  
Data analysis 
Data were analyzed using descriptive statistics: frequencies, percentages and, 
where appropriate, measures of central tendencies and variability. We calculated 
the mean proportion of interventions in each of the three categories 
(education/cognitive, cognitive/behavioural and psychological/affective) that 
participants reported using frequently or all of the time. Participants who reported 
that they frequently or always used one or more intervention from at least two of 
the categories were classified as frequently utilizing a combination of methods to 
enhance medication adherence. The statistical analyses were performed using SPSS 
16 (SPSS Inc, Chicago, Il). Data were analyzed at the item level. 
 
Chapter 5: Adherence interventions used by cardiovascular professionals  
 
 
 
 
113 
Human subject considerations 
All conference attendees were informed twice regarding the aim of the study: once 
when the questionnaires were distributed at registration, and once during a short 
oral presentation at the beginning of the conference. Informed consent of the 
participants was implied by the completion of the questionnaire. No identifying data 
were collected from the participants assuring anonymity of the data.  
 
Results 
Demographic information 
Of the 276 distributed questionnaires, 171 (62%) were completed and returned. 
Thirty-four respondents (20%) provided no direct patient care and were therefore 
excluded from further data analysis. The demographic characteristics of the final 
sample (Table 1), show that the majority of participants were women (83%) with a 
mean age of 41 years. Most (85%) worked with adult patients, and more than half 
(56%) worked in inpatient departments. Just over one-quarter (27%) reported 
receiving formal training in health behaviour modification. 
Strategies to assess adherence  
Figure 1 shows the findings regarding use of the different adherence assessment 
strategies. Questioning patients about non-adherence during follow-up was the 
strategy most often reported, used frequently by 56% of the participants. Next came 
screening for risk factors for non-adherence during follow up, which was used 
frequently by 40% of the respondents. Using an electronic monitoring device to 
assess non-adherence was rare: 86% never used this method. 
 
Interventions to enhance adherence 
Educational interventions were used most often, followed by behavioral and least 
often, affective interventions (Figure 2). More specifically, participants reported 
using a higher proportion of educational/cognitive interventions (mean= 36%, SD= 
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24) than counseling/behavioral (mean= 32%, SD= 26) or psychological/effective 
interventions (mean= 23%, SD= 25). 
Examining the data at the intervention level, we found that providing reading 
materials about cardiovascular care was the most used adherence-enhancing 
intervention, with 66% of respondents using it frequently (Table 2). Almost half of 
the participants (48%) reported that they frequently trained patients about how to 
properly take their medications at home during their inpatient recovery. Nearly half 
of the clinicians (47%) frequently offered individual patient/family instructions 
about medication adherence. 
Using electronic monitoring devices for feedback was the least commonly reported 
method of improving adherence. Establishing support groups or peer mentor 
programs to reinforce adherence were never used in daily practice by 66% and 62% 
of participants, respectively. The other intervention used infrequently was computer 
assisted educational programs: with nearly 60% never using this technology.  
Furthermore, we examined the proportion of the sample reporting frequent use of a 
combination of methods. Ninety-five participants (69%) reported that they 
frequently combined at least two interventions from the educational/cognitive, 
counseling/behavioral and/or psychological/affective categories to enhance 
adherence in daily cardiovascular care.  
 
Discussion 
The high prevalence of non-adherence in the cardiovascular patient population and 
its links to poor clinical outcomes, high (re)hospitalization rates, increased health 
care costs and higher mortality 9-15 demand the implementation of adherence 
enhancing interventions in daily clinical practice. To our knowledge, this is the first 
study to examine the types of medication assessment strategies and adherence 
enhancing interventions used by cardiovascular nurses and allied health 
professionals in daily clinical practice.  
 
Assessment strategies 
The most frequently used medication adherence assessment method in our sample 
was questioning patients about medication adherence during follow-up visits. This 
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self-report method is a simple, inexpensive and feasible method to assess adherence 
in daily care, but is prone to recall and socially desirable response bias 19, 20. 
However, no gold standard exists for assessing patients’ adherence 19 and all 
methods have their strengths and weaknesses 19-21. Osterberg & Blaschke state that 
a combination of different adherence measures is the best approach to maximize 
accuracy 19. 
 
Educational/cognitive interventions 
Although evidence shows that educational interventions do not effectively enhance 
medication adherence 25, educational approaches were used most often in this 
study. A recent meta-analysis showed that despite evidence showing variable 
associations between knowledge and adherence, many interventions in older adults 
are educational 25. In our sample the most frequently utilized method was providing 
reading materials about cardiovascular care. Interesting to note is that the 
previously mentioned meta-analysis did not find significant differences in 
adherence improvement following interventions using written information about 
medication or disease with those that did not. The effect of this intervention on 
knowledge, however, was significant 25. Furthermore, larger adherence effect sizes 
could be found in participants taking 3-5 medications 25. In order for educational 
interventions to be effective, the information materials should incorporate simple 
text and pictograms 30. Patient education is likely to have more impact on 
adherence when it is consistent over time, presented by health care providers and 
tailored to patient characteristics including cognitive, educational, developmental 
and intellectual capabilities 22. Moreover, the WHO report ‘Adherence to long-term 
therapies – evidence for action’ states that, while adherence interventions at the 
patient level have usually focused on increasing knowledge by providing education, 
knowledge alone is not enough to establish and maintain good adherence behavior 
18.  
 
Counseling/behavioral interventions 
The method used least frequently in practice was employing electronic monitoring 
devices as a feedback system. Electronic monitoring devices are pill bottles or 
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blister packets that continuously record the date and time of each opening, which 
presumably corresponds with medication intake 22. Data can be uploaded to a 
computer and printouts of the device’s data show the user’s medication dynamics, 
which the patient and health care team can discuss to jointly establish adherence 
goals. In cases of improved adherence, patients received positive feedback, inducing 
mastery experiences 31. Although electronic monitoring can offer a powerful tool to 
enhance patients’ adherence, it is not often offered in daily practice. This could be 
because electronic monitoring devices are rather expensive, may be too complicated 
for some patients to use and may be too time-consuming for the health care 
provider.  
Although computer based information packages for patients have been shown to 
have a positive effect on self-efficacy and on behavioral outcomes 32, assisted 
learning programs were not frequently used in our sample. Cardiovascular health 
care professionals may be reluctant to use computer assisted programs due to the 
typically older age of their patient population. To benefit from such programs, the 
patient requires access to a computer and, for some programs, internet access, as 
well as the skills necessary to use computer hardware and software effectively. 
These requirements may be barriers to utilization of this type of intervention in 
older patient populations. It has been shown, however, that older patients with 
chronic diseases can be trained to use a computer and computer programs 
effectively 33, 34. 
 
Psychological/affective interventions 
Neither support groups nor peer mentor programs were used by most of the 
participants in this study, although a recent systematic review reported mixed 
outcomes from the use of non-professional volunteers 35. In the literature examining 
non-adherence, one study in three reports a significant effect from these 
interventions 35. Regarding patients’ experiences of peer support, a qualitative study 
in kidney patients found that they greatly valued peer support and that it helped 
them to adapt to their chronic illness by normalizing adherence to their demanding 
treatment regimens 36. 
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Limitations of this study 
This study has several limitations, the foremost of which is that the questionnaire 
focuses only on adherence enhancing interventions at the patient level. 
Interventions at the micro level (strategies focusing on patient-provider 
interactions), the meso level (characteristics of the treatment center or hospital), 
and the macro level (interventions focusing on the health care system or on the 
society in which a patient lives) are also crucial to improving adherence 37. A further 
limitation is the limited generalizability of the findings as conference attendees may 
not accurately represent the population of cardiovascular clinical practice nurses 
and allied professionals. Compared to surveys conducted in previous years (with 
response rates of 33% 38 and 48% respectively 39), this conference’s survey had a 
high response rate of 62%. Unfortunately, we do not have data on the non-
responders so it is not possible to see if they had a different socio-demographic 
profile or if there were more or less nurses/allied professionals not directly working 
in clinical practice among the non-responders. 
 
Recommendations 
Health care professionals working with cardiovascular patients are strongly advised 
to implement adherence enhancing interventions in their daily practice. Moreover, 
they are advised to implement multi-dimensional interventions combining 
educational/cognitive, counseling/behavioral, and psychological/affective 
interventions. To enable health care workers to deliver interventions that optimize 
adherence, they need to receive training in health behavior modification strategies.  
Further research should address which interventions at the micro-, meso-, and 
macro level are most effective to enhance patients’ adherence to their medication 
regimens. Future studies are also needed to examine health care workers’ 
perceptions of the effectiveness of the adherence enhancing interventions they 
utilize. 
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Conclusion 
A variety of interventions are used in daily cardiovascular care to improve 
medication adherence. The most frequently used interventions in this sample were 
educational/cognitive interventions, although evidence shows these are less 
effective than behavioural interventions at enhancing medication adherence. For 
clinicians committed to positively influencing medication adherence, it would be 
more effective to focus on combining interventions, especially implementing 
alternatives to educational interventions.  
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Table 1: Demographic information  
Variable N= 137 
Gender  
Female, n (%) 
 
114 (83) 
Age years 
Mean ± SD 
 
41.36 ± 8.98  
Continent where department is located 
Europe, n (%) 
North-America, n (%) 
Asia, n (%) 
 
129 (94) 
4 (3) 
2 (2) 
Highest level of education 
Basic nursing training, n (%) 
Bachelor, n (%) 
Master, n (%) 
PhD, n (%) 
 
48 (35) 
40 (29) 
39 (29) 
10 (7) 
Current position 
Staff nurse, n (%) 
Advanced Practice Nurse, n (%) 
Head nurse/Nurse manager, n (%) 
Other1, n (%) 
 
46 (34) 
38 (28) 
22 (16) 
31 (23) 
Case load  
Adult patients, n (%) 
Paediatric patients, n (%) 
Both, n (%) 
 
116 (85) 
1 (1) 
18 (13) 
Main specialty department (more than one answer 
possible) 
Critical care (ICU/CCU), n  
Interventional cardiology (e.g. cath lab), n 
Cardiac rehabilitation, n 
Outpatient clinic, n 
Internal medicine, n 
Cardiac surgery, n 
Intermediate CCU, n 
Diagnostic (e.g. EKG, Echo, Nuclear Stress), n 
Emergency Room, n 
Transplantation, n 
Community health care, n 
 
27  
26 
23 
21 
20 
20 
20 
14 
11 
8 
4 
13 
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Other2, n 
Type of hospital 
University teaching hospital, n (%) 
Teaching hospital, n (%) 
Regional or community hospital, n (%) 
Clinic, n (%) 
Community health care organization, n (%) 
 
86 (63) 
21 (15) 
19 (14) 
7 (5) 
2 (2)  
Advanced Practice Nurse working at the department 
Yes, n (%) 
 
83 (61) 
Years practicing 
Mean ± SD 
 
18.16 ± 9.94 
Years practicing in cardiovascular nursing 
Mean ± SD 
 
12.46 ± 9.28 
Years practicing in current department 
Mean ± SD 
 
9.12 ± 8.01 
Percentage of work 
Mean ± SD 
 
87.59 ± 22.71 
Received formal training in health behavior 
modification 
37 (27) 
 
1Other current positions including: Study nurse/nurse researcher, biomedical engineer, 
physiotherapist, medical doctor, nurse manager/care manager. 
2Other main specialty departments including: Physical training centre, patient organization, 
vascular surgery ward, nursing ward. 
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Figure 1: Non-adherence (NA) assessment strategies
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Figure 2: Number of participants reporting that they frequently used the intervention
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Table 2: Adherence enhancing intervention N =137 
Variable 
 
Fr
eq
ue
nt
ly
 
%
 
Se
ld
om
 
%
 
N
ev
er
  
%
 
Educational/Cognitive interventions 
Providing reading materials 66 19 6 
Providing individual patient/family teaching 47 24 18 
Providing printed medication instructions 46 24 18 
Offering educational classes 28 20 40 
Showing video tapes  4 30 56 
Using computer-assisted educational programs 2 31 58 
Counselling/behavioural interventions 
Training patients during inpatient recovery how to take 
medications 
48 22 16 
Teaching patients to use cueing 39 25 21 
Tailoring medication regimen to patient’s lifestyle 37 26 26 
Providing dispensers for organizing medications  33 22 31 
Providing adherence reminders during clinic visits 32 20 28 
Behavioural counselling intervention  31 28 22 
Reducing the complexity of the medication regimen 30 33 21 
Medical counselling by a clinical pharmacist 17 20 51 
Recommend reminder systems 12 26 47 
Using reports from electronic monitoring devices as a 
feedback system 
10 5 69 
Establishing adherence contracts with patients 8 24 53 
Psychological/affective interventions 
Establishing a partnership with patient and significant 
other 
43 26 15 
Involving family or support persons in education and 
behavioural interventions 
33 36 13 
Providing telephone assistance if needed 23 39 21 
Scheduling more frequent clinic visits in case of problems 
with NA 
23 26 34 
Using motivational interviewing 13 27 42 
Establishing case management services for high-risk 
patients 
13 23 46 
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Scheduling calls to patients’ homes in case of problems 
with NA 
13 21 49 
Establishing peer-mentor programs 4 18 62 
Establishing support groups directed at adherence 4 12 66 
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Abstract 
Context: Although medication non-adherence is associated with severe 
complications including graft rejection and loss, its prevalence remains high among 
organ transplantation (Tx) recipients. Still, little information exists on clinical use of 
interventions to improve medication adherence (MA). 
Objective: To identify Tx health care professionals’ MA assessment methods, 
classify the used interventions, and measure those interventions’ perceived 
effectiveness. 
Design, Setting & Participants: A 46-item questionnaire on adherence assessment 
and interventions was distributed at the 2010 International Transplant Nurses 
Society symposium in Germany. Data were analyzed using descriptive statistics.  
Results: Of 141 distributed questionnaires, 94 (67%) were returned. Respondents 
with no direct patient contact (9%, n= 8) were excluded. The most frequently used 
assessment strategy was patient self-reporting (61%, n= 52). On average, 
participants reported using 47% of the educational/cognitive and 42% of the 
counseling/behavioral interventions listed. Training patients to self-administer 
medications and providing printed adherence information were the most frequent 
interventions (79% each, n= 68), followed by providing printed medication 
instructions (69%, n= 59). Most respondents (90%, n= 77) reported combining 
interventions. The intervention perceived as most effective was medication self-
administration training. 
Conclusion: Although available alternatives are demonstrably more effective for MA 
enhancement, this sample relied significantly more on educational interventions.  
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Background 
For solid organ recipients, maintaining graft health following transplantation (Tx) 
demands lifelong medication intake. Successful outcomes are linked closely to 
medication adherence (also called “compliance”), which the World Health 
Organization (WHO) defines as “the extent to which a person’s behavior (e.g. taking 
medications) corresponds with the agreed recommendations of a health care 
provider “ 1 (pg. 3).  
Conversely, the effect of post-Tx non-adherence on short- and long-term outcomes – 
and associated health care costs – can be catastrophic: 15% to 60% of late acute 
rejections and 5% to 36% of graft losses are associated with non-adherence 2-6. In a 
meta-analysis of renal transplantation data, Butler et al. showed that the odds of 
graft failure were seven times higher in non-adherent patients than in their 
adherent counterparts 5. Even faced with such risks, a substantial proportion of 
solid organ recipients fail to take their medication as prescribed 2-4, 7-9. A 2005 
meta-analysis found that, among adult transplant (Tx) recipients, the magnitude of 
non-adherence to immunosuppressants was 22.6 cases per 100 patients per year 
across transplant groups 7. 
A first step in tackling the major problem of non-adherence is measuring adherence 
during follow-up. This can be done using different strategies (e.g., self-reports, 
collateral reports, pill counts, electronic monitoring), each of which has its 
strengths and weaknesses 10-12. The most accurate adherence data are gathered 
using a combination of measures 10 e.g., triangulation of electronic monitoring, self-
reports and pill counts.  
Once a patient’s adherence rate is known, if necessary, interventions aiming to 
improve adherence can be implemented. These interventions can be classified as 
educational/cognitive, counseling/behavioral, or psychological/affective 13. 
Educational/cognitive interventions present information individually or in a group 
setting, delivering it verbally, in written form, and/or audio-visually. 
Counseling/behavioral interventions shape and/or reinforce behavior, empowering 
patients to participate in their own care, while positively changing their skill levels 
or normal routines. Psychological/affective interventions focus on patients’ feelings 
and emotions or social relationships and social support 13. A systematic review 
examining medication adherence interventions after transplantation showed a 
serious shortage of intervention research in transplantation 13. We recently 
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conducted a study assessing which strategies cardiovascular health care 
professionals use to assess patients’ medication adherence and which interventions 
they apply to enhance medication adherence. In the sample surveyed, participants 
reported using a range of interventions to improve medication adherence 14. Russell 
(2005) examined perception of 59 transplant health care providers regarding 
medication non-adherence 15. Yet, both studies did not assess the health care 
professionals’ perceptions of their chosen interventions’ effectiveness. In another 
study, focusing on physicians of patients with chronic myeloid leukemia, Noens et 
al. showed how widely physicians’ perceptions differed regarding the utility and 
applicability of adherence enhancing interventions 16. This wide variation highlights 
the principle that, although medication adherence enhancing interventions are 
clearly necessary, little is known either of which ones health care professionals 
actually use for Tx recipients’ routine care or of how they perceive the results.  
This study therefore has three aims: (1) to identify which strategies Tx health care 
professionals utilize to assess their patients’ medication adherence; (2) to classify 
the medication adherence enhancing interventions  used (i.e., 
educational/cognitive, counseling/behavioral, or psychological/affective); and (3) to 
assess how these professionals perceive their chosen interventions’ effectiveness. 
 
Methods 
Design, sample & setting 
This study used survey methodology, replicating earlier research on health care 
professionals working with cardiovascular patients 17. All participants attending the 
2nd European International Transplant Nurses Society (ITNS) symposium in Berlin 
(Germany) (June 18th – 19th, 2010) were invited to participate. To be included, 
participants had to perform direct patient care. No other inclusion- or exclusion 
criteria were applied. 
Variables and measurement 
The questionnaire was originally developed for our earlier study in cardiovascular 
health care professionals 17 and adapted for transplantation. The listed 
interventions and assessment strategies were drawn from those described in the 
literature 18-22. The draft questionnaire was discussed and adapted a number of 
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times in the research group before being finalized. To evaluate the 
understandability and feasibility of using the scale, we pilot-tested it with 13 Tx 
health care professionals who did not participate at the conference.  
The structured questionnaire was available in two languages: English and German. 
Following Brislin’s guidelines 23, it was first translated from German to English, 
then back-translated and compared to the original. After a number of items on 
participants’ demographic characteristics, the remaining sets queried the 
participants on their medication adherence assessment strategies, the interventions 
they utilized to improve patients’ medication adherence, and their perceptions 
regarding the effectiveness of the interventions they reported using.  
Demographic information included: age in years; gender; highest level of education; 
current position (staff nurse, advanced practice nurse, Tx coordinator, head 
nurse/nurse manager, or other); the patient population they worked with; work 
setting (pre-Tx program, post-Tx program, or both); total years of clinical practice; 
years of clinical experience in Tx care; years worked in the current Tx program and 
percentage of working time spent in their Tx program; formal training in health 
behavior modification (yes/no); country (location) of the Tx center; what kind of 
transplants were performed in the Tx program; type of hospital where the Tx 
program was located; and whether there was an Advanced Practice Nurse working 
in the Tx program.  
Adherence Assessment and Intervention Strategies: On a 5-point Likert scale, 
ranging from never to all the time, participants were asked to indicate the frequency 
with which they utilized three strategies to counter non-adherence (questioning 
patients about non-adherence during follow-up; screening for non-adherence risk 
factors during follow-up; and using electronic monitoring devices to assess non-
adherence). Furthermore, given a list of educational/cognitive (6 items), 
counseling/behavioral (11 items), and psychological/affective (9 items) 
interventions, participants were asked to indicate on a similar scale the frequency 
with which they used each to increase patients’ medication adherence. The 
intervention and assessment strategy lists were comprised of interventions found in 
the literature 18-22. For any intervention they reported using (occasionally, 
sometimes, frequently or all the time) participants were asked to indicate on a 
three-point scale (not at all, somewhat or extremely) how effective they considered 
that intervention.  
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Data collection 
All attendees of the 2nd European ITNS symposium were given the study 
questionnaire at the time of registration and informed about the study by two 
research assistants. The study was also introduced at the opening session of the 
conference. Attendees were asked to deposit their completed questionnaires into 
any of the designated collection boxes. Questionnaires could be submitted during 
both conference days. The distribution process guaranteed that only one 
questionnaire was distributed per attendee. Research associates were available 
throughout the conference to provide information and support in filling out the 
questionnaire as well as to motivate attendees to participate in the survey.  
Data analysis 
Data were analyzed using descriptive statistics: frequencies, percentages and, 
where appropriate, measures of central tendencies and variability were calculated. 
For each of the three intervention categories (education/cognitive, 
cognitive/behavioral and psychological/affective), we calculated the mean 
proportion of interventions that participants reported using frequently or always.  
Participants who reported frequently or always using one or more intervention from 
at least two of the categories were classified as frequently utilizing combinations of 
methods to enhance medication adherence. Prior to analysis, because of the highly 
skewed answer patterns for most items measuring medication adherence 
assessment strategies and adherence enhancing interventions, the Likert scale 
response data were assigned numerical values: never= 0 (‘never’), seldom= 1 
(‘occasionally’ and ‘sometimes’), and frequently= 2 (‘frequently’ and ‘all the time’). To 
analyze the perceived effectiveness of interventions, we ranked them by category, 
from the highest to the lowest proportion of respondents rating them extremely 
effective. Perceived effectiveness was only rated if the health care professional 
personally used the intervention to enhance medication adherence. We calculated 
descriptive statistics (mean, standard deviation and median) to describe the average 
ratings of effectiveness for each category of interventions. Statistical analyses were 
performed using SPSS 16 (SPSS Inc, Chicago, Il).  
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Human subject considerations 
The questionnaire was reviewed and approved by ITNS. Informed consent of the 
participants was implied by completion of the questionnaire. Participants were free 
to decide whether they anted to complete the questionnaire or not. Data were 
collected anonymously (i.e., no identifying data were collected from the 
participants). 
 
Results 
Demographic information 
Of the 141 questionnaires distributed, 94 (67%) were completed and returned. 
Eight respondents (9%) indicated not being involved in direct patient care and were 
therefore excluded from further data analysis. Table 1 shows the demographic 
characteristics of the final sample (N= 86). The majority (86%) of participants were 
female, with a mean age of 41 years (SD: 8.52). Most (76%) worked with adult 
patients; more than half (51%) were working in inpatient Tx departments. 
 
Strategies to assess medication adherence 
The assessment strategies used are shown in Figure 1. Questioning patients about 
non-adherence during follow-up was frequently used by the majority of the sample 
(61%). Screening for non-adherence risk factors was performed frequently by 43% of 
participants. Other methods participants reported using were monitoring blood 
levels (two participants (2.3%) reported using this strategy frequently), and using 
medication diaries (reported by one participant).  
 
Interventions to enhance medication adherence 
Figure 2 shows the percentage of participants who reported frequently using each 
intervention. On average, participants reported frequently using 47% of the 
educational/cognitive interventions, 44% of the counseling/behavioral interventions 
and 42% of the psychological/affective interventions listed. 
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The frequencies at which participants used interventions to promote medication 
adherence are shown in figures 3-5. The two interventions used most frequently 
were providing reading materials (educational/cognitive intervention) and training 
patients during inpatient recovery how to take medications (counseling/behavioral 
intervention). Seventy-nine percent of the sample reported using both interventions 
frequently. The next most commonly used intervention, used frequently by 69% of 
the participants, was providing printed medication instructions. Almost two-thirds 
of the sample (63%) reported teaching patients to use cueing to increase medication 
adherence.  
The intervention employed least frequently was using reports from electronic 
monitoring devices to provide adherence feedback. Most participants (75%) reported 
never using such devices. Fifty-seven percent indicated never using counseling by a 
pharmacist to improve adherence. More than half (54%) never used computer 
assisted educational programs.  
We also examined the proportion of the sample that reported frequently using a 
combination of methods. Of this group, 77 (90%) reported frequently combining at 
least two adherence enhancing interventions from the educational/cognitive, 
counseling/behavioral and/or psychological/affective categories in daily Tx patient 
care.  
 
Perceived effectiveness of used medication adherence assessment 
strategies and MA enhancing interventions 
The intervention perceived as most effective in increasing adherence to the 
prescribed medication treatment was training patients during inpatient recovery 
how to take medications (Figure 6). Of the 73 participants who rated its 
effectiveness, 57 (78%) considered it extremely effective. The second most effective 
intervention was providing medication organizer dispensers. Thirty-eight of the 60 
participants (63%) using this intervention considered it extreme effective. Sixty 
percent of participants reported that establishing a partnership with patients and 
significant other(s) was extremely effective in promoting adherence. Comparing the 
effectiveness ratings per category, the average effectiveness ratings for the three 
categories of interventions were very similar [educational cognitive: mean= 2.52 
(SD= 0.40), median= 2.60; counseling/behavioral: mean= 2.49 (SD= 0.32), median= 
2.50; psychological/affective: mean= 2.51 (SD= 0.36), median= 2.59]. 
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Discussion 
As non-adherence after organ transplantation has a high prevalence 2-4, 8, 9 and is 
associated with poor clinical outcomes and increased health care costs 2-6, 24, 25, it is 
imperative that Tx health care professionals implement medication adherence 
promoting interventions in daily practice. To our knowledge, this is the first study 
examining the types and frequencies of Tx health care professionals’ medication 
adherence assessment strategies and adherence to the medication regimen 
enhancing interventions. 
 
Assessment strategies 
Our sample’s most frequently used adherence assessment method was questioning 
patients about their adherence during follow-up visits. As this strategy is simple, 
inexpensive and feasible for daily care, this result supports our earlier findings in 
cardiovascular health care professionals 14 and the findings by Russell in a small 
sample of transplant health care providers 15. However, this assessment method is 
particularly prone to recall and socially desirable response bias 10, 11. As no gold 
standard exists for assessing patients’ medication adherence 10, i.e., all methods 
have significant weaknesses 10-12, Osterberg and Blaschke promote a combination of 
adherence measures as the most reliable and accurate approach 10. An example of 
an optimal combination is the triangulation of self-report, assay and physician or 
nurse report. 
 
Educational/cognitive interventions 
The most frequently used method to promote medication adherence in this study 
was providing reading material on transplant care; providing printed medication 
instructions was ranked third. Overall, educational approaches to improve 
medication adherence were applied more than any other intervention type, despite 
compelling evidence that educational interventions have particularly limited 
effectiveness – a result consistent with our previous research in cardiovascular 
health care professionals 14. These findings are consistent with findings of 
Hathaway and colleagues 26 who also found that health care providers reported that 
they would used primarily educational interventions to improve adherence.  That 
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study, however, did not focus specifically on medication adherence but also 
included adherence to other aspects of the treatment regimen (e.g., diet, exercise 
and non-smoking). 
The WHO report ‘Adherence to long-term therapies – evidence for action’ concludes 
that, while adherence interventions at the patient level have usually focused on 
increasing knowledge, i.e., patient education, knowledge alone is not enough to 
establish and maintain strong adherence behavior 22. A recent meta-analysis 
showed that, although providing written medication or disease education improves 
knowledge, it is much less effective at translating that knowledge into more 
desirable behavior, i.e., improved adherence 27. However, Mansoor and Dowse 
(2006) had earlier argued that the specific design of the printed material influenced 
its value, i.e., that in order for printed material to be effective at improving 
adherence, it should employ simple text and pictograms 28. Earlier still, Turnbull 
(2003), posited that producing good patient information required a team effort 
between professionals and patients 29.  
Although computer based information packages for patients have been shown to 
have positive effects on self-efficacy and behavioral outcomes 30, computer assisted 
learning programs were not frequently used in our sample. This result is not 
surprisingly, as only very limited computer assisted patient education programs are 
currently available in transplantation. A study evaluating the validity and usability 
of one computer-based training and assessment program developed for transplant 
recipients revealed that the program deviated significantly from current medical 
practice regarding content and language 31. Furthermore, health care professionals 
may be reluctant to use such programs due to the increasing average age of their 
patient population in follow-up. Such programs require that the patient have both 
access to a computer (sometimes with internet access) and the skills necessary for 
effective computer hardware and software use – prerequisites that might deter 
many older patients from using this type of intervention. Responding to such 
concerns, Marziali (2009) showed that older patients with chronic diseases can be 
trained to use computers and software packages effectively 32. The implementation 
of computer assisted learning programs in clinical practice could also save valuable 
health care professionals’ time, as patient/users can receive considerable amounts 
of information from a program rather than a highly-trained professional, and can 
later address specific questions and concerns to their health care providers. Once 
issues such as these have been addressed, and well-designed, accurate computer-
Chapter 6: Adherence interventions used by transplant professionals 
 
 
 
 
139 
assisted patient education packages become available, the savings they offer will 
make them difficult to ignore.  
 
Counseling/behavioral interventions 
The method least frequently used in practice was using reports from electronic 
monitoring devices as a feedback system. Electronic monitoring devices are pill 
bottles or blister packets that automatically record the date and time of each 
manipulation of the system that presumably corresponds with medication intake 33. 
Data can be uploaded to a computer and printed out to show the user’s medication 
dynamics, which can be discussed with the patient and used to establish adherence 
goals. In cases of improved adherence, patients receive positive feedback, inducing 
mastery experiences 34. Yet, while this is a powerful intervention to enhance 
patient’s medication adherence 34, it is not often offered in daily practice, possibly 
because electronic monitoring devices are rather expensive, may be complicated for 
some patients and may be time consuming for the health care provider to 
administer. However, in a study among older kidney transplant recipients, most 
participants gave positive responses regarding their experiences with the electronic 
monitoring device 35.  
Another intervention our sample used infrequently to enhance adherence was 
medical counseling by a clinical pharmacist. This low usage rate of medical 
counseling by clinical pharmacists as an adherence-enhancing method may result 
from the general rarity of clinical pharmacists in European hospitals. Unlike a 
traditional pharmacist, a clinical pharmacist works directly with health care 
providers and patients, providing a broad range of specialized services 36. A 
literature review evaluating the effects of interventions by clinical pharmacists on 
processes and outcomes of care in hospitalized adults showed that medication 
adherence, knowledge and appropriateness improved in 7 of the 11 studies 
reviewed 36. Furthermore, the involvement of clinical pharmacists in Tx cases has 
been associated with decreased mortality, lower complication rates, lower hospital 
charges and reductions in preventable adverse drug events 37.  
In our sample, a large majority of participants (90%) frequently combined two or 
more interventions from the educational/cognitive-, counseling/behavioral- and/or 
psychological/affective categories to enhance adherence in the daily care of Tx 
patients. This is much higher than in our cardiovascular health care professional 
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study, where 69% used multi-dimensional interventions 14. Evidence clearly 
indicates that the most effective method of enhancing medication adherence was 
the use of multi-dimensional interventions, i.e., combining educational/cognitive, 
counseling/behavioral, and psychological/affective interventions 18-21, 38. A 
Cochrane review of 70 trials, testing 83 interventions aiming to improve long-term 
adherence, showed that fewer than half (n= 36) of the interventions were 
significantly associated with improvements in medication adherence, while only 25 
could be linked causally to improvement in at least one treatment outcome 20. No 
simple and few complex interventions resulted in improvement of medication 
adherence and clinical outcomes 20. The interventions most effective for long-term 
care included combinations of more convenient care, information, reminders, self-
monitoring, reinforcement, counseling, family therapy, psychological therapy, crisis 
intervention, manual telephone follow-ups, and supportive care 20. In a recent meta-
analysis of studies regarding older adults, Conn et al. (2009) showed that a number 
of interventions significantly improved medication adherence; however, they also 
reported large differences in the effect sizes of different interventions 27. 
 
Perceived effectiveness of interventions 
Of the medication adherence enhancing interventions listed on our questionnaire, 
training patients during inpatient recovery on medication self-administration was 
perceived as the most effective: 78% of participants who used it rated it as 
extremely effective. This method was also used most frequently. The other most 
frequently used intervention, providing reading materials, was perceived as 
extremely effective by fewer than half of the participants (45%) who used it in daily 
practice. As mentioned above, evidence shows that written medication and disease 
information has limited effect on adherence improvement 27. Interestingly, while this 
intervention was used most often, it was not perceived as effective at medication 
adherence improvement.  
At the bottom of the usage scale, the intervention least frequently employed in 
practice – using reports from electronic monitoring devices as a feedback system – 
was ranked second most often as extremely effective. As stated above, this is clearly 
an effective system of improving patients’ adherence 34. 
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Limitations of this study 
This study has several limitations, beginning with our questionnaire’s focusing only 
on medication adherence enhancing interventions at the patient level. Interventions 
at the micro level (e.g., focusing on the patient-provider interaction or on the 
patient’s social support system), the meso level (i.e., the treatment center or 
hospital), and the macro level (i.e., the patient’s health care system or society) are 
also crucial in improving adherence 39. A further limitation of this study is the 
limited generalizability of its findings, as the participants were conference attendees 
and may not have accurately represented the majority of health care professionals 
working in transplant clinical practice. Although we provided the questionnaire in 
two languages, language barriers may still have existed for participants fully fluent 
in neither. However, one notable strength of this study is its 67% response rate, 
which is high compared to many research studies conducted at conferences 40, 41.  
 
Recommendations 
Health care professionals working with transplant recipients are strongly 
recommended to implement evidence-supported medication adherence enhancing 
interventions in their daily practice. Moreover, they are advised to implement multi-
dimensional interventions, i.e., to combine educational/cognitive, 
counseling/behavioral, and psychological/affective interventions. Further, enabling 
health care professionals to deliver effective interventions that optimize adherence 
will require training in health behavior modification strategies. Further research 
should also assess which interventions are utilized at the health care provider-, 
health care organization-, and health care system level to enhance transplant 
patients’ medication adherence 33.  
 
Conclusion 
Tx health care professionals apply a variety of interventions to improve Tx 
recipients’ medication adherence. Although evidence shows that 
educational/cognitive interventions are less effective than behavioral interventions, 
they were used most frequently by members of this sample. For clinicians 
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committed to enhancing medication adherence, it would be advisable to focus more 
on implementing alternatives to educational interventions.  
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Table 1: Demographic information  
Variable N= 86 
Gender  
Female, n (%) 
 
73 (85.9) 
Age years 
Mean ± SD 
 
41.24 ± 8.52  
Continent where department is located 
Europe, n (%) 
North-America, n (%) 
Australia, n (%) 
 
80 (93.0) 
4 (4.7) 
2 (2.3) 
Language questionnaire 
English, n (%) 
German, n (%) 
 
36 (41.9) 
50 (58.1) 
Highest level of education 
Basic nursing training, n (%) 
Bachelor, n (%) 
Master, n (%) 
PhD, n (%) 
Other (Medical Secretary), n (%) 
Missing, n (%) 
 
55 (64.0) 
12 (14.0) 
15 (17.2) 
2 (2.3) 
1 (1.2) 
1 (1.2) 
Current position 
Staff nurse, n (%) 
Advanced Practice Nurse, n (%) 
Transplant Coordinator, n (%) 
Head nurse/Nurse manager, n (%) 
Other2, n (%) 
Missing/Not applicable, n (%) 
 
56 (65.1) 
12 (14.0) 
8 (9.3) 
3 (3.5) 
6 (7.1) 
1 (1.2) 
Type of transplant performed at transplant program  
Kidney, n (%) 
Lung, Heart, Heart-Lung, n (%) 
Kidney, Liver, Lung, Heart, Heart-Lung, Pancreas, 
Bone Marrow, n (%) 
Heart, n (%) 
Lung, n (%) 
Liver, n (%) 
Combined Organ Transplantation, n (%) 
 
9 (10.5) 
9 (10.5) 
7 (8.1) 
 
6 (7.0) 
5 (5.8) 
3 (3.5) 
47 (54.6) 
Case Load 
      Adult Patients, n (%) 
 
65 (75.6) 
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      Pediatric Patients, n (%) 
      Both, n (%) 
5 (5.8) 
16 (18.6) 
Pre/post transplant program  
Pre-transplant program, n (%) 
Post-transplant program, n (%) 
Both, n (%) 
 
13 (3.5) 
32 (37.2) 
51 (59.3) 
Primarily work in 
An inpatient transplant program, n (%) 
An outpatient transplant program, n (%) 
Both, n (%) 
Other, n (%) 
 
44 (51.2) 
16 (18.6) 
24 (27.9) 
2 (2.3) 
Advanced Practice Nurse working at the department 
Yes, n (%) 
 
32 (37.2) 
Years practicing 
Mean ± SD 
 
18.96 ± 8.88 
Years practicing in transplant nursing 
Mean ± SD 
 
10.61 ± 7.21 
Years practicing in current transplant program 
Mean ± SD 
 
8.15 ± 7.36 
Percentage of work 
Mean ± SD 
 
83.07 ± 30.14 
1Other countries including: Australia, Canada, Spain, and United States. 
2Other current positions including: Staff Nurse & Education, Staff Nurse & Diabetes 
Assistant, Staff Nurse & Organ Donation Agent 
3Other main specialty departments including: Rehabilitation, education. 
 
Chapter 6: Adherence Interventions used by transplant professionals 
 
 
 
148 
   
Figure 1: Non-adherence (NA) assessment strategies
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Figure 2: Percentage of participants reporting that they frequently used the intervention
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Figure 3: Educational/Cognitive interventions
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Figure 4: Counseling/Behavioral interventions
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Figure 5: Psychological/Affective Interventions
65.1
58.1
39.5 38.4
32.5 29.1
15.1 12.8 11.6
19.8
29
20.9 22.1
22.1
23.2
17.4 20.9
18.6
12.8 10.5
26.7
19.8 32.5
26.7
48.8 43 46.5
2.3 2.3
12.8
19.8
12.8
20.9 18.6 23.2 23.2
0%
20%
40%
60%
80%
100%
Establishing a
partnership with
patient and significant
other
Involving family or
support persons in
education and
behavioural
interventions
Providing telephone
assistance if needed
Scheduling more
frequent clinic visits
in case of problems
with NA
Using motivational
interviewing
Scheduling calls to
patients’ homes in
case of problems with
NA
Establishing support
groups directed at
adherence
Establishing case
management
services for high-risk
patients
Establishing peer-
mentor programs
Frequently Sometimes Never Missing/NA
Chapter 6: Adherence Interventions used by transplant professionals 
 
 
 
153 
*Perceived effectiveness was only rated if the health care professional used the intervention to enhance medication 
adherence. 
Figure 6: Perceived effectiveness of used interventions*
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Abstract 
Background: We developed the Chronic Illness Management Implementation - 
Building Research Initiative Group: Chronic Illness Management and Adherence 
in Transplantation (CIMI-BRIGHT) instrument to assess the level of chronic 
illness management implemented in transplant centers. 
Aim: The aim of this study is to describe the development of the CIMI-BRIGHT 
instrument and to assess initial content validity and inter-rater reliability. 
Methods: To evaluate content validity, the relevance of each ‘chronic illness 
management’ construct item (N= 51) was rated on a 4-point Likert scale ranging 
from 1= not relevant to 4= highly relevant by 7 experts (3 from USA, 4 from 
Europe) in chronic illness management. Content validity indexes were 
calculated for each item and the instrument as a whole. To evaluate inter-rater 
reliability, we conducted a pilot study in one abdominal and one renal 
transplant program. Participant agreement by center for the total CIMI-BRIGHT 
instrument was compared by averaging the percent agreement on individual 
items.  
Results: Of the 51 items, 42 had a good content validity. Two of the nine items 
with low content validity were deleted and the remaining seven were revised. 
The percentage agreement in the two transplant programs for the total 
instrument was 84.6% and 74.8% respectively, indicating good inter-rater 
reliability.  
Conclusion: The results of this initial validation of the CIMI-BRIGHT 
instrument are promising, suggesting its value as a measure of the extent to 
which the chronic illness model is being implemented in transplant programs. 
Further validation is needed to fully evaluate the validity and reliability of this 
instrument. 
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Background 
Over the past decades, patient as well as graft survival rates improved for solid 
organ transplant (Tx) recipients. This is mainly due to improvements in 
immunosuppressive management. One year patient survival rates for heart 
transplant patients, for instance, increased from 86.1% in 1998 to 89.2% in 
2007, for renal transplant patients (deceased donor), this increase was from 
94.9% in 1998 to 96.5% in 2007, and for heart lung transplant patients it even 
increased more from 7.2% in 1998 to 90.3% in 2007 1. However, survival gains 
are limited to the first 6 to 12 months after transplantation, with long-term 
survival rates remaining largely unchanged 2-5. Improving long-term outcomes is 
considered a priority in transplantation 3, 4.  
Receiving an organ transplant implies that recipients have to adopt a number of 
long-term health behaviors, including medication taking, self-monitoring for 
signs of rejection and infection, as well as regular follow-up visits to their 
physician. Based on these requirements, transplantation does not cure 
patients, and hence transplant recipients should be perceived as chronically ill 
patients. To-date, however, health care for Tx recipients has most common been 
organized around an acute, episodic model of care. In a care system designed to 
address acute health problems the purpose is to diagnose and to treat a 
patient’s presenting complaint 6. There is generally no need to follow the patient 
over time. Yet, this model of care does not meet the needs of Tx patients who 
are chronically ill 6-8. Providing optimal care for the chronically ill implies a shift 
in the organization of care from an acute focus to a system where the principles 
of chronic care are integrated, namely continuity of care; partnership with 
patients, families and communities; support for patients in improving their self-
management; attention to preventive measures; decision-making support; and 
the availability of clinical information systems 6, 7, 9-11. Studies in asthma and 
diabetes, for instance have reported improved patient outcomes when care 
systems to manage chronically ill patients shift from an acute to a chronic care 
model 11-14.  
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The World Health Organization’s (WHO) Innovative Care for Chronic Conditions 
(ICCC) framework (see Figure 1) presents a framework for health care systems 
to improve care for the chronically ill 6, 15, 16. This framework can help decision 
makers or those who are working in the health care system to progressively 
create or redesign health care organizations and system to expand its capacity 
to manage long-term health problems 6, 16. The framework is based on a set of 
guiding principles acting at three levels 7. The micro level emphasizes the 
partnership between patients and families, and the health care professionals. 
The meso level refers to the health care organization and the community. The 
macro level refers to policy and financial contexts 6, 7, 16.  
Within the health care organization or meso level, there are five essential 
building blocks that health care organizations need to focus on to improve the 
care of chronically ill patients (see Figure 1). First, they need to promote 
continuity and coordination, which refers to the need of chronically ill patients 
for services that are coordinated across levels of care (i.e., primary, secondary, 
and tertiary care) and across providers 6. Second, they need to encourage 
quality care through leadership and incentives; senior and other influential 
leaders need to lend clear support and sponsorship for improving the care of 
chronic conditions in their health care organization. Third, they need to 
organize and equip health care teams by providing them with the skills and 
knowledge (e.g., effective communication abilities) to manage chronic conditions 
6. Forth, they need to  support self-management and prevention; health care 
professionals need to be informed about self-management strategies and know 
how to educate patients and families about self-management 6. Finally, the last 
building block, the use of information systems, means that health care 
organizations must provide timely information about individual patients and 
populations of patients. Information systems are needed to gather and organize 
data about epidemiology, treatment and health care outcomes. The goal is to 
use information systems to improve planning and the general standard of care 
6.  
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Center effects, which can be defined as “differences in outcome among centers 
that cannot be explained by identifiable differences in patients treated or 
specific treatments applied” 17 (pg. 417), are presumed to result from differences 
in the ways health care is delivered. A number of studies demonstrated that 
variations in the practice patterns influence patient outcomes. A study in 
hematopoietic stem cell transplantation in the United States identified the 
following center factors to be associated with decreased 100-day mortality: the 
presence of physicians answering after hours calls and higher patient-per-
physician ratio 18. The Dialysis Outcomes and Practice Patterns Study (DOPPS), 
a prospective, observational study among hemodialysis centers in seven 
different countries showed that center characteristics such as the size of the 
center and the percentage of highly trained staff and the country where the 
dialysis center was located were related to dialysis non-adherence rates 19, 20. 
These center-specific differences regarding outcomes indicate that processes at 
the level of the health care organization are influential and should be further 
examined. 
 
Assessment of level of chronic illness management 
The level of chronic illness management implemented in a health care 
organizations can be assessed either from the patient perspective 21 or from the 
perspective of the health care provider 22. The Patient Assessment of Chronic 
Illness Care (PACIC) questionnaire was developed by the MacColl Institute for 
Health care Innovation to assess the implementation of the CCM from the 
patient perspective 21. To assess the level of chronic illness care through health 
care provider information, Bonomi et al. 22 developed the Assessment of Chronic 
Illness Care (ACIC) questionnaire. There were, however, poor correlations 
between ACIC scores and chronic disease experts’ ratings of team performance 
(r= 0.28 to 0.52) 22. Furthermore, the ACIC questionnaire was not specifically 
developed for transplant populations, identifying a clear gap in the literature on 
how to assess the level of chronic illness care from the meso level perspective.  
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The aims of this study therefore were:  
1) to describe the development of the CIMI-BRIGHT instrument 
2) to assess the content validity of the CIMI-BRIGHT instrument 
3) to assess the inter-rater reliability of the CIMI-BRIGHT instrument 
 
Methods 
1) Development of CIMI-BRIGHT 
The development of the CIMI-BRIGHT instrument was based on the previously 
described conceptual framework of ICCC, as well as on clinical expertise of the 
members of the research team. Based on this framework, we generated items to 
capture each building block of the health care organisation. To test the 
completeness of the instrument, the clarity of the items and the clarity of the 
answer scoring, a focus group interview with a group of 7 international nurses 
who work in transplantation was conducted. The feedback received during this 
interview was integrated in the instrument. After content validity testing (see 
content validity testing) the instrument was adopted (i.e., items deleted and 
items revised) resulting in the CIMI-BRIGHT instrument which was used for the 
pilot study (see inter-rater reliability testing). 
2) Content validity testing 
The framework used to validate this instrument was the Standards for 
Educational and Psychological testing proposed by the American Educational 
Research association, American psychological Association and the National 
Council on Measurement in Education 23. The AERA defines validity as “the 
degree to which evidence and theory support the interpretations of test scores 
implied by the proposed uses of a test” 23 (pg. 9). In this study, we tested the 
content validity of our instrument empirically, in order to provide evidence on 
content area of the measurement 23, 24. 
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Sample and setting: An interdisciplinary group of international (Europe and 
US) experts in chronic illness management were selected by the research team. 
We defined an expert in chronic illness management as a person who was 
recognized in the chronic illness scholarly world as evidenced by at least two 
publications or presentations on chronic illness management. Two authors (LB 
& SE) searched on the World Wide Web for experts, a third author (SDG) 
approved the choices. The expert group was composed of nurses, physicians 
and health policy professionals.  
Measurement: For each individual item, the content experts were asked to rate 
the relevance of the item on a 4-point Likert scale (1= not relevant, 2= 
somewhat relevant, 3= quite relevant, and 4= highly relevant) in relation to the 
construct ‘chronic illness management’ 25 on the Content Validity Form  
Data collection: The identified chronic illness management experts were 
contacted by mail and asked to participate in this study. The CIMI-BRIGHT 
instrument and the Content Validity Form were mailed to those agreeing to 
participate. During a scheduled phone call, the background, aims and 
methodology were briefly described by the first author (LB), as well as 
information on the purpose and use of the Content Validity Form. Participating 
experts were asked to return the completed Content Validity Form by either 
electronic mail or regular mail. If the Content Validity Form was not returned 
within one month, the participants received a reminder mail to return the 
Content Validity Form. If they did not respond to the reminder, they were 
considered non-responders. Data were collected in Autumn 2009.  
Data analysis: To evaluate the content validity of the CIMI-BRIGHT instrument, 
content validity indexes (CVI) were calculated. CVI’s were calculated for each 
item (content validity for item, I-CVI) and the instrument as a whole (content 
validity index for scales, S-CVI). The I-CVI was computed as the number of 
experts giving a rating of either 3 (quite relevant) or 4 (highly relevant) divided 
by the total number of experts 25. To evaluate the content validity on the scale 
level, we averaged the item-level CVI’s. More specifically, the I-CVI’s were 
summed and divided by the number of items 25. An instrument is considered to 
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have excellent content validity if it is composed of items with a I-CVI of .78 or 
higher and the S-CVI is .90 or higher 25.  
3) Inter-rater reliability testing 
To be able to calculate inter-rater reliability of the CIMI-BRIGHT instrument, we 
conducted a pilot-study in two Tx programs. Reliability is defined as “the 
consistency of measurements when the testing procedure is repeated on a 
population of individuals or groups” 23 (pg 25). Reliability can be generated in 
terms of stability, equivalence or internal consistency 24. For the purpose of this 
study we tested reliability as equivalence, more specifically inter-rater (or inter-
observer) reliability, which represents the agreement among raters.  
Sample and setting: The pilot study of the CIMI-BRIGHT study was conducted 
in one abdominal and one renal Tx program in the US. Health care 
professionals were eligible to participate if they were working in the Tx program 
for longer than six months, were employed 50% or more in clinical practice and 
had knowledge about the content of care provided in the outpatient Tx program. 
Student nurses, nursing assistants, and float pool nurses were excluded from 
the sample. The instrument was also completed by the medical Tx director of 
each center. All health care professionals who met the inclusion criteria were 
invited to complete the CIMI-BRIGHT instrument. 
Data collection: The abdominal and kidney Tx programs were identified and 
contacted by a member of the research team. A contact person at each Tx 
program was identified. Data collection for the pilot study was conducted in the 
Tx programs between March and December 2010. Health care professionals 
were surveyed voluntarily and anonymously. The CIMI-BRIGHT instrument was 
distributed by the contact person at the respective Tx program and were 
collected in a secured box located at each of the participating Tx programs. The 
contact person of each Tx program mailed the completed instruments to the 
principal investigator.   
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Ethical considerations: Approval was obtained from each Tx program’s ethical 
committee prior to data collection. Informed consent of health care 
professionals was implied by the completion and return of the CIMI-BRIGHT 
instruments. 
Data analysis: The percent agreement between the different health care 
professionals in each Tx program was calculated for the total CIMI-BRIGHT 
instrument assessing the 5 building blocks of the ICCC framework. Due the 
small sample size and few participant selecting some of the response options, 
they were collapsed into 1) strongly disagree & disagree; 2) agree and strongly 
agree; 3) don’t know, not applicable or missing. Percentage agreement for the 
instrument of > 60% was interpreted as indicating substantial inter-rater 
reliability, 80% or more as almost perfect agreement 26. 
 
Results 
1) Development of CIMI-BRIGHT 
Examples of items included in the CIMI-BRIGHT instrument are shown in Table 
1. The first version of the CIMI-BRIGHT instrument consisted of 51 items 
covering the five ICCC building blocks for the health care organization level: 1) 
promote continuity and coordination (14 items), 2) encourage quality through 
leadership and incentives (6 items), 3) organize and equip health care teams (7 
items), 4) support self-management and prevention (19 items), and 5) use of 
information systems (5 items). After integrating the results of the content 
validity testing, the instrument was composed of 49 items, namely 14 items for 
promoting continuity and coordination, 5 items assessing encouragement of 
quality through leadership and incentives, 6 that assessed organization and 
equipping health care teams, 19 that measured supporting self-management 
and prevention, and 5 that inquired about the use of information systems. 
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2) Content validity testing 
Demographic information 
Eleven experts in chronic illness management (six from USA and five from 
Europe) were indentified and asked to participate in the content validity 
evaluation of the CIMI-BRIGHT. Seven agreed to participate (three from USA 
and four from Europe), a response rate of 64%. One of the seven experts only 
rated part of instrument. 
Content Validity Index 
The experts evaluated the 51 items of the first version of the CIMI-BRIGHT. 
Forty-two items were rated having good content validity with content validity 
indexes ranging from 0.83 (22 items) to 1.00 (15 items). Nine items had low 
content validity. Two of these were deleted (i.e., “we have a highly organized 
quality improvement process, whereby we focus on a small number of 
important problems or conditions over sufficient time to ensure improvements 
are implemented and sustained” and “innovations (e.g., virtual teams linked 
through information or communication technology) are used by the transplant 
team”), the remaining seven items were revised based on suggestions from the 
experts. The Scale Content Validity Index (S-CVI) was 0.83. With the deletion on 
the two items, the S-CVI was 0.86.  
2) Inter-rater reliability 
Demographic information 
The characteristics of the participants are shown in Table 2. In total six health 
care professionals of the abdominal and five of the renal Tx program completed 
the CIMI-BRIGHT instrument. All participants in both groups were women. The 
percentage of work spent in transplant care in the abdominal Tx program 
ranged from 50% to 100%, in the renal Tx program all participants were 
working 100%. Most participants worked in the outpatient transplant unit. The 
median years working in the particular transplant program was 3 years (IQR: 
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0.9 – 6.5), for the abdominal Tx program this was 7 years (IQR: 5.5 – 12.5). In 
the renal Tx program, following transplantation all patients followed by the Tx 
program until the time of death. In the abdominal Tx program, liver and 
intestine Tx patients are followed by the Tx program until the time of death. Not 
all renal Tx patients in this abdominal Tx program are followed by the program, 
some of them were followed by their referring nephrologist after their 
transplant. 
Percentage agreement 
The percentage agreement over all participants included in the abdominal Tx 
program was 84.5%. Excluding the dietician from the calculation, the 
percentage agreement improved to 86.9%. For the renal Tx program, the overall 
percentage agreement was 74.8%.   
 
Discussion 
As practice patterns (i.e., the presence of physicians answering after hours calls 
and higher patient-per-physician ratio 18) are observed, processes at the level of 
the health care organization should be further examined. We, for the first time, 
developed an instrument assessing the extent to which chronic illness 
management is implemented in the follow-up care of transplant patients. By 
developing the CIMI-BRIGHT instrument, we will be able to assess differences in 
practice patterns related to implementation of chronic illness management 
among transplant programs. In this study we conducted the initial validity and 
reliability testing of the instrument.  
This instrument shows preliminary evidence of adequate content validity. While 
the item CVI was good for 42 of the original 51 items, two items with low I-CVI 
scores were excluded from the instrument based on recommendations from the 
expert reviewers. The scale CVI (S-CVI) was 0.86 with the two items removed. 
The I-CVI for seven additional items varied from 0.50 (one item) to 0.67 (six 
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items). Comment from the reviewers suggested that these items were too vague. 
We revised these items to clarify their meaning.  
We measured inter-rater reliability within each of the two Tx programs where 
we pilot tested the instrument. In one of the Tx programs, the percentage 
agreement between the health care providers indicated near perfect agreement 
on the extent to which the chronic illness models, as measured by the CIMI-
BRIGHT instrument, was being implemented in their Tx program. In the second 
Tx program, while the percent agreement was somewhat lower, there was still 
satisfactory agreement. A limitation of this study is that the pilot-testing was 
only conducted in US Tx program, excluding European Tx programs.  
This early testing of the CIMI-BRIGHT instrument suggests that it has promise 
as a measure for the extent to which the chronic illness model is being 
implemented in transplant centers. Additional testing is, however, needed to 
fully evaluate the validity of the instrument and to confirm that its inter-rater 
reliability is acceptable in other transplant programs. If additional testing 
supports the validity and reliability of the CIMI-BRIGHT instrument it could be 
a valuable instrument in not only assessing the current level of chronic illness 
management, but in also evaluating the impact of interventions designed to 
improve the organization of care for chronically ill patients. 
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Figure 1: Innovative Care for Chronic Conditions Framework 6 
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Table 1: Examples items CIMI-BRIGHT per building block 
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Inpatient and outpatient services are coordinated. 
For example, the outpatient transplant program can 
arrange examinations while the patient is in the 
inpatient clinic and vice versa  
1 2 3 4 5 6 
Patients are strongly encouraged (but not forced) to 
see the same health care workers over time 1 2 3 4 5 6 
Patients who cancel their follow-up visits are 
contacted to reschedule the missed appointment 1 2 3 4 5 6 
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Patients are given incentives (e.g., recognition or 
financial awards) for effective self-management¹ 
and/or health outcomes 
1 2 3 4 5 6 
The transplant program has a system for routinely 
monitoring the quality of care 1 2 3 4 5 6 
Senior and other influential leaders clearly help 
improve the quality of care in our transplant 
program 
1 2 3 4 5 6 
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Written guidelines for care are easily available 1 2 3 4 5 6 
Written guidelines for care are supported by 
education/courses 1 2 3 4 5 6 
The heart transplant program is based on a system 
of interdisciplinary team care (not run by physicians 
alone) 
1 2 3 4 5 6 
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The heart transplant team routinely works with 
patients to identify clear, measurable and workable 
self-management¹ goals 
1 2 3 4 5 6 
The heart transplant team lets patients decide on 
the self-management¹ goal(s) they consider best for 
them 
1 2 3 4 5 6 
The heart transplant team gives each patient a copy 
of the agreed treatment plan, including information 
on self-management¹ and medication adherence² 
1 2 3 4 5 6 
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Care guidelines are built into the information 
system through computerized prompts/reminders 
or other support tools 
1 2 3 4 5 6 
The heart transplant team's information system 
automatically gives health care workers specific 
guidance for individual patient care, such as 
reminders to schedule a follow-up visit or to 
perform a blood test 
1 2 3 4 5 6 
The heart transplant team's information system 
automatically flags patients who are overdue for 
routine follow-up  
1 2 3 4 5 6 
1self-management refers to actions performed by patients for themselves in daily life to manage 
their illness and treatment, and to avoid health deterioration  
2adherence deals with how well a person’s behaviour (for example, taking medication) matches the 
recommendations of a health care provider 
 Adherence is a core concept of self-management 
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Table 2: Characteristics of participants 
 Center 1: Abdominal 
Tx program (N= 6) 
Center 2: Kidney Tx 
program (N= 5) 
Age years 
   Median (IQR) 
 
 
33 (28.5 – 39.5) 
 
42 (39 – 50) 
Gender 
   Female, n (%) 
 
 
6 (100) 
 
5 (100) 
Current position in Tx program 
   Tx coordinator, n (%) 
   Advanced Practice Nurse, n (%) 
   Physician assistant, n (%) 
   Agency nurse, n (%) 
 
 
3 (50) 
1 (16.7) 
1 (16.7) 
1 (16.7) 
 
5 (100) 
0 
0 
0 
If Tx coordinator 
   Registered nurse 
   Advanced Practice Nurse, n (%) 
   Registered dietician, n (%)    
 
 
1 (33.3) 
1 (33.3) 
1 (33.3) 
 
5 (100) 
0 
0 
Years practicing 
      Median (IQR) 
 
 
10.5 (6.3 – 18.5) 
 
19 (17 – 28) 
Years practicing in Tx 
      Median (IQR) 
 
 
4 (2.5 – 7.8) 
 
7 (5.5 – 12.5) 
Years in current Tx program 
      Median (IQR) 
 
 
3 (0.9 – 6.5) 
 
7 (5.5 – 12.5) 
Percentage working in Tx care 
      Median (IQR) 
 
 
100 (84 – 100) 
 
100 (100 – 100) 
Working primarily in 
   Inpatient Tx unit, n (%) 
   Outpatient Tx unit, n (%) 
   Both, n (%) 
 
 
1 (16.7) 
3 (50) 
2 (33.3) 
 
0 
3 (60) 
2 (40) 
Completed formal program in Tx 
care 
   No, n (%) 
 
 
 
6 (100) 
 
 
6 (100) 
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Synthesis, Discussion and Perspectives 
Chronically ill patients, a patient population which has increased dramatically 
world-wide and is expected to increase further, are bound to life-long health 
behavioral adaptations and the need to engage in a number of activities to 
insure their physical and psychosocial health 1. One health behavior which is a 
crucial prerequisite for a treatment to be effective is patients’ adherence to their 
medication regimen. Yet, the prevalence of medication non-adherence among 
chronically ill patients is high and associate with poor clinical and economic 
outcomes 2-4. Non-adherence to a medication regimen can be defined as “the 
deviation from the prescribed medication regimen sufficient to influence 
adversely the regimen’s intended effect” 5 (pg. 36). Current research has focused 
mainly on patient and treatment related factors to explain non-adherence. Yet, 
patient behavior is also influenced by factors from the patients’ environment, 
i.e., system level factors. However, to-date there is only very limited research 
examining the impact of system factors on the health behaviors such as 
medication taking in chronically ill patients. This lack of focus on the broader 
system in which patients live as a possible explanation for non-adherence rates 
may explain why currently only a small part of the variability in non-adherence 
can be explained 6.  
Until now, health care system factors have received relatively little attention as 
an explanation for patient behavior. This is in contrast to other disciplines, 
such as education where it has long been acknowledged that predicting 
achievements of students requires not only consideration of student-related 
variables such as intelligence, motivation or self-efficacy, but also variables on 
the level of the teacher, the school, and the educational system 7,8. Health care 
system factors may impact patient behavior, e.g., adherence to their medication 
regimens, in much the same way as educational system variables affect student 
achievement. 
Today, most health care systems are mainly build around an acute model of 
care. However, this model of care does not meet the needs of patients suffering 
of a chronic disease 1,9-12. There are substantial differences between acute and 
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chronic diseases 13. Acute diseases are episodic, and if the patient responds to 
treatment, his/her health returns to normal. There is generally no need to 
follow the patient over time. In contrast, chronic diseases are persistent, and 
there is generally no cure. Chronic conditions are associated with ongoing 
treatment and require behavioral changes to prevent worsening of the disease 
13. It is of extreme importance that care models are adapted to fit the special 
needs of patients suffering of one or more chronic conditions. This implies that 
there needs to a shift in the organization where care takes place 14-16 from an 
acute care focus with limited attention for aspects of self-management, 
prevention and continuity of care to a system where the principles of chronic 
illness management are integrated 1,10,14,17,18. These principles of chronic illness 
management are continuity of care; partnership with patients, families and 
communities; support for patients in improving their self-management; 
attention to preventive measures; decision-making support; and the availability 
of clinical information systems 1,10,14,17,18. Moreover, in providing high quality 
and effective care for the chronically ill, health care providers need to have the 
competencies to work in these new system of care and to support patients in 
their self management such as correct medication taking 19. From this it can be 
inferred that the health care system in which the patient lives and receives care 
for their chronic condition(s) is of upmost importance to achieve favorable 
outcomes.  
This dissertation took an innovative perspective as it explored the role of system 
factors in chronic illness management with a special focus on medication 
adherence in the chronically ill. An ecological model (McLeroy et al.) 20,21 and the 
World Health Organization’s Innovative Care for Chronic Conditions Framework 
11,12,14 served as the theoretical frameworks for the studies performed. The 
patient populations addressed in this dissertation were organ transplant 
recipients, persons living with HIV and patients suffering from cardiovascular 
diseases, all chronically ill patient populations were non-adherence to 
medication regimen is associated with poor clinical outcomes, higher (re-) 
hospitalizations rates and increased health care costs 2,22-30.  
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The findings of these studies strengthen the knowledge base on medication 
adherence as (1) they highlight the state of science about system factors related 
to adherence to medication regimens; (2) they provide insight into current 
practice patterns of health care professionals relative to the assessment and 
support of medication adherence; and (3) they present findings related to the 
development and preliminary psychometric testing of an instrument to assess 
the level of adherence-related chronic illness management implemented in 
transplant centers. These three contributions provide a solid basis to the 
further understanding of the role system related factors and adherence to 
medication regimens play and provide impetus for furthering the research in 
this field. 
 
The manuscripts that are part of this dissertation are following: 
1) A systematic review of quantitative studies addressing factors at the micro-
, meso-, and macro levels of the health care system that are associated 
with adherence to medication regimens in individuals with HIV and organ 
transplant recipients (Chapter 3). 
2) A methodological paper describing the most commonly effect size measures 
and how they are calculated (Chapter 4). 
3) A study describing the strategies cardiovascular nurses and allied health 
professionals utilize to assess patients’ adherence to their medication 
regimens, and the strategies they use to enhance adherence (i.e., 
educational/cognitive, counseling/behavioral, or psychological/affective 
techniques) (Chapter 5). 
4) A study describing the strategies transplant health care professionals 
utilize to assess and promote medication adherence, as well as their 
perceptions regarding the effectiveness of the adherence prompting 
strategies they utilize (Chapter 6). 
5) A study describing the development as well as the content validity and 
inter-rater reliability testing of the Chronic Illness Management 
Implementation - Building Research Initiative Group: Chronic Illness 
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Management and Adherence in Transplantation (CIMI-BRIGHT) 
instrument (Chapter 7). 
We discuss the findings of this dissertation below taking a perspective that goes 
beyond the discussion of the individual manuscripts (Chapters 3 to 7). 
Implications for further research and suggestions for clinical practice will also 
be presented. 
 
Synthesis and discussion of key findings 
This discussion will focus on following key messages:  
1) There remains a significant knowledge deficit in view of the influence of 
health care system factors on medication adherence calling for further 
research investment.  
2) Nurses’ practice patterns in view of adherence-related interventions call for 
a change in curricula. The health care workforce needs to be equipped 
with the required competencies for behavioral management. Moreover, 
practice development focused on integrating behavioral strategies to 
improve adherence management is needed.  
3) The CIMI-BRIGHT instrument is the first and only tool developed to 
systematically assess the level of chronic illness management in transplant 
centers and thus provides a building block for further observational and 
intervention research in transplantation.  
 
1) There remains a significant knowledge deficit in view of the 
influence of health care system factors on medication adherence 
calling for further research investment.  
We performed the first systematic review that examined the relationship 
between multiple factors at the micro-, meso-, and macro levels of the health 
care system and adherence to medication regimens in individuals living with 
HIV and organ transplant recipients (Chapter 3). This systematic review 
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included published studies examining the association between characteristics 
at the micro- (i.e., quality of the patient-provider relationship, medication 
counseling, satisfaction with the health care provider, relationship with health 
care providers, health care providers’ disease-specific experience, 
trust/confidence in the health care provider, clarity of health care providers’ 
instructions about medications, accessibility to the health care providers, 
perceived pressure from the provider to take medications, and perceptions of 
non-judgmental attitudes of health care providers), meso- (i.e., center effects, 
frequency of health care visits, access to disease-specific services, access to 
medications, quality of care, and satisfaction with the health care setting) and 
macro (i.e., health insurance, drug costs, distance from and access to clinical 
site, and country/continent) levels of the health care system and medication 
adherence. Overall, the relationships between the factors examined and 
adherence varied across studies, making it difficult to reach firm conclusions in 
view of which system factors explained most of the variability observed in 
medication adherence. The two factors that were most consistently related to 
medication adherence were trust in the health care provider (a micro level 
factor) and access to medications (a meso level factor).  
Trust in the health care provider can be defined as “the optimistic acceptance 
of a vulnerable situation in which the truster believes the trustee will care for 
the truster’s interests” 31 (pg. 615). While trust/confidence in the health care 
provider was one of the system factors most consistently related to medication 
adherence, the relationship was only statistically significant in 62.5% of the 
eight studies that examined it. Methodological differences in study settings, 
sample characteristics, definitions and assessment of adherence and the 
methods used to measure trust in the health care provider may have 
contributed to these inconsistencies 32. An increasing number of studies have 
examined trust in health care providers 33. One of the factors contributing to 
this increased interest for trust in health care providers is the perceived threat 
that managed care systems might impose to the doctor-patient relationship 33. 
In previous studies, trust in the health care provider was related to a number of 
clinically important outcomes including 34,35 lower blood glucose levels 36-41, 
earlier detection of the cancer 42, fewer post operative complications 43, 
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symptom improvement 44, better mental health related quality of life 45-47, higher 
acceptance of medications 47,48, higher satisfaction with the physician 47,48, 
higher general satisfaction with care 47,48 in addition to higher adherence to 
physicians’ advice and recommendations 34,35.  
Of the studies included in this review, only those focusing on adherence to HIV 
medications examined the relationship between trust and medication 
adherence. It was not examined in any of the transplant studies included in our 
review. Future studies examining predictors of medication adherence in the 
transplant population should examine the role of trust in the health care 
provider. We integrated therefore trust in the health care provider into the Swiss 
Transplant Cohort Study, the first and only nationwide cohort study in 
transplantation that embraced a biopsychosocial perspective assessing not only 
biomedical but also selected psychosocial and system related factors from pre-
transplant to life-long post-transplant 49. The finding that trust in the health 
care provider is significantly associated with non-adherence has also 
implications for clinical practice. As trust in the health care professional does 
not happen instantaneously but evolves over time 50, continuity of care is an 
important aspect of the care of chronically ill patients. Therefore, to the extent 
possible, patients should be followed by the same health care provider. 
Furthermore, as health care providers with good communication skills instill 
more trust, clinical practice settings need to focus on providing education and 
training to improve communication between providers and patients 33. 
Drug access refers to the availability of drugs. In their report “The World 
Medicines Situation” (2004), the World Health Organization states that essential 
medicines should be continuously available for patients 51. In our review, access 
to drugs was associated with better medication adherence. However, in the 
studies that examined the relationship between medication availability and 
adherence multivariately, the relationship was significant in developing 
countries but not in developed countries. This finding is not unexpected given 
the issues with drug access in many developing countries 51. One reason why 
drug access in developing countries is often not guaranteed is the fluctuating 
production of essential drugs 52, which leads to stock shortages in hospitals or 
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pharmacies. This finding has implications for clinical practice sites but also 
implications for health policy and international aid for developing countries.   
Unfortunately, methodological limitations of the studies included in the review, 
hamper firm conclusion regarding the role of individual system factors in 
promoting or inhibiting medication adherence. Major variability across the 
studies was observed in the definition of medication adherence. Different cut-
offs were used to define adherence across the studies. This variability may, in 
part, explain the variability we found in the associations between the health 
care system factor(s) examined and adherence. In addition, there were 
variations in the adherence assessment time period (ranging from “ever” to “the 
previous two days”) and the method used to assess adherence. Furthermore, 
variations in study designs (cross-sectional versus prospective designs), the 
system factors examined and how they were measured, the methods of analysis 
(bivariate versus multivariate analysis techniques), and incomplete reporting of 
statistical findings made the combination of study results (meta-analysis) 
inappropriate. Based on these limitations, we strongly recommend conducting a 
large multi-continental, multi-country, multi-center study to examine the 
associations between multiple factors at the micro-, meso-, and macro levels 
and non-adherence to medication regimens. To address this research gap, we 
designed the Building Research Initiative Group: Chronic Illness Management 
and Adherence in Transplantation (BRIGHT) study, an international multi-
center cross-sectional study to explore the relation between selected patient 
level, health care system factors and non-adherence with immunosuppressive 
drugs in transplant recipients. Forty heart transplant programs (20 from North-
America and 20 from Europe) will be included in this study. A further 
recommendation for future research evolving of this systematic review is that 
authors report the magnitude of the examined system factors’ effect on 
adherence. Our methodological manuscript, which describes the most 
commonly used effect size measures and how they are calculated, will assist 
and encourage authors to provide this essential information in their 
manuscripts (Chapter 4). 
Additionally, most of the studies included in this review did not base their factor 
selection on a theoretical framework such as the ecological model. Use of such a 
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framework will guide the selection of factors to be examined, ensure that all 
important factors are included and contribute to building scientific 
understanding related to the complex phenomena of medication adherence. It is 
only with this knowledge, that we can develop effective strategies to address this 
major public health issue. Future studies are strongly encouraged to use a 
theoretical framework to underpin the selection of the patient-related- as well as 
of the system-related variables included in their study.  
 
2) Nurses’ practice patterns in view of adherence-related 
interventions call for a change in curricula. The health care 
workforce needs to be equipped with the required competencies 
for behavioural management. Moreover, practice development 
focused on integrating behavioural strategies to improve 
adherence management is needed.  
We examined practice patterns related to interventions used to promote 
patients’ adherence to medications by performing two surveys of health care 
professionals, primarily nurses, working with cardiovascular and transplant 
patients, respectively. At two conferences we invited all participants to complete 
an instrument assessing the frequency with which they used 26 adherence 
enhancing interventions. The interventions were identified from the literature 
2,53-56 and classified as educational/cognitive, counseling/behavioral and 
psychological/affective based on the classification proposed by De Bleser 57. 
Educational/cognitive interventions present information individually or in a 
group setting delivering it verbally, in written form, and/or audio-visually. 
Counseling/behavioral interventions shape and/or reinforce behavior, 
empowering patients to participate in their own care, while positively changing 
their skill levels or normal routines. Psychological/affective interventions focus 
on patients’ feelings and emotions or social relationships and social support 57.    
In both samples, participants reported using a higher proportion of 
educational/cognitive interventions than of counseling/behavioral and 
psychological/affective interventions. In the study of transplant nurses, we also 
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asked the participants to rate the perceived effectiveness of the interventions 
used. Their average effectiveness ratings for the three groups of interventions 
were very similar. This is contrary to current evidence that indicates that 
educational interventions are not very effective in promoting adherence 2,56,58. 
There are a number of possible explanations for this finding.  
First, educational/cognitive interventions are relatively simple and inexpensive 
to implement and, therefore, feasible in most clinical settings. Evidence, 
however, indicates that counseling/behavioral and psychological/affective 
interventions are more effective in promoting long-term behavioral changes 59 
such as ongoing medication adherence 60. Yet, they are time consuming to 
implement, require more skills and require more follow-up to be successful. 
They necessitate continuity of care i.e., supervision of the chronically ill patient 
by the same health care professional(s) 61. This may be a major barrier in their 
use as in many health care settings where care is still mainly built around an 
acute model of care which does not meet the specific needs of patients suffering 
of chronic illnesses 1,9-12.      
However, like health care organizations, curricula in health science schools are 
often outdated and static resulting in graduates who are ill equipped to address 
the rapidly shifting balance between acute and chronic health problems 19,62,63. 
In most education settings there is a serious mismatch between the 
development of professional competencies and existing and emerging patient 
and population needs such as the needs of the chronically ill. Indeed, the 
curricula in most health sciences colleges and universities focus much more on 
acute care than on chronic care 13,64-66. While schools address some aspects of 
chronic care in their programs, it is rarely central to their curriculum 13. This 
need has also been recognized by the Institute of Medicine which strongly 
recommend in their 2010 report The Future of Nursing that nursing curricula 
need to be reexamined, updated and adaptive to change as patients needs and 
advances in science and technology 63.  
In response to concerns about the lack of emphasis on chronic care in the US, a 
curriculum task force was established to increase the proportion of schools of 
medicine, nursing and allied health whose basic curriculum includes the core 
competencies in health promotion and disease prevention 67. The Task Force 
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published a Clinical Prevention and Population Health Curriculum Framework. 
One of the recommended domains in this curriculum is counseling for 
behavioral change. This domain includes approaches to behavior change that 
incorporate diverse patient perspectives (e.g., counseling skills training and 
motivational interviewing), clinician-patient communication (e.g., patient 
participation in decision making, informed consent, risk communication, 
advocacy, and health literacy), criteria for successful counseling (e.g., 
effectiveness, benefits and harms, cost, and acceptance by patient), and 
evidence-based recommendations 67. Curricula also need to integrate 
interprofessional education. Interprofessional education occurs when two or 
more professions (e.g., doctors, nurses, physiotherapists, social workers) learn 
with, from and about each other to improve collaboration and the quality of care 
68. A growing body of evidence shows that interprofessional education leads to 
closer collaboration between health care professionals as well as between health 
care organizations. This improved collaboration can, in turn, improve the 
quality of care for patients 68. 
Since the majority of practicing nurses do not have the educational foundation 
recommended in The Future of Nursing 63 report and the Clinical Prevention and 
Population Health Curriculum Framework 67, they often lack the training and 
competencies necessary to provide effective chronic illness care including skills 
needed to promote long term-changes in behavior such as medication 
adherence 69. Therefore, it is essential that educational and organizational 
leaders support the preparation of nurses and other health care professionals 
with the required competencies by providing ongoing education and training. An 
example health care organizations could offer is training in motivational 
interviewing. Motivational interviewing is a client-centered, directive method for 
enhancing the intrinsic motivation to change one’s behavior by exploring and 
resolving ambivalence 70,71. Motivation interviewing has been shown to be an 
effective method to change patient behavior and improving clinical outcomes 72. 
Efforts in curriculum reforms as well as the development of continuous 
education programs are urgently needed to enhance the competencies of nurses 
and other health care professionals in view of interventions to enhance 
adherence to medication regimens. Future studies should evaluate the extent to 
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which these investments 1) increase health care professionals’ competencies in 
implementing counseling/behavioral and psychological/affective interventions 
and 2) improve long-term clinical outcomes for patients with chronic illnesses.  
 
3) The CIMI-BRIGHT instrument is the first and only tool developed 
to systematically assess the level of chronic illness management 
in transplant centers and thus provides a building block for 
further observational and intervention research in 
transplantation.  
Survival gains after transplantation have been limited to the first 6 to 12 
months with long-term survival rates remaining unchanged 73-75. Transplant 
outcomes are determined by the interplay of a number of factors including 
biomedical, behavioral, psychosocial, and socio-demographic as well as system 
factors (e.g., practice patterns in transplant centers) 76-79. In the past, most 
research and clinical interest focused on biomedical factors.  
Improving long-term outcomes is one of the most important future challenges. 
This need has also been recognized by the European Commission, that as part 
of the EU 7th Framework programs, recently launched a call for proposals 
addressing novel strategies to improve long-term outcomes after 
transplantation. Given the fact that transplant patients belong to the group of 
the chronically ill, which means that they are in need of continuity of care, 
support for self-management and preventive measures, it can be put forward 
that transplant care could be strengthened by adopting a care model that 
follows the principles of chronic illness care. Indeed, a shift in attention toward 
the long-term follow-up of transplant patients will have to occur to really make 
an impact on long-term outcomes 74,75. We, for the first time, developed a tool 
assessing the extent to which chronic illness management is implemented in 
the follow-up care of transplant patients. The development of the Chronic 
Illness Management Implementation - Building Research Initiative Group: 
Chronic Illness Management and Adherence in Transplantation (CIMI-BRIGHT) 
instrument was based on the conceptual framework of WHO’s Innovative Care 
for Chronic Conditions (ICCC) framework, as well as the clinical expertise of the 
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members of the research team. As part of this dissertation, we completed initial 
testing of its content validity and inter-rater reliability. The results suggest that 
the CIMI-BRIGHT instrument has promise as a measure of the extent to which 
the chronic illness model is being implemented in transplant centers.  
The work we performed with the development of the CIMI-BRIGHT provides a 
building block for future studies designed to examine the extent to which 
transplant centers implement chronic illness management principles. Data from 
such studies will allow investigators to determine whether differences in chronic 
illness practice patterns impact patient outcomes. These differences may be 
related to the differences to “center effects” that have been observed in some 
studies 80-85. Center effects refer to differences in outcome that cannot be 
explained by identifiable differences in the patients treated or specific 
treatments applied 80. Center effects are presumed to result from differences in 
the ways health care is delivered. For instance, individual centers may have 
different long-term follow-up programs that could potentially influence 
outcomes 80. A number of studies have demonstrated that variations in practice 
patterns influence patient outcomes. In a study in hematopoietic stem cell 
transplantation in the United States, two center factors, ‘presence of physicians 
answering after hours calls’ and a ‘lower patient-per-physician ratio’, were 
associated with decreased 100-day mortality rates: 81. The Dialysis Outcomes 
and Practice Patterns Study (DOPPS), a prospective, observational study among 
hemodialysis centers in seven different countries showed that center 
characteristics such as the size of the center and the percentage of highly 
trained staff, and the country where the dialysis center was located were related 
to dialysis non-adherence rates 82,83. The Swiss HIV cohort study also found 
that the center where the patient is followed up accounted for significant 
variability in adherence rates 84. An 11 country survey of primary care doctors 
by Schoen et al. (2009) found wide variations at a national level in practice 
systems, incentives, perceptions of access to care, use of health information 
technology and programs to improve quality 85. The mere fact that center-
specific differences regarding outcomes for chronically ill patients are observed 
indicates that processes at this level are influential and require to be 
scrutinized. 
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The first step in improving chronic illness management in transplant centers 
should be to design studies to explore the extent to which the principles of 
chronic illness care are implemented by transplant centers. The relationship 
between implementation of elements of the model and adherence-related 
outcomes should also be examined. This knowledge will provide the basis for 
developing interventions designed to improve implementation of the model. The 
CIMI-BRIGHT instrument, if further validation supports it use for these 
purposes, could also be relevant to assess the impact of these interventions on 
medication adherence. 
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Conclusion 
As patient behavior, i.e., patient adherence, is prone to the influence of system 
factors it is of upmost importance to scrutinize these factors. Yet, there is 
limited research examining the impact of system factors on adherence. This 
dissertation contributes to the science of adherence by systematically 
examining current evidence related to the role of system factors in adherence 
and by identifying important gaps in nursing practice and knowledge related to 
adherence-promoting interventions. The findings of this dissertation emphasis 
the need for nurses and other health care providers to be prepared with a 
foundation in systems thinking and competencies to ensure the delivery of 
effective and high quality care. Furthermore, this dissertation points to the need 
for continuous efforts to improve outcomes in chronically ill patients. The 
evidence from this dissertation provides a strong foundation for future research. 
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